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'What every physician wants for every one of his patient old or young, is not 
just the absence of death but life with a vibrant quality that we associate with a 
vigorous youth. This is nothing less than a humanistic biology that is 
concerned, not with material mechanisms alone, but with the wholeness of 
human life, with the spiritual quality of life that is unique to man. Just what 
constitutes this quality of life for a particular patient and the therapeutic 
pathway to it often is extremely difficult to judge and must lie with the 
consciousness of the physician'  
 
                                                                                                      























Background: Pernicious Anemia (PA) is a potentially serious medical 
condition with a complex symptom profile that is under researched in the 
scientific literature. There is little consensus regarding its diagnosis, and 
individual differences in symptom perception and treatment expectation and 
outcome suggest the centrality of psychological factors in managing this 
condition. Health-related quality of life (HRQoL) has been suggested as an 
important health indicator in clinical outcomes in terms of determining the 
impact of illness on daily functioning, and subsequently informing health 
interventions. Given the absence of objective markers of patients’ experience, 
the current thesis describes the development of a patient-centred measure for 
the identification and management of health-related quality of life  in patients 
diagnosed with pernicious anaemia (PA-HRQoL), informed by the findings of 
four exploratory studies. The findings of these studies are supported by 
empirical evidence and provide rich information that reflect the burden of PA on 
individuals’ quality of life.  
 
Methods study 1: Study 1 reflected an audit of patients’ records, aimed to 
establish the parameters for the focus of the instrument development through 
investigating the progression of patients from diagnosis through treatment and 
management of this condition. Data was collected on all PA cases (N=257, 189 
females, 68 males, age range 25-97 years old, Mean age= 65, SD=17) in a 
pilot GP practice. Information recorded included demographics, symptoms, co-











Findings study 1: Results from this audit exercise indicated that specific tests 
carried out to diagnose PA (IFAB and GPC) were only requested for a small 
proportion of the sample. In some cases, discrepancies were noted regarding 
the outcome of these tests and an accurate PA diagnosis. Despite negative 
test results, some patients were diagnosed with PA, which may imply 
inconsistencies in the way PA is managed.  
 
Patients presented with co-morbidities and symptoms such as extreme 
tiredness and shortness of breath as well with psychological symptoms such 
as feeling anxious and/or depressive. B12 therapy was administered regularly 
(1-3 months) in most cases, as per WHO recommendation.  
A few GP observations in the patients’ records emphasized the experience of 
severe symptoms despite regular treatment. The findings of study 1 highlighted 
important clinical issues such as less routine testing than it would have been 
anticipated, having implications in terms of the quality of patient care. 
  
Methods study 2: This was a qualitative study exploring individuals’ 
perceptions of their PA experience. Specific questions regarding diagnosis and 
treatment (highlighted in study 1) were addressed in study 2, with a focus on 
individuals’ perceptions of their PA experience. Semi-structured interviews 
were conducted with six females and one male whose ages ranged from 21 to 
58 years, (SD=14) and analysed using thematic analysis.  
 
Findings study 2: Themes revolved around the issues of misdiagnosis, illness 
perception and treatment effectiveness. Individuals’ emphasized misdiagnosis 
and for some, having the illness affected their sense of identity, making it 
difficult to cope with daily living. Individuals’ reported feeling better since 
undergoing treatment,however some felt the need for more frequent treatment, 
which in some cases was refused by their GP. Mixed feelings towards the 
support provided by health care services were expressed. Results of this study 
indicated that individuals’ perceptions of PA are challenged when the 
legitimacy of their illness is questioned, increasing the psychological distress in 
these individuals and having detrimental effects on their health-related quality 




Methods study 3: A survey was carried out to investigate the PA experiences 
of members of the Pernicious Anaemia Society and to further explore the 
meaningful psychological variables that emerged from study 2. An online 
survey explored treatment supplementation, coping, illness identity, the impact 
of PA on one’s quality of life and the provision of support, through the 
perspective of the members of the PA society ( N=199, 172 females, 26 males; 
age range, 19 to 83 years old; Mean age = 45.5 years old, SD=13), by using a 
mix-methods approach.  
 
Findings study 3: This study highlighted the frequent psychologizing of 
patients’ symptoms (by clinicians), the inability to control and manage 
symptoms, suboptimal treatment, worry concerning prognosis and the poor 
provision of healthcare. Findings from this study have significant implications 
for the management of PA and highlight the importance of measuring 
psychological variables, which will serve as basis for the development of a 
patient-centred tool for the identification and management of health-related 
quality of life in this population. 
 
Methods study 4: This study investigated illness severity and health-related 
quality of life in patients diagnosed with Pernicious Anaemia and involved the 
administration of psychological measures in patients recruited from two local 
GP practices as well as an online sample (N=184; 144 females, 40 males; 
Mean age = 56, SD=16). This study aimed to identify the best predictors of 
HRQoL, and to develop the HRQoL instrument. Multiple regression analyses 
indicated that physical HRQoL was best predicted by illness consequences 
and depression. Psychological HRQoL was best explained by the variables of 
illness identity, illness consequences, treatment control and depression. The 
HRQoL dimension of social relationships was best explained by depression. 
Environmental HRQoL was best explained by anxiety, illness identity and 
illness consequences. Exploratory factor analysis and a comprehensive review 
of the PA literature produced a 43-item HRQoL instrument measured across 
seven dimensions (physical functioning; psychological health; illness 
management behaviours; illness controllability and support; maladaptive 
coping; illness understanding and adjustment; distraction) with acceptable 
levels of internal reliability. These findings suggest that identifying patient 




Conclusions: The PA-HRQoL is the first attempt to identify and manage the 
HRQoL of patients with PA, contributing to the growing body of knowledge in 
this area. There is a crucial need for healthcare education in the recognition of 
PA symptoms, how symptoms impact on health-related quality of life and how 
these can be controlled. Validation of this instrument is yet to be established in 
further studies. It is anticipated that the PA-HRQoL may provide clinicians with 
accurate indicators of individual patient needs, therefore supplementing 
existing approaches to the PA management.  
 
In future research, the PA-HRQoL may inform the development of interventions 
aimed at improving patient agency among PA sufferers. Further economic 
benefits could potentially include the reduction in both the frequency and length 
of consultations as a consequence of the diagnostic tool and the improved 
patient adjustment. 
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Chapter 1  
Introduction 
Pernicious Anaemia (PA), also known as autoimmune metaplastic atrophic 
gastritis is an under-researched medical condition that leads to the destruction 
of the parietal cells in the gastric mucosa and reduced levels of stomach 
acidity. PA results from the failure to produce intrinsic factor (IF), a glycoprotein 
which is essential for the absorption of B12 in the small intestine (Carmel, 
2008).  The clinical manifestations of PA vary according to the severity of the 
condition and may cause serious gastric, intestinal and psychiatric 
abnormalities. Common psychiatric symptoms include delusions (Bar-Shai, 
Gott & Marmor, 2011; Blundo, Marin & Ricci, 2011), depression (Milanlioglu, 
2011; Hanna, Lachover& Rajarethinam, 2009; Durand, Brazo & Dollfus, 2003), 
irrational behaviour (Slade, Bharadwaj, 2010; Gomez-Bernal & Bernal-Perez, 
2007) and social withdrawal (Sahoo, Avasthi & Singh, 2011; Rajkumar & 
Jebaraj, 2008). PA may also reflect varying degrees of neuropathy, causing 
irritation and lack of sensation in the hands and feet as well as mental changes 
including confusion and irritability (Springhouse, 2005; Sethi, Robilotti & 
Sadan, 2004).  
 
Currently, the B12 assay is unreliable where the result is borderline. According 
to current guidelines from the British Committee for Standards in Haematology 
(BCSH), patients diagnosed with PA require lifelong therapy with intramuscular 
vitamin B12, every 3 months (Devalia, Hamilton & Molloy, 2014; NICE, 2014).  
However, the response to B12 therapy may vary markedly between patients 





 In most cases, this is refused since clinicians perceive that symptoms 
presented by patients may be of a psychosomatic nature (Banka, Ryan & 
Thomson, 2011; PAS, 2008). The lack of flexibility to comply with requests for 
more frequent B12 therapy may lead to increased patient anxiety and as a 
result, many patients purchase over-the-counter treatment in which safety is 
not guaranteed, to maintain what they perceive as being an acceptable quality 
of life (Hooper, 2012; Deale & Wessely, 2001). Patients often express 
dissatisfaction with the current standard of care, which reflects the ‘one size fits 
all’ regimen. This represents a dilemma for health professionals who are 
concerned with early medicalisation in mild and transient cases when there is 
no demonstrated clinical benefit of more frequent B12 therapy (Devalia, 2006).  
  
This thesis originated from the need to investigate the reason why some 
patients still experience severe symptoms, despite receiving frequent B12 
therapy. There is no instrument to assess the severity of patients’ symptoms in 
this population. Also, it is currently unexplained whether any potential 
improvements in symptoms relate to patients' expectations towards treatment 
or if patients are in actual need of additional B12 therapy. With this in mind, it 
proves difficult to determine the amount of treatment necessary for adequate 
patient response. The experience of ongoing symptoms and variability in 
treatment response may result from different factors such as time since 
diagnosis, the way individuals perceive their condition, the way they cope 
and/or the potential tendency to somatise symptoms. 
In the absence of physiological parameters of patients’ experience, it is crucial 




Therefore, assessing illness beliefs may be useful for clinicians to further 
understand the perceived severity of patients' symptoms, enabling them to 
select treatment strategies tailored to patients' needs (Nielson and Jensen, 
2004).  Investigating illness severity based on beliefs about one’s illness will 
serve as basis for the development of a patient-centred measure for the 
identification and management of health-related quality of life in patients 
suffering with Pernicious Anaemia. The development of the PA-HRQoL 
questionnaire, built from a patient's perspective, is the contribution to 
knowledge in the present thesis. To the researchers’ knowledge, there is no 
reference to such measure in the current literature. This instrument derived 
from items included in well-established validated psychological measures 
(illness perceptions, health status, somatic focus, coping and HRQoL), as well 
as pilot work conducted throughout this thesis (Study 1- Study 4). 
This instrument taps into seven areas that aim to identify HRQoL in this 
population. These include physical functioning, illness management 
behaviours, illness understanding and adjustment, illness controllability and 
support, maladaptive coping and distraction. Overall, the PA-HRQoL 
comprises of 43 items measured in a 5- point Likert scale. Once tested and 
validated, it may potentially be used in clinical settings to assess the severity of 
patients' symptoms .This will provide clinicians with a further understanding of 








 This tool has the potential to adjust treatment according to individual needs, 
potentially leading to a more effective management and patient care, thus 
improving patients’ health-related quality of life and reducing the care burden at 
primary and secondary levels. 
 
 Further economic benefits could potentially accrue to GP’S and NHS medical 
practitioners in terms of reduction in both the frequency and length of 
consultations. This instrument may also highlight patients in need of direct 























2.1 Literature review  
The symptoms suffered as a result of PA are varied and non-specific. The 
response to B12 therapy may vary markedly with some patients perceiving the 
need for more frequent replacement therapy than others. PA treatment is 
intended to limit symptoms, increase functioning and delay progression of the 
condition. However, the current standard of care may not reflect this, causing 
lifestyle restrictions that may impact on individual’s quality of life. It is 
anticipated that the development of a patient-centred outcome measure for the 
identification and management of HRQoL, in a new area of clinical research, 
may potentially lead to a more effective approach to patient engagement and 
satisfaction with treatment. 
 
This chapter will discuss the theoretical foundations that inform the current 
thesis. It will explain why applying a health psychology perspective 
(biopsychosocial approach) to the management of PA may prove valuable to 
both PA sufferers and health professionals.  Based on this holistic view of 
patients’ experience, this review will address the importance of investigating 
how patients’ beliefs about their illness (illness representations) may 
significantly impact on how individuals adjust to their condition. Existing PA 
literature is mostly medical in nature and there is a gap in research tackling the 
psychological impact of PA. Given the dearth of research in this area, this 
section will present and discuss studies that reflect the impact of chronic illness 
on HRQoL. It will also discuss the need to include patient-reported outcomes 
when measuring HRQoL, as indicators of increased clinical functioning. It will 
then discuss the implications of early screening in PA. 
24 
 
2.1.1 A health psychology perspective on Pernicious Anaemia 
The World Health Organisation has defined health as the ' complete state of 
physical, emotional and social well-being and not merely the absence of 
infirmity or disease' (WHO, 1948). Health psychology focuses on the concept 
of health as a continuum by exploring how psychological factors may impact on 
health by considering illness onset and progression, the direct and indirect 
pathways between psychology and health and variability.  
 
The definition of Health psychology represents the “aggregate of the specific 
educational, scientific and professional contribution of the discipline of 
psychology to the promotion and maintenance of health, the promotion and 
treatment of illness and related dysfunction” (Matarazzo, 1980, pg.815). Health 
psychology claims that illness can be caused by a combination of biological, 
psychological and social factors and is therefore rooted on a biopsychosocial 
framework (Ogden, 2012). The biopsychosocial paradigm (Engel, 1977, 1980) 
emerged from the need for a more contextual and inter-disciplinary approach in 
relation to the reductionism reflected by the biomedical model, a disease 
oriented approach, which has been very useful in the treatment and control of 
infectious diseases. However, with the increased prevalence of chronic 
conditions, its efficacy is limited since it neglects the patient and their 
experience (Borrel-Carrió, Suchman & Epstein, 2004). The biomedical model 
implies a linear relationship between pathophysiology and progression of 
illness; however, this relationship has been challenged by evidence suggesting 
that psychosocial and environmental factors play an important role in this 
process by either aggravating illness or leading to positive outcomes (Tanaka, 




The biopsychosocial model has served as basis for the development of 
research investigating how psychological and social factors may influence the 
course, development and outcome of a condition. This approach has led to 
developments in the field of health psychology as well as 
psychoneuroimmunology. The biopsychosocial model reflects a holistic 
approach to patient care by looking at the biological aspects of the person (e.g. 
organs and tissue), psychological (such as attributes and habitual factors) and 
the social facet (including the physical and social environment interacting with 
the individual). Thus, the biological aspects refer to the physiological causes of 
disease, including genetic issues, hormones, immune function, stress 
reactivity, neurochemistry and physical trauma. However, physiological causes 
alone do not always adequately explain the occurrence of illness. The 
psychological factors in this framework relate to cognitive, emotional and 
behavioural aspects that may directly or indirectly influence an individual’s 
health. In this way, attitudes, beliefs, emotions, negative life events, coping, 
social skills and behaviour play a significant role in one’s condition. The 
acknowledgment that psychological factors play an important role in the 
aetiology and course of a condition has been substantiated in the literature 
(Knowles et al., 2014; Khayyam-Nekoueii et al., 2013; Nash, 2013). A review 
looking at the psychological adjustment in chronic illness has suggested that a 
sense of control and mastery are important indicators of illness adjustment 
(Ridder, 2008). Evidence of the protective role of optimism on health status has 
also been linked with active coping and reduced incidence of anxious and 
depressive symptoms in cancer patients (Gustavsson-Lilius et al.,2012; 
O’Brien & Moorey, 2010) and with decreased incidence of coronary heart 




The social factors are relevant to the individual and his/her environment by 
determining external factors that play a role in the manifestation of illness, 
including social relationships, the physical environment, culture, social support 
and access to health care (Engel, 1977, 1980). The diagram below outlines the 






































Figure 2.1.1 The Biopsychosocial model, Hierarchy of Natural Systems. Engel.G.L 




The hierarchy of natural systems reflects the interaction of levels where every 
level is a component of a higher-system being regarded at the same time as a 
whole and as a part. According to Engel, this represents a way of 
understanding how disease and illness are affected by multiple levels of 
organization, from the molecular to the societal (Engel, 1980). Applying the 
biopsychosocial model to the understanding of PA pathophysiology suggests 
that psychosocial factors and their interaction with physiological mechanisms 
involved in the process of vitamin B12 absorption in the gut, may change 
symptom severity, influence illness experience, and affect health-related 
quality of life. 
Currently, there is no research addressing the variables contributing to HRQoL 
in PA and the variability in treatment response is currently unexplained. The 
application of a biopsychosocial framework within a health psychology 
perspective would be useful for clinicians to understand patient’s perceptions 
that may influence health behaviour and therefore the patients’ condition. 
 
2.1.2 Illness representations 
PA has the potential to cause serious complications for its sufferers, however 
the extent of psychosocial difficulties likely to be experienced by patients is 
unknown and the processes that may render an individual vulnerable to such 
difficulties are not fully understood. Previous research has stressed the crucial 
role that subjective beliefs play in the way individuals’ make sense and cope 
with their existing condition, as significant predictors of illness adjustment 




The common Sense Model of Self-regulation forms a theoretical basis to 
assess individual’s perceptions of a health threat. Self-regulation represents a 
dynamic motivational system in which the management of emotional 
responses in relation to the experience of illness are linked to cognitive 
processes.  
This model suggests that illness perceptions influence coping strategies and 
coping mediates the relationship between illness perceptions and health 
outcomes (Leventhal, Meyer & Nerenz, 1980). This model has been 
conceptualised in three stages, identification, coping strategies and appraisal. 
Identification reflects illness representations and emotional responses. Coping 
strategies are then generated in response to illness representations. The last 
stage reflects the appraisal of coping strategies (see fig.2.1.2). 
 
 
Fig.2.1.2 The common sense model of illness danger. Leventhal, H., Meyer, D., 
&Nerenz, D. (1980). In S. Rachman (Ed.), Contributions to Medical Psychology (Vol. 2, 




This model is structured according to five cognitive dimensions, identity, time-
line, consequences, cause and cure/ controllability, having a significant impact 
on illness outcome (Leventhal, Nerenz & Steele, 1984; Leventhal, Meyer & 
Nerenz, 1980).  
Identity consists of how individuals label their illness and perceived associated 
symptoms. The cause reflects beliefs about factors contributing to the illness 
onset. The timeline refers to beliefs concerning the onset and the expected 
duration of the illness (e.g. acute, cyclical or chronic). The consequences relate 
to the perceived effects of the illness on physical, social, economic and 
psychological well-being, including beliefs about the severity of the same. 
Lastly, cure and control refers to the extent to which one can control the health 
threat. According to Leventhal and colleagues (1997), illness representations 
are organised into clusters. In this way, a strong belief that the illness can be 
controlled or cured is likely to be linked to the belief that the illness will last a 
short time, having relatively minor consequences. Alternatively, a strong belief 
that the illness will last a long time is likely to be associated with an illness that 
can’t be cured or controlled and with a belief in more serious illness 
consequences (Leventhal et al., 1997).  
 
The common sense model of self-regulation has been used to investigate the 
relationship between illness representations, illness response and outcomes in 
various conditions such as diabetes and multiple sclerosis (Hagger & Orbell, 






Previous research has reported the inter-relationship between these 
dimensions.  A strong illness identity has been associated with perceptions of 
high chronicity and perceived low illness control, resulting in serious 
consequences for individuals such as impaired health-related quality of life 
(Larun & Malterud, 2007; Vaughan, Morrison & Miller 2003; Heijmans, 1998; 
Moss-Morris, 1998; Scharloo et al., 1998; Weinman, Petrie, Moss-Morris & 
Horne, 1996).  
 
Studies have found impaired HRQoL in a variety of chronic conditions, to be 
associated with higher symptom frequency and severity, distress, functional 
impairment, poor psychological well-being and mood disturbances (Chen & 
Chen, 2016; Megari, 2013; Franzén, Saveman & Blomqvist, 2007; Lett et al., 
2004; Lam and Louder, 1999). Alternatively, increased HRQoL has been 
associated with the experience of fewer symptoms, better disease 
understanding, better treatment control and less emotional response (Weldam 
et al.,2014;Covic et al.,2004). 
 
Leventhal’s model of illness representations addresses the importance of 
assessing peoples’ cognitive representations of illness to achieve better illness 
outcomes. There is a lack of empirical evidence concerning the nature of 
psychological factors implicated in PA, mainly regarding individual differences 
in symptom perception and treatment expectation, and how these factors may 
impact one’s health-related quality of life. By investigating the role of illness 
perceptions and related variables such as coping strategies and health status 
will prove valuable in understanding how these variables may be associated 





2.1.3 Quality of life and health-related quality of life 
Quality of life (QoL) is a subjective and complex construct that refers to 
individuals’ perceptions of their position in life, which is related to their goals 
and expectations, being also determined by their culture and value systems. A 
person's physical health, independence, psychological state, belief system, 
spirituality, religion and social and environmental relationships have all been 
proposed to influence one's quality of life (WHOQOL Group, 1998, p.1569).  
The term health-related quality of life (HRQoL) covers aspects that are relevant 
to one's health. Therefore, there is no established definition of HRQoL as 
interpretations may vary from a holistic focus on the social, emotional, physical 
well-being and functioning to descriptions of the impact on an individual's 
health and his/her ability to lead an accomplished life (Fayers & Machin, 2000). 
HRQoL also includes both subjective and objective components that are 
necessary to the construct. The former focuses on how the individual perceives 
or appraises their health status in terms of emotions, life satisfaction and well-
being. The objective component is related to the individual’s ability to function 
according to their degree of health, which, may include self-care, and the 
experience of symptoms such as tiredness and pain. Therefore, subjective 
perceptions transform objective functioning in the HRQoL experienced by the 
individual. In this way, individuals' scores on objective and subjective rated 
measures of quality of life vary markedly (Megari, 2013; Eiser, 2004, as cited 
by Lin et al., 2013; Fakhoury & Priebe, 2002; Testa & Simonson, 1996).  
The following table highlights discussions of definitions linked to quality of life 






Table 2.1.3.1   
Examples of definitions of quality of life and health-related quality of life in the 
literature  
 
a) ‘ Quality of life refers to patients' appraisal of and satisfaction with their current 
level of functioning as compared to what they perceive to be ideal.' (Cella & Tulsky, 
1990) 
b) ' Quality of life is an individual's perception of their position in life in the context 
of culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns.'(WHOQOL Group, 1993) 
c) 'Quality of life measures the difference, or the gap, a particular period of time, 
between the hope and expectations of the individual and that individual's experiences.' 
(Calman, 1984) 
d) ' Health-related quality of life is the value assigned to duration of life as 
modified by the impairment, functional states, perceptions and social opportunities that 
are influenced by disease, injury, treatment or policy.' (Patrick & Erikson, 1993) 
e)   ‘Health-related quality of life refers to the level of well-being and satisfaction 
associated with an individual's life and how this is affected by disease, accidents and 
treatments from the patient's point of view.' (Lovatt, 1992) 
 
In the patient’s perspective, the impact of illness is associated with the 
perceived ability to carry on with daily life (Hale, Theharne & Kitas, 2007; 
Chrischilles, Rubenstein, Voelker, Wallace & Rodnitzky, 2002).  The increased 
prevalence of chronic illness over the years has been associated with a great 
impairment in HRQoL, significantly impacting on healthcare delivery (Megari, 
2013; WHOQOL Group, 1998). The clinical features of chronic conditions and 




For chronic illness patients, maintaining a good quality of life is essential for 
disease management and psychosocial adjustment (Davison & Jhangri, 2013; 
McGee, 2001). 
2.1.4 Health-related quality of life measurement 
Measures of health-related quality of life share two common assumptions. 
Firstly, these are multidimensional in their appraisal of health and secondly 
focus on the subjective individual evaluations rather than the perceptions of the 
healthcare professionals or significant others (Bennett et al., 2002). There has 
been a growing interest in both generic and disease-specific evaluations of 
health-related quality of life (Bowling, 2001).  
Generic measurements allow for comparisons between and across conditions 
in relation to dimensions of overall health status and functioning, with the 
potential to generate unexpected findings. Generic tools include health profiles 
and utility measures such as the quality-adjusted life-years (QALY’s; Guyatt, 
Feeny & Patrick, 1993).  QALY’s are calculated by multiplying the years of life 
by morbidity score on a quality of life scale where zero will reflect death and 
one will reflect full health.  Morbidity rates, survival periods, clinical 
assessments, laboratory tests and social measures (e.g. hospital remission 
rates) constitute examples of traditional utility measures. However, one of the 
issues of using QALY’s relates to the notion that people suffering from severe 
illness may not rate their quality of life as significantly poorer than people with 
mild illness may, or healthy people, therefore comparisons between different 
groups of patients may be difficult (Higginson & Carr, 2001). Utility measures of 
quality of life reflect on the evaluation of certain aspects of health such as 
mobility and symptoms by professional or laypeople, which may not account 
for the individual perspective. 
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 However, these measures only seldom cover the emotional and psychological 
consequences of disease (Aaronson, 1988). While generic questionnaires are 
typically used to assess HRQoL in different populations, condition-specific 
instruments are developed to target specific aspects of health that are relevant 
to a particular patient group, potentially ensuring greater clinical validity and 
responsiveness to changes that are meaningful to patients (Megari, 2013; 
Cella & Nowinski,2002).  
Condition-specific measurements possess the advantage of discriminating 
between patient’s illness severity levels as well as being more sensitive to 
clinical outcomes. The criteria to evaluate outcome of care varies across 
different conditions and this is reflected in the condition-specific HRQoL scales. 
Examples of condition-specific measures include the Arthritis Impact 
Measurement Scales (AIMS; Meenan, 1980, 1991, 1992), assessing the 
physical, social and emotional well-being of individuals.  The Inflammatory 
Bowel Disease Questionnaire (IBDQ; Guyatt et al., 1989), addresses domains 
such as  gastrointestinal symptoms, systemic symptoms, emotional health and 
social function, and the MacNew Heart Disease Health-related Quality of Life 
Questionnaire (MacNew;Hillers et al.,1994) is designed to evaluate the 
physical, emotional and social function dimensions of coronary heart disease 
and its treatment.  
As opposed to condition-specific measures, dimension-specific measures of 
health-related quality of life focus on certain aspects of health such as anxiety, 
depression and psychological well-being. Examples include the Beck 
Depression Inventory (BDI; Beck, Ward, Mendelson, Mock & Erbaugh, 1961) 





The decision to use generic or condition specific tools is linked with the aims 
and expected outcomes of a particular study, as its content should reflect the 
nature of the condition under study as well as response to treatment (Bennet et 
al., 2002). 
 Authors suggest that using generic measures alongside disease measures 
ensures a wide coverage of health related dimensions. This is also useful 
when addressing clinical issues as well as detecting unexpected positive and 
negative intervention outcomes in clinical trials (Fitzpatrick et al., 1998, as cited 
by Bowling, 2001). In this way, an individual suffering with pernicious anaemia 
would be expected to undergo investigations for serum B12 levels in the blood.  
The lack of a clear foundation for quality of life assessments has resulted in the 
difficulty in choosing research appropriate tools (Moons, 2004). Nonetheless, 
available generic instruments have been proven suitable in terms of the initial 
assessment of the health-related quality of life of individuals suffering with 
various chronic conditions (Longworth et al., 2014; Skevington, Lofty & 
O’Connell, 2004). Currently, there is no available tool designed to obtain 
health-related quality of life information in patients with B12 deficiency and/or 
pernicious anaemia and patient-centred measures that have found to be useful 
in other chronic conditions may be of little relevance for this effect (Hillers et 
al., 1994; Aaronson et al., 1993; Meenan, 1992; Guyatt et al., 1989). The 
development of patient-centred measures related to quality of life reflects the 









2.1.5 The application of generic health-related quality of life instruments 
in chronic illness 
Whilst there is an array of measures effectively assessing health-related quality 
of life in different groups of individuals, some measures may be more pertinent 
to certain groups when compared to others. Therefore, the selection of 
appropriate HRQoL measures needs to consider essential criteria such as the 
concepts under measurement as well as the psychometric properties of the 
scales under development. HRQoL assessment is also important in terms of 
evaluating the impact of primary care services. Health-related quality of life 
measures have been widely applied in the area of chronic illness by covering 
domains that are relevant to chronic conditions such as physical functioning, 
pain and general health. The associated co-morbidity in chronic conditions 
such as diabetes, arthritis, chronic obstructive pulmonary disease and 
congestive heart failure is generally translated into poorer quality of life 
(Haroon et al., 2007; Alonso et al., 2004).  
 
A comprehensive systematic review was conducted by Hand (2016) to identify 
generic profile-type HRQoL scales for adults with chronic conditions. The 
search criteria were limited to English publications and reviews in order to 
detect the most widely used scales. Inclusion criteria comprised generic scales 
that were developed for clinical use, short, easy to complete and score, and 
applicable to primary care patients with varying diagnoses. It also included 
scales that covered broad content areas (physical, psychological and social 




The search elicited nine scales, which included the Sickness Impact profile, the 
Health Assessment Questionnaire, the World Health Organization Quality of 
Life Scale (WHOQOL-100), the Dartmouth COOP Functional Assessment 
charts, the Duke Health Profile, the Nottingham Health Profile, the Short Form 
Health Survey (SF-12), the Short Form Health Survey (SF-36) and the 
WHOQOL-BREF. This review also acknowledged the three most suitable 
generic assessments for this effect, based on its theoretical basis, content 
development, psychometric properties, scoring and feasibility. The instruments 
included for review were the Short-Form Health Survey-36 the Duke Health 
Profile and the short version of the WHOQOL-100, the WHOQOL-BREF. 
Considering that the primary endpoint of this thesis is to develop a screening 
tool for pernicious anaemia, a good starting point would be to consider 
established health-related quality of life measures. Therefore, it seems 
practical to use Hand’s review as a reference (please refer to table 2.1.5.1). 
The scales identified in the review can be found below.  
 
The Short-Form-36 Health Survey (SF-36; Brazier et al., 1992; Ware & 
Sherbourne, 1992) 
This survey comprises of 36 items developed from the Medical Outcomes 
Study Questionnaire with the objective of evaluating health status in clinical 
practice and research in chronic conditions as well as being applicable for use 
in healthy individuals. It provides a general indication of health status covering 
eight dimensions, physical functioning, role limitations resulting from physical 
health, bodily pain, general health perceptions, vitality, social functioning, role 
limitations resulting from emotional problems and mental health. The SF-36 is 
also useful when used along disease-specific tools in clinical research.  
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Reliability and validity are acceptable in different patient groups with chronic or 
psychiatric conditions (Hubanks & Kuyken, 1993; Jenkinson et al., 1993; 
McHorney et al., 1993). However, a greater variance in scores have been 
reported (ceiling and floor effects), (McHorney et al., 1994).  
This scale has also been found to be non-responsive to clinical change, 
possibly due to comorbidity issues (Spertus et al., 1994). Nevertheless, the SF-
36 was found to be more sensitive to changes in health-related quality of life as 
compared to the Nottingham Health Profile as well as more precise than its 
shorter versions (SF-12; Ware et al., 1995; SF-8; Ware et al., 2001). 
 
The Duke Health Profile (Parkerson & Broadhead, 1990) 
This instrument was developed as a measure of adult functional health status 
in primary care settings. It was derived from the Duke-UNC Health Profile, 
comprised of 63 items across four dimensions reflecting the WHO definition of 
Health (symptom status, physical function, emotional function and social 
function). The shorter version, the Duke Health Profile, consists of 17 items 
across six dimensions (physical, mental, social, general health, perceived 
health and self-esteem). Five of the scales assess dysfunction in terms of 
anxiety, depression, pain and disability. Scores from the anxiety and 
depression subscales make up for the anxiety-depression scale. The elements 
in the Duke Health Profile may be scored separately, combined into an overall 
quality of life score or grouped into several measures. The Duke Health Profile 
reflects a self-administered or interview tool used in the clinical setting as a 
measure of medical, economic and social interventions on health and disease. 
Reliability studies suggest good internal reliability (Hubanks & Kuyken, 1993). 
However, floor and ceiling effects are apparent when compared with other 
measures such as the Nottingham Health Profile. 
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 Furthermore, the physical health scale does not seem to perform well as it 
lacks specificity. In terms of the overall performance, the Duke Health Profile 
seems sound in terms of measuring overall health-related quality of life, being 
analogous to the SF-36.  
 
The World Health Organization Quality of Life Assessment (WHOQOL-BREF; 
Skevington, Lofty, O’Connell & WHOQOL group, 2004) 
The WHOQOL-BREF was originally developed from data from the field-trial 
version of the World Health Organization Quality of Life Scale (WHOQOL-100 
Skevington, 1999; WHOQOL Group, 1994). The WHOQOL-BREF comprises 
two elements from the Overall Quality of Life and General Health and one item 
from each of the 24 dimensions present in the main version. The WHOQOL-
100 was designed for determining the impact of health on an individual’s life, 
taking into account the doctor-patient relationship. The WHOQOL-100 may 
also be used as a primary or secondary measure in clinical applications 
through monitoring progress after treatment or serving as an outcome 
measure. This tool may also be used in health surveys and epidemiological 
studies. It consists of 100 items covering six broad domains including physical 
and psychological health, level of independence, social relationships, 
environment, spirituality, religion and personal beliefs having the advantage of 
being applied across cultures enabling comparative results (Cazzorla et 
al.,2012;Orsel, Akdemir & Dağ ,2004;Skevington & Wright, 2001;O’Carroll et 
al, 2000; Power, Harper & Bullinger, 1999;Skevington, 1999; Bonomi et 
al.,2000). The psychometric properties are very good and the strengths of the 




In abbreviated format, the WHOQOL-BREF is measured across four domains, 
physical health, psychological health, social relationships and environment and 
it has good to excellent psychometric properties of reliability and validity. It has 
been employed in different areas such as medical practice, research and audit, 
policy making as well as assessing the effectiveness of different treatments. 
 It may also be used to assess cross-cultural variation, to compare sub-groups 
within the same culture and to measure change across time in response to 
change in life circumstances (Baumann, Erpelding, Régat & Collin, 2010; Min 
et al., 2002). The WHOQOL tools reflect the views of individuals regarding their 
condition.  
All of the measures described above address the physical, mental and social 
domains of health, in line with the definition put forward by the WHO (1948). 
The WHOQOL-BREF also assesses environmental aspects that may influence 
an individual’s health status. Its development stems from a conceptual 
framework, which is stronger when compared with the other two scales. 
Information regarding the psychometric properties is less available for the duke 
health profile as well as the small amount of individualized items, which makes 
it less useful for patients with chronic conditions. The SF-36 has been reported 
as being useful when evaluating outcomes to improve health status. The 
WHOQOL-BREF does not have floor and ceiling effects and has the 
advantage of having the highest proportion of individualized elements, which  







Despite some caveats, such as the uncertain ability to detect meaningful 
change with patients suffering from chronic conditions, it seems that the 
WHOQOL-BREF may be one of the most suitable instruments to be used in 
adults with chronic conditions in primary settings. The areas covered are 
broad, outcomes may be assessed in clinical practice and it addresses 
individual’s concerns. Given the nature of the present thesis, the WHOQOL-
BREF seems as the most appropriate measure to use for patients with PA and 
its associated co-morbidity. This measure is an asset for research when 
compared with other health-related quality of life measures that may be too 
broad or less practical to use in health care settings (WHOQOL Group, 1998). 
Please refer to table 2.1.5.1.  
Table 2.1.5.1 
The psychometric properties of scales measuring health-related quality of life in 
individuals suffering with chronic conditions (e.g. cardiac conditions, arthritis, 
diabetes or chronic obstructive pulmonary disease). 
HRQOL scales The Duke Health Profile  SF-36 WHOQOL-BREF 
Scale 
description 
17 items 36 items 26 items  
Domains Physical, mental and social 
health; general and perceived 
health; self-esteem, anxiety, 
depression, pain and disability 
Physical function, mental health, 
social function, physical role, 
emotional role, pain, vitality, general 
health 
 Physical, psychological, 
social and environmental 
Individualized 
items 
5 individualized items 16 individualized items 20 individualized items 





predictive (Parkerson et 
al.,1995) validity among 
primary care patients 
Conflicting evidence found regarding 
the factor structure(Kosinski et 
al.,1999;Wolinsky et 
al.,1998;McHorney et al.,1993;  
Evidence of discriminant(Ten 
Klooster et al.,2013;Linde et al.,2008; 
Parshall et al.,2008;Whitfield et 
al.,2006;Salaffi et al.,2005;Brown et 
al.,1999; Kosinski et 
al.,1999;Woodcock et 
al.,2001;Lalonde et al.,1999;Ruta et 
al.,1998;Wolinsky et al.,1998;Prieto 
et al.,1997; McHorney et al.,1993) 
convergent(Ten Klooster et 
al.,2013;Cruz et al.,2009; Linde et 
al.,2008; Kosinski et al.,1999;Stavem 
et al.,1999; Ruta et al.,1998;and 
predictive validity ( McHorney, 1996)  
Evidence of factor 






al.,2007; Skevington et 
al.,2004; WHO,1998) and 
convergent validity (Cruz 
et al.,2009;Haroon et 












Good levels of reliability in 
primary care patients (α=.85) 
for the emotional subscale, 
(Parkerson et al., 1995). Lower 
levels of reliability in certain 
subscales (α=.55 -.78), 
(Parkerson et al.,1990,1992) 
 Evidence of good levels of 
reliability(α.75-.95) in all subscales in 
some studies (Ten Klooster et 
al.,2013; ;Linde et al.,2008 Kosinski 
et al.,1999;) however lower reliability 
found for the social function 
scale(α=>.60) (Ruta et 
al.,1998;Prieto et al.,1997). 
Good levels of reliability 
for 3 subscales (α=0.80-
0.87) and lower levels for 
the domain of social 
relationships (α=.64) 
(Taylor et al., 2004; WHO, 
1998). 
Responsiveness Evidence of responsiveness in 
most subscales for individuals 
undergoing cardiac 
rehabilitation(Parkerson,2002) 
Evidence of responsiveness found 
for most subscales generally for 
adults with chronic conditions.  
Evidence of 
responsiveness found for 
the physical and social 
domains in adults 
suffering from rheumatoid 
arthritis( Taylor et 
al.,2004) 
Scoring  Each question has 3 possible 
answers, rated 0, 1 or 2. 
Responses to the items in 
each measure are added 
together and then the means 
of the raw item scores are 
normalized to a scale of 0 
(worst) to 100 (best). 
Responses are presented in 
the form of a profile of the 
scores calculated for each of 
the domains. 
Precoded numeric values are 
recoded and then each item is 
scored on a 0(low) to 100 (high) 
range. Then items in the same scale 
are averaged together to create each 
scale. Scale item scores represent 
the average for all items in the scale 
answered by the participant. 
This scale derives four 
domain scores. Two items 
are derived in separate 
(overall quality of life and 
overall perception of 
health). The mean score 
of items within each 





Issues with measurement 
noted. It may be self-
administered or through 
interview. 
Self-administered, postal or interview 
administered. Coverage of a wide 
range of areas affected by ill health. 
However, it has been suggested to 
fail to address certain areas related 
to function such as sleep. 
Acceptability and 
feasibility in a wide range 
of conditions.  A high 
quality patient-centred 
generic tool suitable for 
individual assessment, 
research and audit. 
 
Adapted from Hand (2016). Measuring health-related quality of life in adults with chronic 










2.1.6 Health-related quality of life and its impact on chronic illness 
The studies that will be reviewed below reflect the broad investigation of 
HRQoL and are helpful in terms of providing an insight into how chronic illness 
may influence different areas of an individual’s life. Research has documented 
poor levels of HRQoL in individuals experiencing a variety of chronic 
conditions. In some studies, impaired HRQoL has resulted from low feelings of 
personal control and limited functional ability (George, Bergin, Clarke, 
Courtney & Codd, 2016; Riihimäki et al., 2016; Megari, 2013). In other studies, 
increased HRQoL has also been linked to illness acceptance, positive affect 
and social support in different chronic conditions (Vilhena et al., 2014; Eaton, 
Bradley & Morrissey, 2014; Kurpas et al., 2013). Self-management in chronic 
disease has been pointed out as an important factor related to improved 
HRQoL (Benzo, Abascal-Bolado & Dulohery, 2016; Pouwer& Hermanns, 
2009). The findings of these studies need to be examined by considering 
factors such as the type of condition under study as well as levels of co-
morbidity (Muldoon, Barger, Flory & Manuck, 1998). The relationship between 
HRQoL, co-existing conditions and acute health care use was explored in a 
prospective longitudinal cohort study with 1999 adult participants (mean age of 
63 years old) suffering from various chronic conditions such as diabetes, 
chronic respiratory disease and cardiac disease. Participants were enrolled in 
a chronic disease management program and HRQoL was measured through a 
self-report utility assessment covering five dimensions (independent living, 
social relationships, physical senses and psychological well-being). Findings 
suggested that the number of comorbidities and levels of HRQoL predicted 
acute health care use over three years of follow-up, and that poor HRQoL was 
predicted by an increased number of co-morbidities. 
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 However, the authors noted concerns such as sample bias, as the participants 
of the study were enrolled in disease management programs; and the possible 
underreporting of co-morbidities as these were assessed through previously 
recorded administrative data (Hutchinson et al., 2015). 
HRQoL has also been investigated in 535 patients suffering from chronic 
kidney disease in different stages of the condition at the start of dialysis 
treatment. Assessment was made in conjunction with clinical markers such as 
blood and hormone analyses. HRQoL was measured using  the Short-Form 
health survey (SF-36) and was found to be significantly impaired across all 
domains that include physical function, social function and role limitations 
caused by emotional problems.   
Poor physical functioning and impaired general health were prominent in the 
later stages of the condition. Patients in earlier stages of the condition also 
reported deteriorated HRQoL compared to matched controls. Co-morbidity was 
also found to be an important predictor of reduced HRQoL along with disease 
biomarkers such as reduced renal function (Pagels, Söderkvist, Medin, 
Hylander & Heiwe, 2012).  
 
A multicentre study examining the response to replacement therapy for 
patients suffering from primary hypothyroidism has reported low levels of 
HRQoL in untreated patients particularly in the physical and emotional facets, 
regardless of biochemical status (Vigario et al., 2013). Another study assessing 
HRQoL in thyroid disorders has found greater impairment in domains such as 
physical and emotional role, general health and social functioning, in the 
absence of physiological measures. Mood and behaviour disturbances have 





A retrospective cross-sectional study investigated the relationship between 
anaemia and HRQoL and activities of daily living in 838 long-term care 
residents. Data was achieved through a patient database. The findings of this 
study suggested that declines in haemoglobin levels in anaemic residents led 
to poorer levels of HRQoL and reduced physical functioning, independent of 
demographic characteristics (Bailey, Reardon, Wasserman, McKenzie & Hord, 
2012). A few methodological issues were noted, such as the measurement of 
HRQoL which was largely assessed by proxy (e.g. spouse or healthcare 
professional), limiting the quality of the data.  
Also, the measurement of anaemia status was performed by using a single 
haemoglobin index value, making it difficult to accurately determine whether 
















2.1.7 Measuring HRQoL in patients suffering from chronic illness: the 
inclusion of patient reported outcomes 
 
Existing research has emphasized the beneficial role of patient reported 
outcomes (PROs) in clinical health research (Nelson et al., 2015; Deshpande, 
Rajan, Sudeepthi & Nazir, 2011). A patient reported outcome (PRO) may be 
defined as any patient account of their health status, as opposed to an 
observer reported outcome (FDA, 2011). Patient reported outcome measures 
(PROMs) are designed to evaluate HRQoL and the quality of care delivered to 
patients by focusing on the patient perspective. PROMs are developed to 
improve the doctor-patient relationship by bridging the gap between both 
health professional and patient’s concerns and therefore tailoring treatment to 
individual needs, (Barry & Edgman-Levitan, 2012) substantially improving 
patient satisfaction with care (Chen, Ou & Hollis, 2013; Marshall, Haywood and 
Fitzpatrick, 2006). Even though the use of PROMs has been suggested as 
valuable, their use may have also been limited (Snyder, Jensen, Segal & Wu, 
2013; Haywood, Marshall & Fitzpatrick, 2006).  Barriers to using PROMs may 
be linked to factors such as worry about emotional involvement with the 
patient, a professional identity based on the biomedical stance or lack of 
awareness of the impact of psychosocial factors in the progression of illness 
(Zimmerman & Tansella, 1996). The issue of patient burden and focus on 
elements that may bear more value to the health professional have also been 
put forward as reasons that may restrict the use of PROMs (Nelson et al., 






Research documenting the advantages of using PROMs, has been useful in 
tracking the benefits of consistent treatment over time. For example, the 
routine use of PROMs in clinical visits has resulted in lower disease activity in 
patients with rheumatoid arthritis (Hendrikx, de Jonge,Fransen, Kievit & van 
Riel, 2015) and it has led patients to report improved health in conditions such 
as depression (Ahles et al.,2006). The use of PROMs has been varied, from 
investigating the health outcome of surgery patients to using Web-based 
applications to the monitoring of health-related quality of life of patients 
suffering from serious conditions (Devlin & Appleby, 2010; Devlin, Parkin & 
Browne, 2010; Haverman, Engelen, van Rossum, Heymans & Grootenhuis, 
2011). In conditions such as cancer, PRO tools are used to assess HRQoL to 
identify the needs of supportive care, the negative impact of treatment when 
survival time is long as well as identifying problems to enable clear 
communication in clinical practice (Acquadro et al., 2003). PROMs are best 
achieved if they are co-developed with patients and health professionals. 
Patients often report the need for better outcomes, reflected by the 
development of better systems of care (Devlin & Appleby, 2010). The 
development of a disease-specific measure, based on patient reported 
outcomes, relates to the primary endpoint of the current thesis. 
The investigation of distinctive indicators of illness burden (e.g.symptom 
severity) may potentially fuel decision making in terms of how PA is managed, 
resulting in more effective treatment practices. This may improve patients’ 
satisfaction with treatment and improve the patient and clinician rapport. Since 
clinical indicators of disease do not provide enough information to improve the 
quality of services provided to patients, the use of HRQoL tools based on a 
patient perspective may serve as guidance to improvement of these services 
(Chen, Lu & Kochen, 2005).  
48 
 
2.1.8 The cost-effectiveness of early screening in the management of 
Pernicious Anaemia  
 
Traditional methods of assessing change in patients have been focused in 
laboratory and clinical tests. These methods often provide a clinical picture of 
the patient in terms of disease progression; however, these methods do not 
take into account the personal and social context that may influence the course 
of a condition (Higginson & Carr, 2001). Even though quality of life 
assessments have been widely used as an aid to measure adjustment and 
evaluate treatment, there is a concern that in general, these measures are not 
routinely used in clinical practice (King et al., 2016; Baumstarck et al., 2013). 
The practicality of using these measures carries a great value in terms of 
facilitating the communication in the clinical encounter, screening and 
prioritising problems, identifying patient preferences that will aid decision-
making, monitor changes and response to treatment as well as providing 
enhanced care to specific population groups such as the one under study 
(Jaar, Khatib, Plantinga & Powe, 2008).  
Research addressing the clinical and cost-effectiveness of measuring HRQoL 
in conditions such as chronic kidney disease, diabetes and hypertension has 
reported better health outcomes. Measuring HRQoL in these sub-optimally 
managed conditions has been suggested to be more cost-effective when 
compared with conventional management, however evidence of randomized 
controlled trials is lacking in these types of studies (Black et al., 2010; Howard 
et al., 2010). A systematic review investigating the cost-effectiveness of 
anaemia screening in people with underlying illnesses has stated that that 
there is not enough evidence of screening for decision-making.   
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However, data comparison is limited by the heterogeneity of these studies (e.g. 
different types of conditions), demographic factors (e.g. different age groups) 
and sampling issues (e.g. not using healthy participants as a comparison 
group), (Nosratnejad, Barfar, Hosseini, Barooti & Rashidian, 2014). A 
structured review and gap analysis against UK national screening criteria was 
conducted to investigate whether the prevalence of iron deficiency anaemia 
could be reduced through a national screening programme. Research 
evidence has suggested that even though most studies assessed the 
haematological status of anaemia, there was not sufficient evidence regarding 
the evaluation of clinical consequences (Rukuni, Knight, Murphy, Roberts & 
Stanworth, 2015). There is no research addressing the clinical and economic 
benefits of improved primary care for patients suffering with B12 deficiency and 
pernicious anaemia. Evidence shows that treatment of B12 deficiency in 
targeted groups may significantly improve prognosis. Studies with elderly 
people have suggested daily B12 therapy to normalise the metabolic status and 
improve neurological symptoms, however, there is still a propensity to 
misdiagnose B12 deficiency (Iqtidar & Chawdary, 2012).  
A better understanding of B12 deficiency, where evidence is lacking, is 
essential to improve health outcomes particularly in preventing the associated 
risks resultant from a delayed diagnosis. Although, the availability of new 
biomarkers may be promising, the disease burden is still not fully addressed. 
Therefore, it seems plausible to introduce complementary psychosocial 
screening in this population group aiming to detect the extent to which illness 
severity impairs HRQoL. This would possibly enable evaluating and treating 




There is a clear need for timely responses to address the management of PA. 
Early PA screening and individualised treatment would potentially reduce the 
economic costs of untreated disease in an already over-stretched health 
system (Wouters, O’ Donoghue, Ritchie, Kanavos & Narva, 2015; Higginson & 
Carr, 2001).  
 
There is no available patient-centred measure that allows clinicians to 
understand the health status and treatment benefits of individuals suffering 
with PA. This thesis aims to fill this gap in response of a tool that can be used 
in clinical health research to assess the severity of patients’ symptoms, 
therefore enhancing health-related quality of life. This tool will be grounded in 




















Study 1: Investigating the demographic profile of patients suffering with B12 
deficiency: An exploratory audit of patients’ records 
3.1 Study aims 
To investigate the clinical variables that may be relevant for establishing the 
parameters for developing a patient-centred health-related quality of life 
measure to assess the severity of patients’ symptoms.  
3.2 Background  
Pernicious Anaemia (PA) represents an autoimmune condition with a chronic 
course that can have serious implications for sufferers and for medical 
managers. Patients experience a range of symptoms with differing degrees of 
severity including extreme tiredness, pins and needles and gait disturbances. 
Psychological symptoms may include depression, negative affect, cognitive 
problems and inability to cope with daily living. However, if timely diagnosed 
and effectively managed, it can lead to a better prognosis. It is anticipated that 
the development of a patient-centred outcome measure to identify and manage 
HRQoL will prove valuable for both patients and clinicians. This instrument 
may provide information regarding individuals’ health status, allowing for 
adjusting the treatment according to patients’ needs. This may result in the 
improvement of patients’ symptoms and subsequently improved illness 
adjustment. The clinical features of PA may manifest in the absence of 
anaemia or low B12 status (Devalia, Hamilton & Molloy, 2014; Quadros, 2010).  
When untreated, PA may cause permanent neurological impairment even in 
the presence of adequate dietary intake (McCaddon, 2013; Langan & 
Zawitoski, 2011; Bupa, 2008).  
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Evidence from case studies describes patients suffering from severe 
neurological manifestations for a long period because B12 deficiency was not 
included in the differential diagnosis from their primary care physicians 
(Ralapanawa, Jayawickreme, Ekanayake & Jayalath, 2015; Pacholok & Stuart, 
2011). These include paralysis (Matrana, Gauthier & Lafaye, 2009), sub-acute 
combined degeneration (Paul & Reichard, 2009), gait and balance disorders 
(Malizia, Baumann, Chansky&Kirchhoff, 2010), paraesthesia and numbness 
(Wong, Van Spall, Hassan, Coret-Simon, Sahlas & Shumak, 2008; Kumar, 
2004), ataxia (Celik, Barkut, Oncel& Forta, 2003) and impaired cognitive 
functioning (Madksi & Kadrie, 2009).  
 
It is estimated that PA affects approximately 0.1% of the general population 
and 1.9% of individuals over the age of 60 years (Andrès & Serraj, 2012). 
However, there is limited research in terms of the prevalence of PA in the UK. 
Early studies investigating the prevalence in Great Britain, diagnosed locally by 
blood examination, reported prevalence rates between one per thousand 
cases to over two per thousand cases in different locations.  
In general, the prevalence was 1, 27 per thousand cases (Scott, 1960). The 
prevalence of B12 deficiency has  proven difficult to estimate since existing 
reports are based on values according to inclusion criteria set by different 
laboratories (Devalia, Hamilton & Molloy, 2014; Hunt, Harrington & Robinson, 
2014; Langan & Zawistoski, 2011; Thorpe, Heath, Blackmore, Lee, Hamilton, 
O’Broin, Nelson & Pfeiffer, 2007).  B12 deficiency may be influenced by 





The incidence of B12 deficiency has been proposed to increase with age with 
the elderly population being more likely to develop B12 deficiency through 
malabsorption or malnutrition (Hinds, Johnson, Webb & Graham, 2011; Evatt 
et al., 2010; Stabler & Allen, 2003; Carmel, Green, Rosenblatt & Watkins, 
2003).  However, there is evidence to suggest that the occurrence of B12 
deficiency in young adults may be comparable to that of older adults and that 
PA may be underdiagnosed in the elderly as well as in younger patients (Allen, 
2009; Hershko, Ronson, Souroujon, Maschler, Heyd & Patz, 2006; Clark & 
Grimley, 2004, Carmel, 1996).  Early research has suggested PA to be more 
common in females in comparison to males (Wintrobe, 1981, Carmel, 1996). 
However, more recent studies conducted with patients from the United States, 
Japan, Turkey and Italy, didn’t find gender differences in the diagnosis of PA 
(Lahner & Annibale, 2009; Zittoun, 2001). 
 
 Recent epidemiological studies investigating the potential impact of ethnicity in 
the development of pernicious anaemia have reported higher prevalence in 
black and Latin American individuals (Carmel, 1996). However, PA diagnosis 
has been suggested to be prominent in Italy, the United States, Japan & 
Turkey (Scarpa et al., 2013; Lee-Guzman et al., 2011; Oh & Brown, 2003; 
Takasaki et al., 2002; Kocak & Paydas, 1992). This may be explained by 
differences in the genetic background, diagnostic practices and awareness of 
this condition in different countries. Nevertheless, there is a paucity of research 
to support the true impact of demographic factors in relation to B12 deficiency 
and the distribution of PA among different ethnic groups is not clear (Allen, 




Autoimmune profiles carried out in individuals suffering from other autoimmune 
disorders may reveal antibodies, which may be associated with PA, increasing 
the chances of co morbidity in these patients (Osborne & Sobczyńska-
Malefora, 2015). Although there are no clear guidelines proposing PA 
screening in individuals suffering from other autoimmune disorders, 
epidemiological research supports their coexistence with PA (Bizzaro & Antico, 
2014; Zulfiqar et al., 2014; Lahner & Annibale, 2009). These include thyroid 
disorders (Toh,2017;Osborne & Sobczyńska-Malefora, 2015; Poye et al., 2014; 
Ness-Abramof,2006; Weetman, 2005; Antonijević, Nesović , Trbojević & 
Milosević,1999; Irvine, Davies, Delamore ,Teitelbaum & Williams, 1962; 
Carmel & Spencer, 1982), type 1 diabetes mellitus (Angelousi & Larger, 
2015;Pinto, Dantas, Araujo, Barone, de Souza Papi, Egídio de Oliveira, 
Zajdenverg & Rodacki, 2013; Thrasivoulos et al.,2009; De Block, De Leeuw & 
Van Gaal, 2008; Perros, Singh, Ludlam & Frier, 2000) and vitiligo (Gill et 
al.,2016; Ezzedine, Sheth, Rodrigues, Eleftheriadou, Harris, Hamzavi& 
Pandya, 2015). Other chronic conditions that have been also found to manifest 
in individuals presenting with PA include multiple sclerosis (Deleva, Tzoukeva, 
Kaprelyan & Drenska, 2012; Kocer, Engur & Yilmaz, 2009; Reynolds & Linnell, 
1991) and Addison’s disease (Bizzaro & Antico, 2014; Alkhateeb et al., 2003; 
Dittmar & Kahaly, 2003; Zelissen et al., 1995). PA sufferers have also been 
found to be at a higher risk of developing gastric cancer and carcinoid tumours 
(Boursi, Mamtani, Haynes & Yang, 2016; Wu, Chen & Lin, 2005; Annibale et 
al., 2001; Kokkola, Sjoblom, Haapiainen, Sipponen, Pulakkainen & Jarvinen, 





Studies have reported the annual incidence of gastric cancer ranging 
approximately from 0.1% to 0.5% in these patients (Kokkola et al., 1998; 
Schafer, Larson, Melton, Higgins & Zinsmeister, 1985, as cited by Lahner & 
Annibale, 2009). A survey completed by 889 members of the Pernicious 
Anaemia society has reported PA co-existing diagnoses. These mainly 
included depression (45%), tinnitus (34%) and folic acid deficiency (23%) 
(Hooper, Hudson, Porter & McCaddon, 2014). Nevertheless, despite the 
potential link between the conditions above-mentioned and pernicious 
anaemia, studies undertaken have not been able to identify why this may 
happen. What is certain is the burden caused by PA and associated co 
morbidity and the restrictions on an individual's quality of life (Hooper, Hudson, 
Porter & McCaddon, 2014). 
 
One of the major problems in diagnosing B12 deficiency stems from the fact 
that there are no ‘gold standard’ tests that provide a clear clinical picture of the 
deficiency. This becomes a problem when its features are in discordance with 
test results (Devalia, Hamilton & Molloy, 2014; Berg & Shaw, 2013; Herrmann 
& Obeid, 2013; Willis, Elshaug, Milverton, Watt, Metz & Hiller, 2011; Devalia, 
2006). Although the serum B12 remains the first-line test to investigate B12 
deficiency, this test lacks in specificity and sensitivity to successfully diagnose 
PA (Devalia, Hamilton & Molloy, 2014; Hooper, 2012; Pacholok & Stuart, 2011; 
Devalia, 2006). The anti-intrinsic factor antibody test (IFAB) is generally carried 
out in individuals presenting with low serum B12, and in the majority of cases 
(95%) a positive IFAB identifies PA with high specificity (Devalia, Hamilton & 




However, this test has low sensitivity, being accurate in only 40-60% of the 
cases. Therefore, a negative test outcome may not rule out PA (Wainwright, 
Narayanan & Cook, 2015; Carmel & Agrawal, 2012; Toh, van Driel & Gleeson, 
1997).  
A further problem relates to subclinical deficiency, low serum B12 with no 
evidence of clinical symptoms. Subclinical B12 deficiency restricts prognosis 
and the identification of health consequences due to its unknown causes in 
approximately 60% of the cases (Devalia, Hamilton & Molloy, 2014; Carmel, 
2012). This represents a key problem that may result in the suboptimal 
management of PA.  
 
The treatment of Pernicious Anaemia involves the administration of cobalamin 
in its various forms (methylcobalamin, cyanocobalamin, hydroxocobalamin and 
adenosylcobalamin) and it takes into account factors such as the cause of the 
deficiency, treatment toleration and individual variability in absorption (Andrès 
et al., 2014; Devalia, Hamilton & Molloy, 2014; Stabler, 2013; Andrès & Serraj, 
2012; De Paz et al., 2005; Lane & Rojas-Fernandez, 2002). There is no cure 
for PA, although continuous cobalamin replacement may result in the cessation 
of anaemia related symptoms. Currently, there are no tailored guidelines for 
patients suffering with PA that need more frequent B12 therapy. 
 Expert consensus in the UK, suggest treatment to be initiated with 
hydroxocobalamin injections, anticipated as being more effectively absorbed 
and metabolised (Devalia, Hamilton & Molloy, 2014). According to the British 
National Formulary (BNF), initial treatment for patients without neurological 
involvement consists in receiving loading doses of B12 to build up the levels of 
the vitamin, three times a week for two weeks.   
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Patients presenting with neurological symptoms should receive B12 treatment 
on alternative days until there is no further improvement. Maintenance 
treatment typically includes lifelong intramuscular hydroxocobalamin injections 
(1000 µg) between one and three months for patients with neurological deficit 
and without neurological deficit (Devalia, Hamilton & Molloy, 2014). Despite 
receiving regular treatment, many patients perceive the need of taking more 
frequent B12 therapy due to relapse of symptoms before the next treatment is 
due. While the administration of more intensive therapy is at times at the 
discretion of the health professional, some GPs decline more frequent 
treatment since they may be concerned with early medicalisation in mild and 
transient cases, when there is no demonstrated clinical benefit (Andrès, 
Fothergill & Mecili, 2010; Carmel, 2008; Nyholm et al., 2003; Lane & Rojas-
Fernandez, 2002).  
 
The absence of objective markers to successfully diagnose PA means that 
patient care is compromised. A delay in the diagnosis of PA may result in the 
progression of illness and subsequent reduced health-related quality of life, 
resulting from the inadequate management of symptoms. Hence, developing 
the HRQoL instrument may potentially supplement existing approaches to the 
management of this complex condition. 
 
Pernicious anaemia represents a condition with slow onset and progression. 
Clinical management should involve prompt diagnosis, effective treatment and 
monitoring to prevent the long-term consequences associated with this 
condition. Therefore, understanding the health care needs of this population is 
key to effective PA management. 
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 Since there is very little existing research into this condition, the present audit 
aims to identify key issues and variables of importance regarding the diagnosis 
and treatment of PA, guiding the structure of the subsequent studies that form 

























This study involved an exploratory design in the form of an audit. The use of 
electronic health recorded data for research purposes is part of clinical 
governance. The Quality Care and Clinical Excellence (Welsh Office, 1999) 
has defined clinical governance as “a framework through which NHS 
organisations are accountable for continuously improving the quality of their 
services and safeguarding high standards of care, by creating an environment 
in which excellence in clinical care will flourish”.  
 
Patient recorded information included demographics and clinical data. The 
variables recorded included, age, gender, ethnicity, marital status, offspring 
information, occupation, PA family history, types of tests conducted to 
diagnose B12 deficiency/PA,  B12 therapy type and frequency, time since 
diagnosis, consultation history, diseases, signs and symptoms, B12 therapy  
and information related to haematology and gastroenterology referrals. 












3.3.2 Ethical considerations 
The Research and Development Committee in the Abertawe Bro Morgannwg 
University Health Board (ABMU) was approached for advice and it was agreed 
that for the present study, Local Research Ethics Committee review (LREC) 
was not required. Subsequently, a local GP practice in the area of Bridgend 
agreed to enable access to patients’ records. The data collection period started 
in April 2010 and ended in August 2010.  
After the data collection period, approval was granted from the GP practice for 
the research team to make use of the data as required (Appendix 1). The 
University of South Wales (USW) granted ethical approval for the present 
study. Confidentiality was maintained for any published data. The 
confidentiality and management of medical data was ensured, in compliance 
with the Data Protection Act (1998) and BPS guidelines (2010). Patient 
identifiable information was anonymized and computer files were encrypted. 
Paper records were retained in a secure access-restricted storage cabinet, 
password-protected and only accessible by the research team.  
3.3.3 Sample 
Existing routinely collected data was recorded for all patients (Appendix 2) 
recorded as receiving B12 therapy (N=257, 189 females, 68 males, age range 
25-97 years old, mean age= 65, SD=17). This sample included 87 patients 
diagnosed with PA and 135 patients diagnosed with B12 deficiency. Records 
regarding 35 patients suggested as receiving B12 therapy did not specify why 
this was the case. Therefore, data from these participants were excluded from 






The Database, Egton Medical Information System (EMIS) was accessed.  
Currently known as EMIS Health, represents one of the UKs leading clinical 
systems IT supplier. This database is used by a great number of healthcare 
organisations, from GP practices and out-of-hours services, to community 
services. This system enables health professionals to access the same 




Access to the EMIS database was facilitated by the manager of the GP 
practice in the Bridgend area. Records of all the patients recorded as receiving 
B12 therapy were scrutinized. Patient data was initially recorded as specified in 
the medical records. Information included patient demographics and clinical 
data. After the data collection period ended (April 2010-August 2010), all of the 
variables were recorded into a password-protected database. Data 
confidentiality and security followed the University of South Wales’s guidelines 
in compliance with the Data Protection Act (1998), NHS Caldicott Guardian 
(department of health; DH, 2003) and The Research Governance Framework 









3.4 Results  
Prior to analysis, disease and signs and symptoms’ data were categorised by 
type (Appendix 3) using the 10th revision of the international statistical 
classification of diseases and related health problems (ICD-10). The ICD-10 
has been recommended as a valuable tool, capturing quality data, aiming to 
improve diagnostic procedures and disease management (Bowman, 2008). 
This classification system comprises of codes for diseases, signs and 
symptoms, abnormal findings, complaints, social circumstances, and external 
causes of injury or diseases (WHO, 2010). 
 
 
3.4.1 Descriptive analyses 
Patient recorded data included demographics and clinical data. The variables 
recorded included, age, gender, ethnicity, marital status, offspring information, 
occupation, PA family history, haematology and gastroenterology referrals, 
types of tests conducted to diagnose B12 deficiency/PA,  B12 therapy type and 
frequency, time since diagnosis, consultation history, signs and symptoms and 
diseases. Data was checked for normality prior to computing descriptive 
analyses. 
 
The Shapiro-Wilk test was employed as numerical means of assessing 
normality for the variables of ‘age and ‘gender’ in relation to a PA diagnosis. 
This test is appropriate to use in small sample sizes <50 (Field, 2009).  
The data collected indicated that the variable ‘age’ did not fit the normal 
distribution. The observed value of the Shapiro-Wilk (W=0.966) and the exact 
probability of the outcome was statistically significant (p=0.000), with skewness 
of -0.37 (SE=0.16) and Kurtosis of -0.77 (SE=0.32).  
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This may be explained by the age of diagnosis where the typical onset has 
been suggested to be over the age of 60 years for both males and females 
(Hinds, Johnson, Webb & Graham, 2011). 
 
For the variable ’gender’, the observed value of the Shapiro-Wilk (W=0.548, p= 
0.000) indicates that the PA diagnosis according to gender is non-normally 
distributed, with skewness of -1.09 (SE=0.16) and Kurtosis of -0.81 (SE=0.32). 
A possible explanation refers to the uneven distribution in gender in relation to 
the diagnosis of B12 deficiency/PA weighing towards females. 
 
The above values indicate that the data deviates from the normal distribution in 
age and gender according to the diagnosis of PA/B12 deficiency. This seems to 
fit the distribution for this population, where diagnoses seem to be more 
common in females and in older individuals. However, it may be argued that 
this sample is partly representative of the PA population, since there is mixed 
evidence regarding the predominance of a PA diagnosis in females (Hooper, 
Hudson, Porter & McCaddon, 2014; Lahner & Annibale, 2009; Zittoun, 2001 
Carmel, 1996; Wintrobe, 1981). 
 Normality was further explored for the remaining variables in the study to 
investigate potential data skewness. The data also deviates from normality for 
the other recorded variables. It has been previously suggested that audit data 





3.4.1.1 Characteristics of the population under study 
Patients’ records (N=257; 189 females, 68 males; Mean age = 65.5 years old, 
SD=17.1) indicated that the majority of the population was White British (79%). 
Only a small proportion of the population were Asian (1.2%), Irish (0.4%) and 
Italian (0.4%). There was no information regarding the ethnic background for 
19% of the cases. More than half of the sample was married (55.6%), 25.7% 
were recorded as living alone, 7.4% were widows and 2.3% were recorded as 
living in a nursing home. Marital status indicated that 5.8% of the population 
were single, 1.6% divorced and 1.6 % living in partnership. Further, 45.5% of 
the patients were recorded as having offspring. Patients’ records regarding 
‘occupation’ were only available for 9% of the population and mainly included 
occupations in the areas of education, hospitality and healthcare. 
 
3.4.1.2 Clinical data 
The diagnoses of B12 deficiency and Pernicious Anaemia were reported in 
52.5% (n=135) and 34% (n=87) of the cases, respectively. There were no 
diagnoses of B12 deficiency or Pernicious Anaemia in 13.5% of the cases 
(n=35). Although these patients (n=35) were recorded as receiving B12 therapy, 
it was not clear why this was the case. For the effect, data regarding these 
patients were removed from the analyses. Descriptive analyses were 
computed for the remaining records of patients diagnosed with PA/B12 






Family history of PA for these patients (n = 222) was recorded for 8.1% of the 
individuals. Referrals to haematology were recorded for 26% of the cases and 
in 6% of the cases, referrals were made to gastroenterology. Time since 
diagnosis varied from 1 year to 25 years, being the most common 5 years 
(15%). The number of consultations per year varied from 1 to 23 
consultations/year, being the most common 3 consultations/year (23%).  
Data was further inspected to investigate the prevalence of B12 deficiency and 




The prevalence of B12 deficiency and Pernicious Anaemia in different age 
groups (n = 222) 
 
Prevalence                      Age groups (yrs.) 
 25-34 35-44 45-54 55-64 65-74 75-84 85-97 Total (%) 
B12 deficiency (n=135) 5.9 7.4 14.8 15.6 20.7 23 12.6 100 
PA (n=87) 6.9 10.3 15 16.1 20.7 19.5 11.5 100 
 
The above table shows some similarity in the prevalence of both diagnoses 
across different age groups. The above table seems to indicate a higher 
prevalence of both diagnoses, increasing with age up until the age of 74 yrs. 
old. However, a decline is observed in older patients. This may suggest that 
these conditions may be missed in the elderly population or due to the likely 





3.4.1.3 Diagnostic testing 
Testing undertaken to achieve a diagnosis of B12 deficiency/PA indicated that 
the serum B12 test was carried out in 61% of the cases and the complete blood 
count in 18.4% of the cases. Further tests aimed at detecting B12 deficiency, 
the intrinsic factor antibody test and gastric parietal cell test were carried out to 
a lesser extent in 12.6% and 11.1% of the cases, respectively. The main tests 
















3.5 Signs and symptoms 
Patients experienced general signs and symptoms in 37% of the cases, signs 
and symptoms involving the respiratory and circulatory systems (37%), 
involving the digestive system and abdomen (27%), involving cognition, 
perception, emotional state and behaviour (24%), skin and subcutaneous 
tissue (12%) and signs and symptoms involving the nervous system (11%). 
Signs and symptoms were broken down to include the most common signs 
and symptoms within each category. The main signs and symptoms 
experienced are presented in the graph below (Fig.3.5.1) 
 
 
Figure 3.5.1 Most common types of signs and symptoms recorded in patients’ 








This figure shows that extreme tiredness (29%), anxiety state (28%) and 
shortness of breath (20%) were the most common symptoms experienced in 
this population, followed by headaches (17%), dizziness (17%) and depression 
related symptoms (12%). These symptoms have been previously suggested to 
be linked to a diagnosis of PA/B12 deficiency (NIH, 2011). 
 
3.6 Co-morbid diseases 
Generally, the main conditions that individuals presented related to diseases of 
the musculoskeletal system and connective tissue (34%), digestive system 
(34%), circulatory system (26%), skin and subcutaneous tissue (24%), 
genitourinary system (24%), mental and behavioural (23%), nervous system 
(23%), respiratory system (21%) and eye and adnexa (18%). 
Disease categories were broken down to include the main diagnoses that 
formed each category. The main conditions experienced are presented in the 




Figure 3.6.1 Most common types of co-existing conditions recorded in patients 
diagnosed with B12 deficiency/PA. 
 
The above graph indicates that depression was one of the most common co-
existing conditions (35%) followed by hypertension (32%), arthritis (28%) and 
anxiety (23%). Other conditions included hypothyroidism (18%), angina (13%) 
and stress (8%). However, it is not clear the link between these conditions and 






Figure 3.6.1 Comorbidities of B12/PA patients 
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3.7 B12 therapy type and frequency 
B12 treatment was recorded as being administered regularly (between 1 -3 
months) in 87% of the cases and intermittent in 2.3% of the cases. Other 
frequencies of treatment related to every four months (0.9%). Regarding the 
type of B12 therapy, a great majority of the patients were receiving B12 in the 
form of injections (95.9%). 
 
Data were further explored to investigate records of patients in regular receipt 
of cobalamin therapy (1-3 months), (N = 193, M = 64 years old, SD = 17.4). 
This population was composed of 144 females with ages ranging from 25 to 97 
years old (M = 61.7, SD = 18.3) and 49 males with ages ranging from 36 to 93 
years old (M = 71, SD = 11.8). The table below presents key characteristics of 




 Key characteristics of patients diagnosed with PA/B12 deficiency in 




Absolute frequency (n) Relative frequency (%) 
Background (White British) 149 77% 
Specific diagnostic testing 30 16% 
Haematology referrals 23 12% 
Gastroenterology referrals 13 6% 




The above table shows that the majority of this population was White British 
(77%) 12% of these patients were referred to haematology and PA family of 
history was recorded in 3% of the cases.  
Specific diagnostic testing was recorded as being carried out in a small 
proportion of the population (16%). The diagram below shows the flow of 
patients undergoing specific diagnostic testing (Figure 3.7.1) 
 
 
Figure 3.7.1 Flow of patients undergoing the Intrinsic-Factor Antibody (IFAB) and 











Figure 3.7.1 Specific tests carried out to diagnose B12/PA. Generally, a positive IFAB 
result will be indicative of PA. Combining the IFAB and GPC results will strengthen 
laboratory findings (Devalia, Hamilton & Molloy, 2014). However, a negative IFAB 
result will not rule out PA (Carmel, 2008; Hooper, Porter & McCaddon, 2014). 
 
The flow chart suggests that for 12% of patients who underwent IFAB testing 
(n=23) only 2% (n=4) received an accurate PA diagnosis, signified by the 











































 However, in some cases where the IFAB was negative patients were still 
diagnosed with PA. This may reflect variations in the management of PA, 
which may potentially be determined by the lack of accuracy in diagnostic 
testing (Hooper, Porter & McCaddon, 2014). 
 
3.8 Signs and symptoms 
 
Table 3.8.1  
Signs and symptoms recorded in patients diagnosed with PA/B12 deficiency in 
regular receipt of B12 therapy 
 
Signs and symptoms(n=193) Frequency (%) 
Extreme tiredness 27% 
Shortness of breath 21% 
Dizziness 16% 
Depression related symptoms 12% 
Confusion 6% 
 
Table 3.8.1 suggests extreme tiredness, followed by shortness of breath and 
dizziness as the most common symptoms present in this population. To a 
lesser extent, depression related symptoms and confusion were recorded as 











Diseases recorded in patients diagnosed with PA/B12 deficiency in 
regular receipt of B12 therapy 
 




Type 2 diabetes 16% 
Dementia 8% 
 
The table above shows the predominance of depression in these patients, 
followed by arthritis, anxiety and type 2 diabetes and to a lesser extent, 
dementia. This section has outlined the demographic profile of patients 
diagnosed with PA/B12 deficiency by focusing on patient characteristics and 












The aim of the present study was to investigate the progression of patients 
diagnosed with B12 deficiency, from diagnosis through treatment and 
management of the condition.  Results of the present study were useful in 
terms of providing information regarding the demographic profile of these 
patients as well as to further highlight what appear to be inconsistencies with 
the management of PA. These mainly include clinical investigations that 
appear to be carried out to a lesser extent than it would have been anticipated. 
 
Patients’ records indicated that the diagnosis of B12 deficiency seemed to 
increase with age. While there is no recent research documenting the true 
prevalence of B12 deficiency in the UK, previous studies conducted suggest a 
higher prevalence of PA in the older population (Hinds, Johnson, Webb & 
Graham, 2011; Evatt et al., 2010).  However, findings also show a decline in 
the prevalence of B12 deficiency and PA at a later age (75 years old onwards), 
potentially suggesting that B12 deficiency may be underdiagnosed in the elderly 
(Iqtidar & Chaudary, 2012; Allen, 2009). This may also be related to other 
factors such as subclinical B12 deficiency (O’leary & Samman,2010), no  
routine screening for nutritional deficiencies in the elderly (Hanna, Lachover & 
Rajarethiram, 2009) or the association with other conditions that may mask the 








Previous research has also suggested that the occurrence of PA/B12 deficiency 
in young adults may be comparable to that of older adults (Allen, 2009; 
Hershko et al., 2006); however, this is not clearly reflected in the current 
findings. However, it may also be the case that these diagnoses are potentially 
missed at an earlier age. It has been previously stated that PA/B12 deficiency 
manifestations appear to be non-specific, presenting as developmental delays 
in children and adolescents (Goraya, 2002; Rasmussen, Fernhoff & Scanlon, 
2001).  
 
PA/B12 deficiency was shown to be more prevalent in females in comparison to 
males. Whilst early studies (Wintrobe et al., 1981; Carmel, 1996) have 
supported gender predominance in these conditions, other studies suggest that 
this may not be the case (Lahner & Annibale, 2009; Annibale et al., 2000; Sarit 
al., 2000; Haruma et al., 1995). It is unclear what pathogenic mechanisms may 
explain this difference, although, behavioural gender differences in seeking 
health care may constitute one possible explanation for the results of the study, 
as literature suggests that women are more likely to report health complaints in 
comparison to men (Schmetzer & Florcken, 2012; Regitz-Zagrosek, 2012; 
Zandman-Goddard et al., 2012). Previous studies addressing gender 
differences in health care utilization, have suggested the higher frequency of 
somatic morbidity and poor perceived health status as the main reasons for 
women seeking help to a higher extent than men (Koopmans & Lamers, 2007; 
Mackenzie, Gekoski & Knox, 2006; Lahelma et al., 1999). However, the link 
between somatic morbidity and gender-based misdiagnoses is scarce.  
Available research that may partly support this is mainly qualitative and refers 
to misdiagnoses of psychological distress occurring in women presenting with 




Although studies suggest a strong genetic predisposition in the development of 
the PA (Banka, Ryan, Thomson & Newman, 2011; Conrad, 2009; Wangel, 
Callender, Spray & Wright, 1968 Wittingham, Mackay, Ungar & Mathews, 1969 
Callender and Denborough, 1957), family history was only recorded for a small 
proportion of the population. Therefore, records in the present study were not 
indicative of a strong genetic link. 
 
Guidelines for the management of B12 deficiency in primary care (Grey, Wright 
& Athar, 2015) based on expert consensus, propose that referrals are 
generally determined by the cause of B12 deficiency. Referrals to haematology 
are usually forwarded in cases where patients may be pregnant, present with 
neurological symptoms or the cause of B12 deficiency is unclear. In other cases 
such as suspected malabsorption, patients are referred to gastroenterology 
(Kuipers, 2015; NICE, 2013). In the present study, only a small proportion of 
patients were referred to haematology and an even smaller proportion were 
referred to gastroenterology. However, it is unknown whether this could be 
potentially related to poor practice or no perceived need to further investigate 
these patients. 
 
However, screening for B12 deficiency may not be on the health professionals’ 
radar. Initial investigations may only include a full blood count and serum B12 
may not be routinely requested (Hooper, 2015). On a positive note, findings 
from this study indicated that the serum B12 test was requested in the majority 
of cases. According to the NHS Atlas of Variation in Diagnostic Services, 




Figures of tests ordered per 1000 patients indicated that in certain areas, B12 
levels were approximately five times more likely to be investigated when 
compared to other areas. This may be explained by health professionals 
relying solely on haematological manifestations, which do not represent an 
accurate indicator of PA/B12 deficiency (NHS, 2013). 
 
Patients’ records indicated that the IFAB was only carried out in a small 
percentage of the population. Further, negative test results were also indicative 
of a PA diagnosis, supporting previous research (Wainwright, Narayanan & 
Cook, 2015; Devalia, Hamilton & Molloy, 2014; Carmel & Agrawal, 2012; Toh, 
van Driel & Gleeson, 1997).  Alternatively, the GPC accounts for positivity in 
80% of the cases, it bears low specificity, being also positive in 10% of normal 
individuals. Thus, findings of the GPC are inconclusive (Khan, Del-Duca, 
Fenton, Holding, Hirst, Dore & Sewell, 2009).  In the present study, GPC single 
investigations were recorded to a much lesser extent. Findings from a 
retrospective study have anticipated that in cases of suspected PA, both tests 
should be measured concurrently since the IFAB tends to manifest in the 
presence of GPC antibodies (BNF, 2010; Lahner, et al., 2009). This was true 
for nearly half of the cases, where both investigations were carried out with a 
positive outcome for PA.  
Nevertheless, considering the number of PA/B12 deficiency diagnoses, this was 
carried out to a lesser degree. In view of this, the extent to which B12 deficiency 






According to the British National Formulary, test monitoring should be 
performed to ensure haemoglobin levels are maintained (BNF, 2010). Records 
in the study do not provide enough data to support that response to B12 therapy 
was effectively managed. There were gaps in the data regarding how often 
tests were monitored as well as gaps in the results of haematological 
investigations. B12 values that would reflect pre and post B12 therapy would 
have been useful to ascertain if levels were maintained over time (Aktas et al., 
2014). 
 
Despite potential caveats in the patients’ records, the majority of diagnosed 
patients were in receipt of B12 therapy, mainly in the form of intramuscular 
injections, previously suggested as being more effectively absorbed and 
metabolised when compared to oral treatment (Devalia, Hamilton & Molloy, 
2014). For most cases, B12 therapy was also administered on a frequent basis 
as per expert recommendation (NICE, 2013). One of the main complaints by 
members of the PAS reflects the need for more frequent treatment to alleviate 
perceived symptoms (Hooper, Porter & McCaddon, 2014, Devalia, 2006). 
Whilst there was no way of knowing how many diagnosed patients were also 
members of the PAS, a very small number (n=12) of GP observations in the 
patients’ records suggested that while patients’ perceived improvement in their 
symptoms since initiating B12 therapy, such as feeling more energetic, some 
also suggested relapse of symptoms a couple of weeks before treatment was 
due, feeling fatigued and depressed.  
It was interesting to note that there was no documented request for more 
frequent therapy, even though one patient was advised by her GP to have 
earlier treatment, due to the severity of symptoms presented.  
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These observations also indicated patient’s perceptions of injections being 
painful and treatment being discontinued or interrupted without apparent 
reason, despite PA diagnosis.  
It would be very helpful to investigate beliefs on how PA is managed and how it 
may affect response to treatment. Individuals’ beliefs regarding their illness 
experience have been widely investigated and associated with illness 
adjustment in conditions such as multiple sclerosis (de Seze,Borgel & Brudon, 
2012, Vaughan, Morrison & Miller, 2003) and rheumatoid arthritis (Kumar, 
Peters & Barton, 2016;Taylor et al.,2010). 
 
The most common symptoms in this study included extreme tiredness and 
shortness of breath (PAS, 2012) as well as the experience of psychological 
symptoms such as anxiety and depression (NIH, 2011; Brian & Kelly, 2000). 
One of most common co-morbidities recorded in this population indicated 
depression. PA has been previously associated with depression (Milanlioglu, 
2011; Hanna, Lachover& Rajarethinam, 2009; Durand, Brazo & Dollfus, 2003). 
However, most of the studies describing the psychiatric manifestations of PA 
including depression, delusions and anxiety, emerged from case reports 
(Mrabet, Ellouzi, Ellini & Mrad, 2015; Carneiro, Couto, Braz & Andrade, 2009; 
Durand, Brazo & Dollfus, 2003). Findings of an online survey investigating 
diagnosis and treatment of PA, have suggested depression as one of the main 
co-existing conditions present in PA patients (Hooper, Hudson, Porter & 
McCaddon, 2014). This may be not surprising, as depression has been 
highlighted as one of the most common complications, adversely affecting the 




Studies tend to report an increased prevalence of depression in individuals 
suffering with chronic conditions (Boing et al., 2011; Katon, 2011; Ali et al., 
2006). However, it is unclear whether depression in these patients reflects an 
established diagnosis. Nevertheless, psychological problems need to be 
addressed. Experiencing chronic illness may affect one’s mood and result in 
distress, making it difficult to cope with illness demands.  Other recorded 
conditions in this study included hypertension and arthritis. While 
epidemiological research supports the coexistence of PA with other conditions, 
there is no evidence of a causal link between PA and these conditions (Toh, 
2017; Angelousi & Larger, 2015; Bizzaro & Antico, 2014).  
 
While exploratory studies generate quality information, interpretation of such 
type of information may also be subjected to bias. One reason for this could 
relate to common errors in record keeping such as not updating patient 
information. Exploratory studies usually make use of a modest number of 
samples that may not adequately represent the target population. Further, the 
present study did not take the form of a clinical audit, in the absence of a 
rigorous approach to aid implementation of change in clinical practice (NICE, 
2013). Although the information presented here may be useful in terms of 
highlighting ways to improve the quality of patient care, the present audit 
(survey) was only performed in one local surgery. Further research should 
focus on scrutinizing the records of different GP practices in different areas in 






The present study has provided a good insight into the potential issues with the 
management of B12 deficiency. These issues revolve around poor practices in 
testing, diagnosis, treatment and record keeping. Further research is required 
to explore what seem to be inconsistencies in the management of B12 
deficiency. The present study is lacking on the patients’ perspectives, an 
important aspect in the assessment of care. Patient-centred measures that 
consider individual experiences emphasise the meaningful aspects of one’s 
illness. For the effect, the next pilot study will aim to investigate diagnostic and 
treatment experiences of PA sufferers to help fill the gaps that were highlighted 
in the current study, leading to a better understanding of PA/B12 deficiency. 


















Study 2: Exploring individuals’ perceptions of their PA experience: a small-
scale qualitative study 
4.1 Study aims 
To investigate the diagnostic and treatment experiences of individuals suffering 
with pernicious anaemia 
4.2 Background 
Pernicious Anaemia is a chronic condition where clinical diagnosis is difficult to 
establish, having serious consequences for patients (Carmel, 2008). Patients 
present with non-specific symptoms, increasing the chances of a delayed 
diagnosis. This has profound implications in terms of managing one’s 
symptoms, social lives and relationships (Hooper, Hudson, Porter & 
McCaddon, 2014). Given the issues regarding diagnosis and treatment 
mentioned in the previous study (study 1), this chapter aims to provide a 
rationale for the need to include patient perspectives as part of the 
management of PA. There seems to be a pattern in the literature documenting 
the experience of chronic illness patients (Pierret, 2003; Thorne et al., 2002). 
This pattern reflects the journey  from the awareness of symptoms to receiving 
an established diagnosis, negotiating treatment and the acknowledgment of 
how one’s illness disrupts one’s identity and relationships, therefore impacting 
on one’s overall quality of life. The provision of information and support is also 
crucial in this process (Miller & DiMatteo, 2013; Falk, Wahn & Liddell, 2007; 





The following studies investigate the illness experience from diagnosis through 
treatment and management, in different chronic conditions. These studies 
document recurrent problematic issues faced by PA patients, such as the 
experience of delayed diagnoses and the poor provision of healthcare support. 
 
Similar to PA, gout may be difficult to diagnose due to the lack of precise 
testing. A study by Liddle et al., (2015) has investigated the extent of 
suboptimal management in this condition, by mapping patients’ experiences 
from initial symptoms to diagnosis. Semi-structured interviews were conducted 
with 43 British individuals. The main themes that emerged from these narrative 
accounts included symptom interpretation, decisions to seek health care, 
diagnostic delays and the meaning of getting a diagnosis. Findings suggested 
that patients’ experience of severe symptoms elicited fear of being diagnosed 
with a life-threatening condition.  Diagnostic delays were influenced by financial 
pressures, the inability to get timely appointments, self-diagnosis and delayed 
treatment. In this study, gout patients also expressed lack of confidence 
regarding the accuracy of their diagnosis. This was linked to preconceptions of 
a gout diagnosis (e.g. lifestyle). Once diagnosed, patients did not feel that they 
received enough information and support to be able to deal with gout. 
Nevertheless, they actively engaged in lifestyle changes and self-monitoring of 
their condition.  
 
A phenomenological study was employed to understand the experience of 14 
individuals living with chronic obstructive pulmonary disease and how this  
condition affected patients’ lives. The main findings emerging from this study 
related to symptom control, functional disabilities and emotional trauma.  
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This study highlighted the experience of severe symptoms such as 
breathlessness resulting in fear and anxiety, reflecting changes in priorities 
such as avoiding social interaction.  Patients also conveyed loss of social roles, 
frustration and emotional trauma resulting from the need to be reliant on 
relatives for support (Avşar & Kaşikçi, 2010). 
 
 An earlier study by Cheek and Oster (2002) looked at patients ‘understanding 
of living with asthma and diabetes as well as the perception of risks associated 
with both conditions. Feelings of denial, uncertainty regarding prognosis, 
feeling stuck with the condition and changing as a person, were highlighted as 
major concerns by these patients.  
 
In a survey study, individuals reflected on approaching chronic fatigue 
syndrome from a holistic point of view. The experience of severe symptoms 
such as breathlessness was suggested to disrupt one’s pattern of daily living 
(Tuck & Human, 1998). Other psychological and social  factors that are 
commonly mentioned by patients as a consequence of living with a chronic 
condition refer to frustration whilst seeking validation for their symptoms 
(Swoboda, 2008; Dickson, Knussen & Flowers, 2007), strained relationships 
(Dejean, Giacomini, Vanstone & Brundisini, 2013; Dickson, Knussen & 
Flowers, 2007) and the experience of social stigma (Tucker, 2008; Johnson, 
2007). However, there is also optimism in these accounts. This relates to 
positive experiences emerging from diagnosis and treatment, such as 
accepting the condition and taking control, facilitating one’s adjustment 




The aforementioned studies provide an insight into the general experience of 
living with a chronic condition. While there seem to be similar features in terms 
of the diagnostic process and management of various conditions, individual 
experiences tend to be overlooked by health professionals (Wilson, 2011; 
Davis, 2006; Cheek & Oster, 2002). This has implications for clinical practice in 
terms of developing effective strategies that are patient-centred, and aim to 
improve patient outcomes. Late diagnosis, dissatisfaction with the treatment 
regime and distrust in the medical profession has been previously reported in a 
survey with the members of the PA society. While this survey represents the 
first published study to date investigating issues with diagnosis and treatment 
in this population, it does not focus on the psychosocial impact of PA (Hooper, 
Hudson, Porter & McCaddon, 2014). In the absence of previous qualitative 
research specifically exploring the experiences of PA diagnosis, study 2 aims 
to fill this gap by capturing individuals’ perceptions of their PA experience by 
conducting individual semi-structured interviews with a purposive PA sample. 
Findings from the present study will provide an understanding regarding the 
variables that may influence the illness experience in this population. This 














The present study employed a qualitative design in the form of seven face- to-
face semi-structured interviews, aiming to capture in-depth the lived 
experiences of PA sufferers. Interviews were analysed using thematic analysis, 
a widely used analytic method in qualitative research, flexible in nature, 
providing a rich and comprehensive account of the data corpus (Braun & 
Clarke, 2006). Thematic analysis is a useful method for interpreting and 
reporting meaningful themes within the data (Boyatzis, 1998). Themes were 
interpreted using a semantic approach “directed towards understanding 
informants’ perspectives of their lives, experiences or situations as expressed 
in their own words” (Taylor & Bogdan, 1984, p.77). The analysis followed six 
stages outlined by Brown and Clarke (2013; 2006). These recursive stages 
refer to the familiarisation with the data, coding, the search for themes, 
reviewing themes, defining themes and the contextualisation of themes. 
  
4.3.2 Ethical considerations 
The School of Psychology in the host institution (University of Glamorgan) 
granted ethical approval. Individuals agreed to be interviewed and provided 
their verbal consent to participate in the interviews. At the start of the interview, 
participants were informed of the purpose and aims of the research being 
carried out. The researcher asked for permission to use their accounts for 
purposes of research dissemination, ensuring data anonymity and 
confidentiality.  Participants were also informed of their right to withdraw from 
the research at any time. Data were stored according to the university 




The present study represented a sub-sample of 7 individuals who had received 
a formal diagnosis of PA, recruited through an advert posted online in the 
University of Glamorgan intranet (Appendix 2.1). These participants were 
purposefully selected, aiming to achieve information-richness (Oliver, 2011). 
Seven participants were interviewed (6 females, 1 male; age range 21-58 
years old). All participants lived in the Cardiff area. Family history of PA was 
recorded for six of the participants. 
4.3.4 Materials 
Data collection was guided through a semi-structured interview schedule that 
included open-ended questions. This interview guide was developed based on 
a comprehensive review of the PA literature and informed by the need to 
further explore the issues that were highlighted in study 1, such as the 
experience of diagnosis, provision of health information and treatment. Central 
questions in the interview guide related to the understanding of the condition, 
beliefs regarding treatment, symptom perception, locus of control and quality of 
life. These questions were discussed by members of the wider research team 
and were pilot tested in an individual suffering with pernicious anaemia. This 
allowed for the refinement of the interview schedule ensuring relevant content 
and structure. Questions asked included ‘can you please describe the process 
leading up to the diagnosis of PA?’, ‘when diagnosed, did you feel that you 
were informed by your GP about your illness? Was this information beneficial?’ 




Participants were encouraged to be open about their experiences of living with 
PA. Interviews were recorded using a Sony voice recorder (V.1.1.1) and data 
were transcribed verbatim of audio-recordings.  
 
4.3.5 Procedure 
An advert requesting PA sufferers to share their experience of living with the 
condition was posted in the University of Glamorgan’s intranet (Appendix 2.1). 
After responding to the advert, participants were interviewed in their place of 
choice. This included their home environment (5 out of 7) or their workplace (1 
out of 7) and lasted an average of 30 min each. The accuracy of the transcripts 
was checked against the recordings a few times, to ensure familiarity with the 
material before transcription. Interpretive challenges regarding the transcription 
in textual form were minimised as the researcher checked for potential errors 
several times against the recordings (Poland, 2002). Identifying information 
was removed from the transcripts and replaced with identifiers attached to 
each quote (gender, age and line number). After transcribing the interviews, 
transcripts were read several times to identify meaningful patterns within the 
data. These units of meaning were assigned to a theme and relevant sub-
category. Transcripts were read and analysed by a second researcher to both 
challenge and finally achieve inter-coder agreement, as recommended by 
Braun & Clarke (2006) and Denzin & Lincoln (2005) .After reaching a 





4.4 Research findings  
This section includes the main characteristics of the population under study 
and the outcome of the analyses of the semi-structured interviews. 
The sample includes 7 PA sufferers, 6 females and 1 male with ages ranging 
from 21 to 58 years old. The main characteristics of this population are 
described in the below table (table 4.4.1). 
 
Table 4.4.1  




Age Gender Ethnicity MS FH(relatives) AD(years) Comorbidities  
Individual 1 25 Female 
White 
British 
Married Grandmother 18 None 
 




























Individual 5 38 Female 
White 
British 
Single No  FH 38 Asthma 
 
Individual 6 56 Female  
White 
British 






Individual 7 58 Female 
White 
British 









The above table suggests that the diagnosis of PA is predominantly seen in 
females (6) as compared to males (1). The age at diagnosis seems to vary 
across different life spans for this population. Five out of seven of the PA 
sufferers are married and family history suggests a strong genetic link in 
developing the condition (6 out of 7). This table also shows that half of the 
sample revealed being diagnosed with other conditions besides PA. 
 
As a result of the analytic process, data interpretation originated five major 
themes.  These were transitions to the PA diagnosis, PA beliefs, B12 therapy, 
symptom experience and management and finally the impact of PA on 
individuals’ lives. These themes mirror individuals’ understandings of living with 
pernicious anaemia and are discussed below (Fig.4.4.1). 
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4.5 Transitions to PA diagnosis  
The superordinate theme of transitions to PA diagnosis considers the 
experience of being misdiagnosed prior to reaching an accurate diagnosis that 
would explain the experience of symptoms. The extent to which adequate 
information and support were provided at the time of diagnosis, as well as to 
what extent seeking online information was crucial towards the understanding 
of PA, is also discussed here.  
4.5.1 Misdiagnoses 
Individuals expressed their sense of frustration in not having an answer for 
their complaints. In this way, misdiagnosis seemed to reflect a traumatic event 
in individuals’ lives.  
 
“…I knew something was not right… so I went to the doctor which said, ‘you 
are getting older’.” (Female, 49) 
 
“...it was quite traumatic to begin with because I didn’t know what was wrong 
with me...” (Male, 55) 
 




While some individuals were initially given more than one misdiagnosis, 
depression seemed to be one of the most common misdiagnoses in this 
population. Nevertheless, individuals conveyed not really accepting the 





“...the first diagnosis, they thought it was Sleep Apnoea because I was 
sleeping for a long time. ...then my GP on my first visit decided that I was 
depressed and prescribed me with anti-depressants...they have mentioned 
myalgic encephalomyelitis if they didn’t find anything”. (Female, 38) 
 
“...I went back to see my GP the one that was good at the beginning and she 
said we had to investigate whether it was depression.”(Female, 21) 
 
As a result of misdiagnosis, prescribed medication didn’t seem to be of any 
help. On the contrary, in some cases it appeared to add up to the existing fear 
and uncertainty. While one individual decided to discontinue taking prescribed 
antidepressants, another individual felt not being taken seriously. 
 
“….nobody understood what was happening... started treating me for a 
nervous breakdown, put me on antidepressants which were terrifying” (Female, 
49). 
 
“I didn´t have the idea of where I was or what was happening... I didn´t want 
any more tablets...” (Female, 56) 
 
“I have been treated for almost two and a half years with anti-depressants 
which obviously didn´t work, so I didn´t know what was wrong with me” 
(Female, 38) 
 
“They did keep me on it but I stopped taking them… because they didn´t work” 
(Female, 25) 
 
“...well, I didn’t feel I was depressed... ... they have doubled my anti-






4.5.2 Arriving at a PA diagnosis  
 
Individuals considered different ways in which health professionals reached 
their PA diagnoses. Individual accounts suggested that tests carried out to 
diagnose PA mainly included blood tests. However, some seemed unsure of 
what the testing entailed or the outcome of specific tests.  
 
“After the blood test results, there appeared to be an imbalance in the red and 
white cells.” (Female, 25) 
 
“I have had lots of blood tests .It came back that my intrinsic factor, I didn´t 
have it or something...” (Female, 49) 
 
“I had the blood tests not the absorption test, so they decided they would give 
me a course of injections” (Female, 38) 
 
 “I took a blood test that was the first thing that was done, bone marrow test 
(Female, 56) 
 
Individuals also mentioned that doctors expected the presentation of symptoms 
to reflect the observed levels of serum B12. 
 
“... B12 was a bit low, the second blood test results came back at 80 
[<200pg/ml] which was the level that the GP was expecting (Female, 49) 
 
“...the doctor expected my B12 to be lowest given the amount of symptoms that 
I was displaying” (Female, 38) 
 






Whilst some of the diagnoses were known by chance, other diagnoses were 
established because of suspected heredity and through further testing, 
motivated by the presentation of persistent symptomatology, in some cases. 
 
“I was diagnosed by accident since my GP found a case similar to mine” 
(Female, 25) 
 
“It was an accidental diagnosis rather than a proper one and it worries me that 
it could have been missed and I would have carried on the way that I have 
been feeling and it is such an awful thought “(Male, 55) 
 
“…it was a straight diagnosis...my mum already suspected it” (Female, 21) 
 
“Took about 3 months and it was by chance …My sister had been checked and 
explained how I was and told her to tell me to get checked” (Female, 49) 
 
“Symptoms persisted… they doubled my medication on antidepressants... I 
was still tired, dizzy...so they searched for another possible cause” (Female, 
56) 
 
“...it’s really bad that I can't remember... I think that it could have been just a 
routine check for hormone replacement therapy...’’ (Female, 58) 
 
 
At last, reaching a diagnosis provided a sense of positivity and reassurance 
that complaints were finally acknowledged. 
 
 “...having it diagnosed and confirmed was in some sense a relief.” (Female, 
25) 
 
“...since the PA diagnosis I feel much more positive, the relief of knowing that 
something was wrong with me.” (Female, 38) 
 





4.5.3 Provision of diagnostic information and support 
At the time of diagnosis, individuals’ didn’t feel they received enough 
information from their clinicians. While some individuals suggested that basic 
information was provided and that they didn’t question the information, others 
felt the need to seek for further support. One individual conveyed getting 
information from a specialty clinician.  
 
 “No real information that I have been given after diagnosis” (Female, 25) 
 
“They explained what B12 deficiency was and that you have injections... as far 
as it goes...” (Female, 21) 
 
“He gave me a printout off the internet, you know they do, telling me about that 
so I read that and I have learnt from that” (Female, 38) 
 
 “No [information], I went to see a private consultant and he just didn’t say a lot” 
(Male, 55) 
 
 “I just went along with what the doctors said” (Female, 56) 
 
 “In fact I had more information of a nutritionist than from anywhere else” 
(Female, 38) 
 
However, the ability to discuss PA related issues didn’t seem to be encouraged 
by some health professionals in comparison to others. 
 
“...Well, it is not encouraged by the GP. I think that they just think that you have 
got the condition, you have the injections and there is no more to discuss; up 
until now and after the diagnosis I have had little or no discussion on my 




“I don´t really... in my surgery not something you wish to discuss... the myth 
that they don´t understand why people still feel the symptoms” (Male, 55) 
 
 “There are two doctors...one I wouldn’t really talk to because he is 
rubbish...the other, he is quite happy to listen” (Female, 21) 
 
“I feel that I can discuss it with my doctor if I wanted…” (Female, 49) 
 
In general, short consultation times, less monitoring and lack of awareness and 
understanding seemed to be the main reasons suggested for the perceived ill 
support provided by health-care services. 
 
 “But how many minutes to we get? It wasn’t really the lack of information but 
the lack of people listening” (Female, 38) 
 
“...the medical profession should be able to give some kind of feedback and 
review patients on a regular basis" (Male, 55) 
 
“I don’t know why it hasn’t been picked up earlier and don’t know whether or 
not doctors will expect to see it “(Female, 56) 
 
“They were nice but not particularly helpful, I felt that they wanted me to be 
depressed because that was the easy answer and they could prescribe me 
with medication” (Female, 38) 
 
 “I would hate to think that there are other people going through the same 








As a result, some individuals searched for online information and considered 
accessing support groups to help them deal with their condition. This was 
helpful for some as it provided reassurance; however, it also made them feel 
less confident in their ability to cope, due to the perceived off-putting 
information that was presented online, focused on the negative illness 
experience.   
 
“I kind of looked into it more myself… on websites and on the PA society” 
(Female, 25) 
 
“It was a real sense of relief because I have found the information pages” 
(Female, 38) 
 
 “It is nice to see that my symptoms are on the list” (Female, 56) 
 
“I felt reassured that the symptoms that were described were similar to mine, 
but whether they were too spread out, I don’t know" (Female, 49) 
 
“A lot of what you read is very negative… makes you feel like you will never be 
able to achieve certain things” (Male, 55) 
 
  
Others felt that they were already dealing with their condition and therefore did 
not feel that asking for support at the current time, would potentially be of 
benefit to them. 
 
 “I have joined [the PA Society] but I don´t engage with them… I wanted to 
access the information... but found a bit whingey for my liking...” (Female, 25) 
 




“No, probably at the beginning I would have found that quite helpful… for 7 
years I have been left to cope with this. I would see as a step backwards...” 
(Female, 49) 
 
 “Absolutely not, I am gullible about it, and there is no information anywhere" 
(Female, 58) 
 
Whilst managing a complex condition, support provided by the immediate 
family and friends seemed to be valuable. However, one individual reported 
concealing the illness from other individuals. 
 
“Definitely, I think that is really necessary [support] “(Male, 55) 
 
 “My friends and family support me; they completely accept it [my condition]... 
in work as well” (Female, 38) 
 
“S [my daughter] she took over when I was unable. My husband has the 
patience… I think it must have been very hard for him...” (Female, 49) 
 
“Yes, my mum, she is good and we talk about it and stuff” (Female, 21) 
 
“Lots of people don’t even know... my wider family knows, they probably don’t 













Brief summary discussion of the superordinate theme ‘transitions 
to PA diagnosis’ 
 
 
It may be reasonable to suggest that B12 deficiency might not be on the health 
professionals’ radar (Hooper, 2014). Further, chances of a delayed diagnosis 
may also be increased, as available testing is not reliable (Devalia, Hamilton & 
Molloy, 2014). These results support a survey study with members of the PA 
society (N=889) suggesting lack of testing at time of diagnosis (for one-third of 
respondents) and delays between experiencing symptoms and getting a 
diagnosis (10 years for one-third of respondents), (Hooper, Hudson, Porter & 
McCaddon, 2014). Previous literature has suggested an increased prevalence 
of depression misdiagnoses in individuals presenting with chronic conditions 
(Boing et al., 2011; Moussavi et al., 2007). The nature of symptoms presented 
in PA such as negative affect, irritability, fatigue and sleeping disturbances may 
overlap with other conditions such as depression (Boswick & Rackley, 2012). 
Misdiagnosis occurrences have also been documented for various chronic 
conditions such as chronic fatigue syndrome (Griffith & Zarrouf, 2008), multiple 
sclerosis (Chwastiak & Ehde, 2007) and type 2 diabetes (Parry, Peel, Douglas 
& Lawton, 2004). The outcomes from a study looking at the transition from the 
experience of initial symptoms to a diagnosis of gout in 43 British patients are 
closely related to the findings of the present study (Liddle et al., 2015).  It was 
suggested that diagnostic delays resulted in misdiagnosis and the difficulty in 
arranging timely consultations. However, unlike PA sufferers, other reasons for 
diagnostic delays related to delays in seeking medical advice due to financial 
pressures and self-diagnosis/treatment.  
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Patients were also not very accepting of their gout diagnosis, due to 
misconceptions attached to the condition (e.g. lifestyle, stigma), (Liddle et al., 
2015).   
 
A CFS study by Dickson, Knussen & Flowers (2007) also reported findings of 
delayed diagnoses and dismissive experiences, which added strain to doctor-
patient relationships when patients contested their misdiagnosis. Doctors 
seemed to have encouraged adherence to anti-depressants. However, patients 
decided to discontinue the anti-depressants. CFS patients felt reassurance 
once the diagnosis was confirmed and suggested being active agents in 
managing their condition as they changed doctors and sought  for the 
validation and support that they needed (Swoboda, 2008; Dickson, Knussen & 
Flowers,2007). Similar to PA sufferers, both gout and chronic fatigue syndrome 
patients expressed the desire for more information and support at the time of 
diagnosis as patients were not aware of limitations in diagnostic testing for both 
conditions, or that gout reflected a condition with a chronic course. Taking 
action after receiving the diagnosis was a predominant theme. Patients asked 
for referrals, searched for further information and joined discussion groups to 
help them manage their condition. A qualitative study exploring the diagnosis 
of type 2 diabetes in 40 newly diagnosed patients emphasizes the relief of 
accomplishing a diagnosis and the crucial need for information and 
management advice (Parry, Peel, Douglas & Lawton, 2004). 
 
Support from family and friends has been previously reported as providing a 
safety net for promoting self-esteem (Miller & DiMatteo, 2013; Falk, Wahn & 
Lidell, 2007), however this is not always the case.  
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Studies have also reported loss of friendships and individuals’ feeling isolated 
due to their family and friends not being able to understand what they were 
going through (Dejean, Giacomini, Vanstone & Brundisini,2013; Dickson, 
Knussen & Flowers, 2007). 
 
4.6. PA beliefs  
This theme incorporates individuals’ beliefs regarding the causes of PA and 
views regarding the condition, oneself and one’s overall health. 
4.6.1 Causes of PA 
Individuals expressed their understanding regarding what could be the possible 
causes of PA. These mainly incorporated genetic and nutrition related causes.  
Biochemical changes, stress, viral illness and nutritional deficiency were also 
perceived as potential causes of PA. However, genetics emerged as the most 
common perceived cause for developing the condition. 
 
“... I suppose there is an imbalance between the cells inside your system.” 
(Female, 21) 
 
“I had a very bad gastroenteritis, I don’t know but I have read that PA may be 
misdiagnosed as IBS, I do wonder if there was something that was triggered or 
whether or not you fit things that may not have a connection but because it is 
convenient. Whether I can say that was definitely the cause I can’t say that 
…there was a lot of stress leading up to this so whether that was a factor I 
don´t know.” (Female, 38) 
 
“… just the vitamin in my blood… don´t know if I would say it is a genetic thing” 
(Female, 58) 
 
 “Well, genetic because there is a strong link in the family” (Female, 49) 
103 
 
“I don't know if it was anything... when my mother said, I have got that, I 
thought, well it has been passed through her, so I did think that” (Female,56) 
 
 “I have been told it is hereditary as my brother and father had it.” (Male, 55) 
 
4.6.2 Views regarding the condition, oneself and one’s overall health 
One individual has mentioned the importance of not perceiving her condition as 
a disability, whilst another appeared to be aware that she had changed as a 
person. 
 
 “My supervisor wanted me to put it down as a medical illness in case I couldn’t 
fulfil work... no... I don´t class it as a disability” (Female, 38) 
 
” …it does affect you, it has changed me… I am not as spontaneous as I would 
be before. I had bags of energy” (Female, 49) 
 
Whilst no major problems were mentioned regarding one’s overall health, one 
of the participants affirmed worry of developing a serious illness. In addition, 
one participant has stated that although she perceived herself as being sick, it 
did not seem to have an impact on her overall health. 
 
“My health is good” (Male, 55) 
“I am pretty fit and well... the only thing is that I have read that there is an 
increased risk for stomach cancer... a bit of a worry” (Female, 25) 
 
 “I don’t have any other major problems" (Female, 21) 
 “I am quite a sickly person... but there is nothing majorly wrong with me...I feel 






Brief summary discussion of the superordinate theme ‘PA beliefs’ 
Individuals often make causal attributions when trying to make sense of their 
condition (Grayson et al., 2014; Hoth et al, 2011). Individual interpretations of 
the causes of PA are mainly supported by the literature, suggesting a strong 
link with genetics (Banka, Ryan, Thomson & Newman, 2011; Conrad, 2009). 
Research has suggested that gout patients attributed ‘infection’ and ‘working 
too much’ as causes for symptoms experienced (Liddle et al., 2015), while 
patients with systemic vasculitis mentioned ‘stress’ and ‘immunity’ as the main 
causes for their condition (Grayson et al., 2014). It is not uncommon for 
individuals to perceive challenges to their personal identities as a result of 
being diagnosed with a chronic condition such as multiple sclerosis, asthma or 
diabetes (Bell, Tyrrell & Phoenix, 2016; Voltzenlogel et al., 2016; Cheek & 
Oster, 2002).  
Narratives of patients living with CFS also highlight perceived changes in self-
awareness because of the stigma attached to the condition (Tucker, 2008). 
This is also reflected in two accounts of PA sufferers, in terms of their 
perception of having PA.  Individuals living with chronic conditions seem to 
overall perceive a poor health status (Barreto & Figueiredo, 2009; Machón, 
Vergara, Dorronsoro, Vrotsou & Larrañaga, 2015), however the opposite may 
also be true (Megari, 2013).  
PA sufferers in the currently study did not seem to feel that their overall health 
was compromised by their diagnosis, even though they expressed worry about 
their prognosis. The likelihood of developing gastric carcinoids as a 
consequence of PA has been previously reported in the literature and may 




Fears concerning illness progression have also been reported by individuals 
suffering from various conditions such as diabetes, chronic fatigue syndrome 
and arthritis (Papaspurou et al., 2015; Berenbaum et al., 2014; Clements, 
Sharpe, Simkin, Borrill & Hawton, 1997). 
 
4.7 B12 therapy 
B12 therapy represents an overarching theme in the present study. This theme 
includes the sub-themes of treatment frequency, response to treatment, 
disruption of treatment and symptom persistence, and request of treatment and 
its outcome.  
 
4.7.1 Treatment frequency 
The frequency of treatment seemed to vary between 6 weeks to 3 months. 
One individual mentioned that blood tests were monitored concurrently with her 
scheduled injections. However, one individual confirmed only receiving initial 
B12 treatment (loading doses) and another individual seemed to still be waiting 
to receive initial B12 treatment. 
 
 “…I go every 3 months” (Female, 25) 
 
“…only for the 3 monthly injections” (Male, 55) 
 
 “ A bit robotic, you go every three months, they give you the jab and check 
bloods every six weeks to 2 months” (Female, 49) 
 




“I haven’t been back to see her since... I will go back before my loading doses" 
(Female, 38) 
 
4.7.2 Response to B12 therapy 
Most individuals seemed to have perceived a considerable improvement in 
symptoms as a result of treatment. Receiving B12 therapy was conveyed as a 
joyful experience for one individual.  
 
“I think I was the happiest person in the world to have the PA injections, it got 
to a stage that I thought that I was going mad, I could feel that something was 
wrong with me.”  (Female, 49) 
 
“ Feel better 2/3 weeks after the injections… full of energy not just a foggy 
brain” (Female, 25) 
 
“Before it was a complete stop of your body really. It works for me... feel much 
better” (Female, 38) 
 
“You could see a noticeable difference" (Male, 55) 
 
“Having the injections have made me feel better. I have the injection and 
definitely have got more energy” (Female, 56) 
 
However, mixed perceptions regarding the benefits of B12 therapy were also 
manifested. Whilst receiving treatment seemed to work for one person, another 
person questioned her perception of symptom improvement. 
 
“…as long as I get my jabs, won’t make a difference" (Female, 21) 
 
“I think I have seen the difference but as I say I don’t know how much of that is 




4.7.3 Treatment disruption and persistence of symptoms 
Whilst receiving treatment resulted in the improvement of symptoms for the 
majority, it was also revealed that for a few individuals, treatment disruption 
resulted in symptom relapse. Two individuals revealed missing scheduled 
treatment and one individual said that her clinician initiated treatment 
disruption, reflecting inconsistencies in the management of the condition. 
 
 I have missed injections… meaning that had injections late and that made me 
feel really bad,  tiredness, toes and feet numb... dizziness” (Female, 25) 
 
“I have had a year without the injections and I have missed the timeline" 
(Female, 21) 
 
“...it was the B12 injection every three months and I did that for a couple of 
years and then the doctor said that my level was fine and that I didn’t need it 
anymore. I have had a year without the injections, and my doctor said I should 
never have stopped having the injection, and I said I did not stop it, he did. 
After my injections were stopped for about a year, then I was being breathless 
all the time and I was tired and I went back to him and he did a blood test and 
that was the problem, it was really low and I needed the B12” (Female, 58) 
 
4.7.4. Treatment request and outcome 
 
Participants felt the need to ask for more frequent injections due to perceiving 
decline in symptoms before their next scheduled treatment. Whilst requesting 
early treatment appeared to be optional for one individual, it did not seem to be 
the case for the other individuals.    
 
“I have discussed to see if I could go a week over because I am feeling a lot 




“I have asked for more frequent injections in the past… times when I need 
more energy... feel I need every 2/2.5 months. I have asked for 3 times... they 
are not willing to give me… because you may become dependent... they think 
it is psychological. My B12 levels are so high... It is not nice... my feet and toes 
go numb… doesn´t make you feel very nice... I just get on with it. If I had a 
choice I would have more frequent injections” (Female, 25) 
 
 “No I haven’t requested it, I was kind of dictated" (Male, 55) 
 
“Changing the initial treatment... there is a fear... so I am assuming that they 
know what they do" (Female, 38)  
 
Brief summary discussion of the superordinate theme ‘B12 therapy’ 
There is mixed evidence regarding treatment satisfaction in chronic illness and 
this varies according the type of condition presented, individual responses to 
treatment and it may also be dependent on factors such as self-management 
(Spessotto et al.,2016; Clarke, Yates, Smith & Chico, 2016; Schulman-Green 
et al.,2012). One individual has mentioned not being able to acknowledge 
whether treatment resulted in the improvement of physical or psychological 
symptoms. This could possibly be related to one’s illness identity. Further, 
misattributions of one’s symptoms may negatively impact on the self-
management of one’s condition (Clarke, Yates, Smith & Chilcot, 2016; Liddle et 
al., 2015; Petrie & Weinman, 1997).  
These accounts of PA sufferers are partly supported by findings in the PA 
survey (Hooper, Hudson, Porter & McCaddon, 2014). In this survey, members 
expressed dissatisfaction with their current treatment regimes and reported 




 The need to request more frequent treatment may seem unusual when 
generally there is documented evidence of poor adherence to prescribed 
treatment in chronic illness (Chiolero, Burnier & Santschi, 2016; Brown & 
Bussell, 2011; Rose, Comino & Zwar, 2005). However, literature has 
previously documented frustration with treatment in other conditions that are 
complex in nature such as chronic fatigue syndrome (Ax, Gregg and Jones, 
1997) and rheumatoid arthritis (Barton, 2009), where tailored treatment is 
crucial.  
 
4.8 Symptom experience and management 
This theme encompasses the types of symptoms perceived by individuals as 
well as ways in which they have attempted to deal with these. Individuals 
appear to have experienced similar symptoms with varying degrees of severity. 
These included general symptoms such as fatigue, symptoms involving the 
nervous system such as pins and needles, and symptoms of a psychological 
nature such as mood swings and concentration problems.  
 
“Brain fogginess, memory lapses, tiredness, feeling that I could sleep all day, 
numb fingers and toes and a bit achy... before I was diagnosed I used to pass 
out a lot, pins and needles in my legs...”(Female, 25) 
 
“Exhaustion and knock on effects of sleeping deprivation” (Male, 55) 
“Really tired... very stressful... my arm aching” (Female, 21) 
 
“Pins and needles, tiredness, falling asleep a lot, concentration, low energy, 
less tolerant and more irritable" (Female, 49) 
 
“Extreme tiredness, sleepiness, headaches, nerve pains, weepiness, more 




“Tired and lethargic and breathlessness, that's the biggest thing, I feel like that 
when my injections are due, about 2 weeks before” (Female, 58) 
 
 
4.8.1 Ways of coping 
Whilst some individuals felt they could manage their symptoms, others didn’t 
feel able to control their symptoms. Ways of coping included lifestyle changes 
such as exercising and changing one’s diet and/or giving in to symptoms. 
 
”I don’t, how do I manage it? I don’t know, I never think about it” (Female, 56) 
 
 “I don’t manage them; just make sure that I get the appointment in the diary” 
(Male, 55) 
 
“Your body wouldn’t obey you…before I would feel completely out of control 
because I didn’t understand what was going on…" (Female, 49) 
 
"When I eat certain things for a while I feel better…if I go to the gym I can do a 
lot more stuff in general” (Female, 25) 
 
 “I still go to the gym 4 times a week even if I am exhausted… I ignore them 
[symptoms]. I think it may be psychological, when you pay too much 
attention…” (Female, 58) 
 
“I have changed my diet and transformation has been dramatic… exercise is 
brilliant…everything I have to plan” (Female, 38) 
 
“I have to say that I pretty much have given into them [symptoms]... I have 






Brief summary discussion of the superordinate theme ‘symptom 
experience and management’ 
Symptoms resulting from PA have been reported elsewhere and these include 
general (e.g. extreme tiredness) neurological (e.g. pins and needles) 
psychological (e.g. mood swings) and gastrointestinal symptoms. However, 
some individuals found it difficult to deal with symptoms on a daily basis 
(Hooper, Hudson, Porter & McCaddon, 2014). Attempts to cope with symptoms 
vary from ignoring symptoms to engaging in meaning-focused coping 
(Cameron & Wally, 2014; Ax, Gregg & Jones, 2001). A study with chronic 
kidney disease patients has found that patients engaged in maladaptive coping 
such as holding on to feelings of anxiety and depression, as well using  
adaptive behaviours such as engaging with healthier lifestyles and physical 
activity (Clarke, Yates, Smith & Chilcot, 2016; Knowles et al., 2014). These 
types of coping strategies have been extensively reported in the literature (Ji et 














4.9 The impact of PA on individuals’ lives 
Mixed views regarding how PA affects one’s life seem to be noticeable. 
However, accounts’ regarding the impact PA poses on their lifestyle and close 
relationships give the impression of the burden in one’s life. 
 
4.9.1 Lifestyle Restrictions 
Individuals seem to have the understanding that PA is limiting in different ways 
from affecting one’s mood to preventing individuals’ from fulfilling their social 
roles. 
 
 “Only if I don’t have the supplement …you have to remember to organise in 
order to get your supplement or you will deteriorate rapidly” (Female, 25) 
 
“Times which is very hard to get up... feel quite irritable and I am exhausted” 
(Female, 56) 
 
“Tired and stressed about stuff” (Female, 21) 
 
 “It inhibits your lifestyle because you have to be mindful of how you are going 
to feel “(Male, 55) 
  
 “You are so limited when having a bad time” (Female, 49) 
 
 “I found that in the past my social life disappeared” (Female, 38) 
 
“Yes, it does sometimes, because when I am due for the injection I am more 
aware of myself and that I do probably less because I haven’t got as much 
energy and because of the breathlessness. I am very careful when I am in 
work, we have got lots of stairs where we are, so I go up to the 4th floor quite 
often, so when it’s getting to the end of the treatment you know I need it again 




Some individuals acknowledged that PA didn’t seem to impact on their lifestyle, 
as they accepted the condition and since moved on. 
 
“I don´t think it impacts on my life that much... only my productivity may drop at 
work” (Female, 21) 
 
 “I guess I try to get on with it" (Female, 25) 
 
 “Yes, definitely  not for the better, however I accept it maybe too easily, so that 
is what you have got, that’s how I feel, so you just carry on” (Female, 58) 
   
 4.9.2 Close relationships 
 
PA seems to affect close relationships. In one way, knowing that  family and 
friends are aware of the condition seems to ease the pressure placed on 
individuals’; however, mood changes have also been suggested to impact on 
one’s family to a greater extent.  
“My friends are aware of it now so they know that they need to give me 
warning of what is going on. It has caused difficulties but I think that they could 
see how unhappy I was” (Female, 38) 
 
“I think that the only person noticing is my partner… it might be a bit lonely for 
him” (Female, 49) 
 
“It has been hard on the family”... and still does to a certain extent” (Female, 
58) 
 
“It will cause difficulties for those close to me in terms of becoming more 








Brief summary discussion of the superordinate theme ‘the impact 
of PA on individuals’ lives’ 
PA seems to create a burden to individuals by impacting on different areas of 
their lives and consequently affecting adjustment to their condition (Hooper, 
Hudson, Porter & McCaddon, 2014). Accounts of strained relationships and 
disruptions on one’s social structure have been previously reported in the 
literature (Golics, Basra, Finlay & Salek, 2013; Wittenberg, Saada & Prosser, 
2013).  Alternatively, illness acceptance and have been found to facilitate the 
adaptation to one’s illness (Kostova, Caiata-Zufferey & Schulz, 2014; Pierobon, 



















4.10 General discussion  
 
The present study sought to investigate individuals’ experiences of living with a 
chronic condition such as PA. The superordinate themes that surfaced from 
this study related to transitions to PA diagnosis, PA beliefs, B12 therapy and 
symptom experience and management. Each of these individual themes 
contributed to the impact of this condition on individuals’ daily lives, mainly 
resulting in lifestyle restrictions and affecting close relationships. The process 
implicated in achieving a PA diagnosis reflected patients’ perceived need of 
validating and improving the severity of symptoms experienced. However, 
these decisions were dependent of clinicians’ judgements, inaccurate in most 
cases. Progressions to diagnosis involved the experience of misdiagnosis for 
the majority of individuals. Emotional trauma, feelings of uncertainty and 
isolation characterised responses to the dismissive attitudes of GP’s (Duck et 
al., 2014).  A reasonable shift in these responses was identified once a 
diagnosis of PA was achieved and B12 therapy initiated, as individuals 
expressed more positivity and energy. However, for some individuals, current 
treatment practices didn’t seem to be effective in the management of individual 
symptoms. Perceptions of symptom relapse and dissatisfaction with these 
practices that did not take into account individual variations in symptoms, 
seemed to have influenced  the way individuals’ coped with their illness 
experience , subsequently impacting on symptoms and psychological 
adjustment. The link between these superordinate themes highlights the 
influence of illness identity and locus of control as factors that are associated 
with the development of specific coping styles that may be adaptive or 
maladaptive in nature, affecting health outcomes.  
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Perceptions of low illness control may also be related to the perceived 
suboptimal management of PA (Joseph, Neeraj & William, 2014; Klok, Brand & 
Moss-Morris, 2010). Perceptions of illness control have been previously 
suggested to predict illness adjustment through behavioural responses such as 
cognitive reappraisal and seeking social support (Wiley, Cleary, Karan & 
Stanton, 2016; Diefenbach & Leventhal, 1996). Alternatively, engaging with 
denial and avoidance have been suggested to have a detrimental effect on 
illness adjustment (Kaptein, Klok, Moss-Morris & Brand, 2010; Hagger & 
Orbell, 2003). The findings of the current study have significant clinical 
implications in terms of guiding the development of psychosocial interventions 
aimed at improving perceptions of control and coping responses in PA 
sufferers. 
 
The current study draws attention to the difficulty of managing a chronic 
condition such as PA, where symptoms may be varied and non-specific 
(Devalia, Hamilton & Molloy, 2014). The attribution of symptoms to 
psychosomatic causes have contributed to the delegitimization of the illness 
and challenged one’s sense of identity (Åsbring & Närvänen, 2002; Ware, 
1992; Strauss & Corbin, 1990; Charmaz, 1983).  
Nevertheless, whilst GP’s may not initially identify pernicious anaemia, 
misdiagnosis ought not to be a justification for not further seeking a differential 
diagnosis and not listening to patients’ complaints (Otto, 2017; Carmel, 2008). 
Individuals’ scepticism regarding clinicians’ PA knowledge seemed to have 
affected the doctor-patient encounter and consequently, the management of 
the condition. However, to a lesser extent, confidence in the management of 
PA, illness acceptance and provision of valuable support have also been 
reflected in individuals’ accounts.  
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The current study findings are partly supported by a survey investigating issues 
with diagnosis and treatment with this population (Hooper, Hudson, Porter & 
McCaddon, 2014). The findings of the current study mainly fit with existing 
chronic illness research, supporting the notion of the impact of a diagnosis and 
its effect on the individual as a whole (Spessoto et al., 2016; Cameron & Wally, 
2014; Liddle et al., 2015; Grayson et al., 2014; Dejean, Giacomini, Vanstone & 
Brundisini, 2013; Golics, Basra, Finlay& Salek, 2013; Megari, 2013; Boswick & 
Rackley, 2012). 
 
This study has contributed to the understanding of the psychosocial factors 
implicated in PA and highlighted the need to improve patient experiences of a 
PA diagnosis. However, as a small-scale qualitative study, findings may not be 
generalizable. Nevertheless, this study presented information with appropriate 
depth and contextually representative of the purposive sample (Burmeister & 
Aitken, 2012), allowing replication of the current study (O’Reilly & Parker, 
2012). While thematic analysis is an appropriate method to analyse the 
perceptions of living with PA, being driven by the research question, its 
interpretive power may also be challenged. For example, it would be possible 
to infer on the use of language if another method such as discourse analysis 
was used (Poland, 2002). Previous studies have highlighted the power of 
linguistics in inviting or rejecting the patient into the process of diagnosis 
(Undeland & Malterud, 2008; Fleischman, 1999).  Further, the interpretation of 
themes would have been more reliable if feedback was requested from 





This study included participants from one ethnic group. While this is important 
regarding the primary endpoint of this thesis, which is to develop a screening 
tool that will be validated for the British population. It would also be useful to 
explore the experiences of patients from diverse ethnic backgrounds to 
investigate the role of cultural factors in defining one’s experience of a PA 
diagnosis (Davidson et al., 2007). Another potential limitation could relate to 
the retrospective nature of individuals’ accounts. However, this may also 
represent a potential strength as the sample included individuals’ that were at 
different stages of their PA diagnosis. Respondent bias could have potentially 
influenced the results, however this may be inherent to the research process 
(Bowling, 2005). 
 
Conducting focus groups to explore routes to diagnosis and treatment of PA 
would also be helpful to gain an insight on the challenges faced by health 
professionals. This way, both patients and clinicians’ perspectives would be 
considered. 
 
There is still the need to further study psychosocial factors to a larger extent in 
this population. Therefore, this study will serve as basis to develop study 3, an 
online survey aimed to further explore topics that emerged from the current 
findings, such as treatment supplementation, coping, identity, the impact of PA 
on one’s quality of life and the provision of support, through the perspective of 





Individual perceptions are key determinants on the way individuals’ manage 
their illness, directly impacting on one’s emotions and response to treatment. 
However, investigating these is not usually sought by health professionals. 
 The current study is the first to effectively address individuals’ perceptions of 
their PA experience. The qualitative nature of this study has further developed 
the understanding regarding the pathway from diagnosis through treatment 
and management of this condition, taking this research a step closer to its 
overall aim.  This has implications for clinical care in terms of considering 
effective practices that would provide tailored care, considering the individual 
variability in the response to B12 therapy. These practices ought to consider a 
holistic approach which would be valuable when treating and measuring 
outcomes in PA. Greater recognition of this condition would also strengthen the 
patient-doctor relationship, and potentially reduce the burden of disease at 
















4.11 Reflexive analysis 
 
Patients’ perspectives are crucial in the development of effective approaches 
to the management of chronic illness, and contribute to the overall aim of the 
current thesis. In the current study, I have conducted semi-structured 
interviews with individuals suffering with pernicious anaemia. There was a 
great contrast concerning data collection procedures in study 1 and the 
qualitative nature of the current study. The experience of conducting face-to-
face interviews as opposed to collecting patient recorded data was stimulating 
as I was able to further clarify any issues arising from the research and add 
more meaning to the data. This study has strengthened and developed my 
current knowledge of PA. 
 I felt that individuals were comfortable in the environment where the interviews 
took place. This most included their homes (as per choice) which may have 
provided a sense of security and control (Ecker, 2017). In this way, rapport was 
not difficult to achieve. 
  
Whilst conducting interviews allowed individuals freedom in answering the 
questions, I acknowledge that my presence may have influenced this, in 
comparison to using other data collection methods, such as self-report 
questionnaires. I have probed individuals to express deep views to obtain rich 
data. Nevertheless, it may be argued that this is part of the research process, 








Whilst there was an attempt to provide summaries of the understanding of 
individuals’ accounts throughout the interviews to ensure no information was 
missed it is acknowledged that the validity of the data would have been 
strengthened if participants were asked for their feedback on the themes that 
emerged from the data analysis, as it would further ensure addressing 
interpretive inconsistencies by challenging researchers’ assumptions. The 
interview transcripts were read by an additional experienced researcher to 
ensure data reliability.    
 
The themes reflect meaningful issues beyond the topics that were raised. 
Examples refers to the lay understanding of the nature of individual symptoms 
and worry regarding the prognosis of PA. 
It was evident from one individual account that participating in this research 
made the person consider their pattern of symptoms and acknowledge the 
perceived need to request earlier treatment. In this way, this study may have 
possibly elicited a cathartic experience.  
 
I have felt an empathic understanding toward individuals’ experiences, 
specifically regarding the lack of information and support in dealing with their 
condition. Even though I could not relate to the experience of living with a 
chronic condition, this might have helped reduce the subjectivity of the 
analysis. Nevertheless, it may also be argued the extent to which empathic 
understanding may have overemphasized individuals’ powerlessness in 




I am also aware that individuals’ expectations of improved management were 
possible despite attempts to explain that the aim of the current research was to 
develop a further understanding of the condition. 
Data generation and interpretive analysis support the theoretical framework in 































Study 3: A survey study of the PA experiences of members of the Pernicious 
Anaemia Society 
 
5.1 Study Aims 
The present study aims to investigate the experience of PA, through the 
perspective of the PAS members’. 
 
5.2 Background  
The current standard of care in PA follows the "one-size fits all regimen" 
(Hooper, Porter & McCaddon, 2014). The perceived severity of patients’ 
symptoms, the inability to control these and the constant fight to get adequate 
treatment results in increased psychological distress. This drives maladaptive 
illness responses and directly impacts on health-related quality of life. 
 
This poses profound implications for PA patients, resulting in lifestyle 
restrictions such as the inability to fulfil social roles that may influence 
individual's illness beliefs and sense of control, inhibiting coping, and affecting 
quality of life. Many individuals turn to patient organisations and/or forums for 






Existing literature has documented the beneficial impact of support groups in 
facilitating illness adjustment therefore enhancing quality of life (Beacham, 
Linfield, Kinman & Payne-Murphy, 2015; Sherman et al., 2008; Coppa & Boyle, 
2003). For example, the vitamin B12 deficiency charity support group (B12d) 
assists people who are B12 deficient due to various causes. Patient 
organisations such as the Pernicious Anaemia society (PAS, 2008) strive to 
empower individuals and help reduce the stigma of being diagnosed with PA.  
The PAS is an international charity, based in the Bridgend area that provides 
information and support for individuals diagnosed with PA as well as their 
families. The PAS was founded in 2005 by the current Executive Chairman, 
Martyn Hooper and in 2006 was part of the U.K’s charity commission. The 
members of the PAS contribute to its sustainable funding which was introduced 
in 2009. The PAS is run by volunteers and includes eight trustees across the 
UK and currently, it includes more than 7000 members. The PAS has 
developed nine sub-groups (Gloucester, Isle of Man, South Wales, Los 
Angeles, Berkshire, Anglesey and North Wales, Missouri, Worcestershire and 
Wiltshire).  The support provided by the PAS consists of  leaflet information 
which outlines a description of the condition and problems that newly 
diagnosed individuals are likely to face; local support groups to  minimise the 
social problems encountered, such as isolation, and a helpline which also 
provides a ‘call back service’.  
 
The PAS endeavours to raise awareness of the problems with diagnosis and 
treatment, by engaging with scientific research and making contact with 





One of the most common complaints of the members of the PA society refers 
to PA treatment. Whilst replacement therapy may significantly improve 
symptoms, many patients remain symptomatic, perceiving the need for more 
frequent treatment. This represents a challenge for both individuals and 
clinicians.  In many cases, individuals tend to resort to private treatment and/or 
self-treat to relieve their symptoms. Not receiving treatment tailored to one’s 
needs significantly affects one’s life in every aspect, from experiencing 
relationship problems to the inability to fulfil social roles (Hooper, Hudson, 
Porter & MacCaddon, 2014). 
A survey carried out by the PAS have suggested that approximately half of the 
respondents (N=900) reported having low levels of B12, however, further 
investigations were not carried out. This survey also indicated that 44% of the 
patients were initially misdiagnosed, 22% waited for 2 years for a diagnosis, 
19% waited for 5 years and 14% waited for 10 years or more. However, the 
occurrence of misdiagnosis may potentially relate to the experience of 
symptoms that may not be generally associated with PA. These include mood 
swings, irritability and confusion (PAS, 2012). These findings support 
preliminary research (studies 1 and 2) which emphasized misdiagnosis, lack of 
control, symptom severity, social support and the impact of PA on one’s quality 
of life.  
Considering the dearth of research in this area, and to ensure that the findings 
of preliminary studies (study 1 and 2) reflect the issues faced by PA sufferers 
in general, investigating   PAS members’ illness experiences would ensure that 
a wider audience is reached. It is unknown how many patients diagnosed with 
PA, benefit from the type of support provided by the PA society. 
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PAS affiliates may be more focused on their condition and therefore may feel 
more empowered to voice their concerns. In this way, it would be expected that 
these individuals hold different illness perceptions. 
Research with this population group would potentially strengthen existing 
findings as well as highlight any further issues with the management of PA. 
5.3 Methodology 
5.3.1 Design 
An exploratory survey design containing both quantitative and qualitative 
components aimed to investigate PAS experiences of diagnosis and treatment. 
The data was collected online via Survey Monkey and included closed and 
open-ended questions, eliciting detailed responses. Given the comprehensive 
accounts of members’ experiences, thematic coding was carried out (Braun & 
Clarke, 2006; Joffe & Yardley, 2004).  
 
5.3.2 Ethical considerations 
Ethical approval was granted by the School of Psychology in the host 
institution (University of Glamorgan) in line with the BPS guidelines (2010). 
Consent was obtained from participants via Survey Monkey. Participant data 
was kept anonymous and confidential. Participants were informed of their right 
to withdraw from the research at any time. Data were stored according to the 






The purposive sample consisted of 199 members of the PA society. This 
included 172 females and 26 males with ages ranging from 19-83 years old 
(Mean age=45.5 years old, SD=13.3). Family history was recorded for 35% of 
the cases (n=70). 
5.3.4 Materials 
An advert was placed on the PAS platform inviting members to participate in 
the survey study (Appendix 3.1). The survey instrument combined 
demographic and clinical information and included closed and open-ended 
questions. The survey development was driven by the expertise of the 
research team, informed by a comprehensive review of the PA literature as 
well as findings of study 1 and 2. Examples of questions included ‘’ do you feel 
that treatment is working? How?’ and ‘how do you cope with your symptoms? 
Please explain’. (Appendix 3.2).   
5.3.5 Procedure 
The researcher contacted the chair of the PAS to post the advert and grant 
permission for members to access the survey link. Once this was agreed, the 
study was advertised by the researcher, in the PAS members’ forum. The 
survey took approximately 30 minutes to complete and it was available for 
approximately five months (August 2012-January 2013). Once the research-
associated tasks were completed, the researcher provided the summary of the 






This sub-section includes the quantitative and qualitative components of the 
survey. These findings were integrated, where pertinent, to reflect how the 
qualitative component links with the quantitative component.  
 
5.4.1 Descriptive analyses 
Data recorded included respondents’ demographic information and PA related 
data. Data were checked for normality prior to computing descriptive analyses. 
 5.4.1.1 Normal distribution 
The Shapiro-Wilk test was computed as numerical means of assessing 
normality for the variables of ‘age and gender’ for this population. This test is 
generally employed in small sample sizes <50 (Field, 2009). 
Table 5.4.1.1. 
Normal distribution for the variables of age in gender  
 
        Observed values  
Variables Shapiro- Wilk (W) Skewness Kurtosis 
Age W = 0.985 (p=0.031) - 0.14 (SE=0.17) 
 
- 0.70 (SE = 0.34) 
 
Gender W = 0.430 (p= 0.000) - 1.90 (SE=0.17) - 0.81 (SE=  0.32) 
 
 
Note.  SE = standard error; p = significance value. 
 
The table above shows that the observed distribution for the variable ‘age’ 
does not fit the normal distribution.  
This may be explained by the age of diagnosis which points to a higher 
demographic, where the typical onset is over the age of 60 years old for both 
males and females (Hinds, Johnson, Webb & Graham, 2011).  
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The variable ‘gender’ is also non-normally distributed. The uneven distribution 
in gender in relation to the diagnosis of B12 deficiency/PA, weighs towards 
females.  
 
Therefore, the data deviates from the normal distribution in age and gender. 
Nevertheless, this sample is partly representative of the PA population, where 
a higher prevalence would occur in older individuals and females. There is 
mixed evidence regarding the predominance of a PA diagnosis in females. 
While some studies confirm this (Hooper, Hudson, Porter & McCaddon, 2014; 
Carmel, 1996; Wintrobe, 1981), others confirm this may not be the case 
(Lahner & Annibale, 2009; Zittoun, 2001). 
 
5.4.1.2 Respondent demographics 
The sample (N=199; 172 females, 26 males; Mean age =44.4 years old, 
SD=14.6) indicated that the majority of the population were British (57%), 
followed by American (7%), Dutch (6%) and Australian (5%). To a lesser 
extent, other nationalities recorded included Canadian (2%), Indian (0.9%)   
Belgian, Swedish (0.4%), Norwegian (0.4. %), Polish (0.4%), New Zealand 
(0.4%) and Italian (0.4%). There was no information regarding the ethnic 
background for 20.1% of the population. Main occupations included the areas 
of healthcare (13%), education (10%), administration (9%) and 
business/finance (8%). 10% of the individuals were retired, homemakers (4%) 




5.4.1.3 Clinical data 
Diagnostic information was available for 166 of the respondents. The diagnosis 
of PA was recorded in 56% of the cases, B12 deficiency in 9% of the cases and 
malabsorption for 1% of the cases. Approximately 4% of the population were 
still waiting for a diagnosis and for 29%, this information was missing. In 
individuals with the reported diagnoses of PA/B12 deficiency (n=154), PA family 
history was recorded for 32% of the population. 65% reported not having a 
family history of PA and 3% were unsure. Individuals suggested that B12 
deficiency investigations mainly comprised of a complete blood count (63%), 
followed by serum B12 investigations (32%) and the IFAB (18%). Time since 
diagnosis was recorded for 69% of the population and it varied between 2 
months and 30 years, being the most common being 1 year (12%). It was also 
suggested that test monitoring was not carried out since diagnosis(16%). 75% 
of the respondents reported having other existing conditions as opposed to 
25% who confirmed not having any other conditions than PA. The most 
common conditions included hypothyroidism (9%) and asthma (6%). 64% of 












5.4.1.4 Qualitative analysis 
A full thematic analysis was carried out as wide-ranging accounts of members’ 
experiences were provided. The interpretation of the data corpus reflected six 
super ordinate themes, revolving around the overarching theme of ‘the impact 
of PA on one’s life’. Themes are outlined in the below figure (Fig.5.4.1.4) 
 
Figure 5.4.1.4. Themes that reflect the diagnostic and treatment experiences of PA 
sufferers. 
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5.5 Misdiagnosis  
The theme of misdiagnosis has been quite prominent given the complex nature 
of PA. The majority of the respondents felt they were misdiagnosed, prior to 
receiving a PA diagnosis (65%), compared with 35% of the respondents, who 
didn’t feel they were misdiagnosed. Misdiagnoses ranged from a viral infection 
to depression and irritable bowel syndrome. Further, diagnostic delays resulted 
in the exacerbation of symptoms leading to neurological damage. 
Nevertheless, some individuals had to deal with the uncertainty of a diagnosis. 
 
“Anxiety, depression, chronic fatigue syndrome, IBS” (Female, 46) 
 
“They told my mother I had leukaemia” (Female 29) 
 
“Fatigue was considered to be related to psychogenic depression” (Male, 50) 
 
“Irritable bowel, no diagnosis related to breathlessness and dizziness - just 'if it 
gets worse come back' type of thing…” (Female, 22) 
 
"I have permanent nerve and neurological damage because of the delayed 
diagnoses" (Male, 37) 
 
“I was just told I was an enigma" (Female, 60) 
 
"As I am currently seeking a diagnosis again, I feel I have recently been 
misdiagnosed.  My haematologist recently referred me to a sleep specialist as 
they have suggested I am tired due to sleep apnoea (despite no evidence of 
this).  They have also suggested that I may be depressed and stressed which 
is why I am tired.  They have also said my dizziness feeling/loss of balance is 
not a known symptom of B12 deficiency and that maybe I should see a 




"I felt betrayed and talked to friends and family to find another doctor who 
finally made the diagnosis. I have permanent nerve and neurological damage 
because of the delayed diagnoses" (Female, 26) 
 
“I went so long undiagnosed so symptoms and damage are extremely severe" 
(Male, 58) 
 
"In some ways I feel I will never be truly well again due to being undiagnosed 
for so long. I feel the lack of B12 caused irreparable damage" (Female, 72) 
 
Given the non-specific nature of PA, it has been suggested that its symptoms 
may be masked to reflect in particular, other autoimmune conditions, making 
diagnosis difficult (Hooper, 2012; Banka, Ryan, Thomson & Newman,2011; 
Pacholok & Stewart,2011; Conrad,2009; PAS,2008; Stabler & Allen, 2004). PA 
sufferers may have a disposition towards developing other co-morbidities; 
however, studies undertaken have not been able to explain why this happens 
(Pacholok & Stewart, 2011; PAS, 2008; Alkhateeb et al, 2003).  Co-morbidities 
such as depression (Kurlowicz et al, 1997;Onder et al.,2005;Fafouti, 
Paparrigopoulos,  Liappas, Mantouvalos, Typaldou, Christodoulou,2002), 
vitiligo(Alkhateeb et al,2003), autoimmune thyroiditis (Zelisseen et al, 
1995),multiple sclerosis(Miller, Korem, Almog, Galboiz,2005) and diabetes 
(Tzellos, Tahmatzidis,Lallas, Apostolidou & Goulis, 2009)  have been 
associated with PA. Research conducted by the PAS has reported that more 
than 50% of individuals have been diagnosed with another illness before being 






Several studies have described patients suffering from severe neurologic 
manifestations for a long period of time because B12 deficiency was not 
included in the differential diagnosis from their primary care physicians 
(Pacholok & Stewart,2011; Fragasso,Mannarella, Ciancio & Sacco, 
2010;Matrana, Gauthier & Lafaye,2009;Paul & Reichard,2009;Turner & 
Talbot,2009; Kalita & Misra, 2008; Svenson,2007; Norman,2000).  
Common neurologic complaints include weakness, paraesthesia, motor 
disturbances and various cognitive and behavioural changes such as 
dementia, depression and personality changes (Baik, 1999, as cited by Evatt et 
al., 2010; Savage & Lindebaum, 1995). Late diagnosis may significantly affect 
one’s life, undermine the confidence in the medical profession and 
subsequently influence the doctor-patient relationship (Armstrong et al., 2017). 
 
5.5.1 Feelings of being misdiagnosed prior to PA diagnosis 
Throughout the process of misdiagnosis, individuals experienced feelings of 
hopelessness, fear, mistrust, frustration, disappointment, depression, anger, 
isolation and prejudice. While some accepted the diagnosis given at the time, 
others were determined to fight for a diagnosis that would match their 
symptoms. 
 
"I gave up trying as doctors often made me feel like a fraud" (Male, 56) 
 
"My partner thought I was dying of cancer I was too tired to care" (Female, 62) 
 
"I thought I actually had cancer. I was preparing for the worst and I didn't 
believe I had any energy to fight it anymore"(Female, 53) 
 




“I felt let down by the medical establishment “(Female, 31) 
 
"Felt dismissed. Treated like a hypochondriac. Felt lost and demoralised but 
knew that it was not in my head. Had positive results ignored by specialists as 
it did not fit with what they were looking for MS, Lupus etc..." (Female, 41) 
 
“I felt humiliated, ignored, not taken seriously and I am fed up of doctors only 
looking at the numbers of blood test results and not weighing up the relation of 
different results alongside symptoms. It is very hard to get an overview" (Male, 
56) 
 
“I feel very annoyed at previous GP surgery - I feel I have lost 3 years of my life 
– after the first course of injections I feel 10 years younger - but because of 
negligence I might have permanent nerve damage" (Female, 36) 
 
“I nearly committed suicide, I was so sick and nobody cared. I was 16" 
(Female, 29) 
 
"Are they having me on, is it because I am a woman, and a professional one at 
that, how come others get diagnosis and treatment? Do they think my 
symptoms are imaginary...’hysterical’, ‘psychiatric’?" (Female, 53) 
 
"I was frustrated as all the tests were normal yet I wasn't getting any 
better"(Male, 63) 
 
“I was isolated and alone, with no future, no one listened to my symptoms." 
(Female, 24) 
 
"I have pushed myself so no one could see how ill I was and how much I was 
breaking down inside" (Female, 52) 
 






 "I trusted the doctors to know what they were doing and just got on with it, for 
the next couple of years I learnt to live with my sore tongue and put it down to 
being run down or a bit stressed. The same applied to my sore joints I learnt to 
live with the pain" (Female, 79) 
 
"I felt I was going to have to fight to get help, to demand some quality back in 
my life" (Female, 33) 
 
"I knew something was being missed so I kept pressing" (Male, 58) 
 
“I researched causes of symptoms and asked my doctor for more tests" (Male, 
83) 
 
"I have learnt to disagree, question, do my own research and ask for further 
tests or second opinions and I have paid for private blood tests and consultants 
to prove GPs wrong. The results from St Thomas's were a catalyst for better 
treatment as they realised that I knew more about B12 than they did. It has 
been a very difficult fight" (Female, 41) 
 
 
Studies have reported feelings that come with the emotional stress that 
individuals' experience when going through the process of misdiagnosis. These 
feelings include confusion, isolation, anger, frustration, fear, anxiety, disbelief, 
numbness, shock, worry and feeling overwhelmed (Duck et al., 2015; 
Armstrong et al., 2012; Conroy, 2004; Wilson & Fletcher, 2002). Other studies 
have reported depressive reactions (Jeon, Kraus, Jowsey & Glasgow, 2010; 
Floyd, 1997) long-term anxiety, emotional trauma and self-doubt (Barais et al., 
2014; Kharrazi & Kharrazi, 2005). Illness perceptions in response to a 
diagnosis may be associated with different outcomes, which in turn change the 




Research assessing illness experience, depression and anxiety with 
individuals with CFS has mentioned the beneficial role that legitimization of the 
illness has on improved psychological health. Individuals with CFS who stated 
that their GP failed to legitimize their illness reported more psychological 
distress as compared to their counterparts (Lehman, Lehman, Hemphill, 
Mandel & Cooper, 2002).  Explanations of patients' common rejection of a 
psychiatric diagnosis are based on the interpretation of their symptoms being 
approached by doctors as mainly fictitious. Individuals experiencing chronic 
illness are often susceptible to psychosomatic interpretations of their 
symptoms, from healthcare professionals (Armstrong et al., 2017; Deale & 
Wessely, 2001).  
 
Research investigating healthcare professionals' attitudes towards chronic 
illness patients' has reported psychological labelling as a source of distress for 
these individuals, aggravating the severity of their illness. However, there is 
also evidence to suggest that doctors may face interactional challenges when 
trying to ascertain symptoms that initially may appear unexplained (Monzoni, 
Duncan, Grünewald & Reuber, 2011; White 2001). 
 
Delaying a diagnosis may result in the impairment of an individuals' health 
related quality of life (HRQoL). Reducing the diagnostic delay may significantly 
ease the burden of one’s disease (Norstrom, Lindholm, Sandstrom & Ivarsson, 
2011; Walters, Hansen, Walters & Wood- Baker, 2008). 




5.6. PA diagnosis 
The super-ordinate theme of PA diagnosis appears to be controversial since in 
most cases an early and straightforward diagnosis was not always reached. 
Reasons for this may include the lack of reliable testing and lack of awareness 
within health professionals to successfully diagnose PA. This theme 
encompasses the process of reaching a diagnosis, positive and negative 
perceptions of a B12 deficiency/PA diagnosis and emotional responses 
resulting from the same. 
 
5.6.1 Reaching a diagnosis  
Individuals experienced different ways of achieving a PA diagnosis. In most 
cases, diagnosis was provided by their GP’s following routine testing and/or 
patients' complaints of ongoing symptoms.  
 
"Dr. took bloods for high blood pressure and noticed that I had very abnormal 
blood cells" (Male, 50) 
 
"GP, after routine blood test" (Female, 22) 
 
“I have repeated the tests three times until I got a positive result for PA” (Male, 
60) 
 
"I complained of tiredness, shortness of breath and cognitive problems. My GP 
ordered pathology tests which indicated PA, based on intrinsic factor 
antibodies and low serum B12 levels" (Female, 36) 
 
 
Family history seems to be a strong element to consider when reaching a 
diagnosis of PA. In addition, individuals' awareness/knowledge of their 




“Known for almost 12 years something wasn't right related to B12 absorption 
but doctors always would blow it off.  I get B12 shots from time to time... last 
week it barely improved, so I happened to Google anaemia and stumbled upon 
PA, never heard of it before. Texted my mom to ask if we had anaemia in the 
family... she replied that my Great Grandfather died from PA and both 
her/sister were treated for it too.  This morning I already had an appointment to 
go over blood tests with the Dr. and I asked how my B12 levels looked.  She 
said they looked great, they are so high! I asked her if we could do a urine 
MMA test to check my B12 and explained my family history and my symptoms 
that get blown off.  She said because of your history and symptoms, we are 
going to start treatment today" (Female, 51) 
 
“Went to give blood, they refused my blood, advised me to go to the doctor. He 
was testing for iron and I asked him to test PA as my mother was just 
diagnosed (in her 70s.). He was reluctant but did it. When results came he 
apologised and started me on injections" (Male, 46) 
 
 
There are a range of existing routes to determine B12 deficiency, however 
these may not be entirely accurate (Pacholok & Stuart, 2011; Devalia, 2006). A 
common form of diagnosis would refer to the search of typical haematological 
abnormalities and measurement of serum B12. However, further investigations 
(e.g. MMA) and a therapeutic trial may be required (Devalia, Hamilton & 
Molloy, 2014; Savage& Lindenbaum, 1995). Nevertheless, it has been 
suggested that one of the issues with the diagnosis of PA may not be directly 
related to the nature of the tests performed but to an uncertain margin between 
B12 depletion and disease (Carmel, 2003; Matchar, McCrory, Millington & 





Some individuals also experienced an accidental diagnosis while being tested 
or treated for other co-morbidities. 
 
“Diagnosed incidentally when visiting the Rheumatologist who was following 
me up for Polymyalgia Rheumatica" (Female, 51) 
 
“I found out by accident by trying a B12 skin patch as a remedy for the fatigue 
aspect in ME, the difference in me was rapid, substantial and almost 
unbelievable" (Female, 53) 
 
“Diagnosed immediately following diagnosis of Hashimoto's Thyroiditis” (Male, 
50) 
 
“Originally saw the GP in 2006 complaining of tiredness.  Blood tests revealed 
that B12 was just below cut off point. GP told me I had post viral fatigue.  In 
2011, I saw a friend who is a doctor.  I had Vitiligo and she advised me to get 
checked for heart murmurs etc.  Looking up Vitiligo, I saw connection to PA 
and demanded a repeat blood test from my GP, subsequently diagnosed." 
(Female, 47) 
  
PA sufferers are at increased risk of developing other autoimmune conditions 
such as thyroid disorders (up to 32%), rheumatoid arthritis, vitiligo, ME 
(Pacholok & Stuart, 2011; PAS, 2009; Alkhateeb, Fain, Thody, Bennett and 
Spritz, 2003; Zelissen, Bast & Croughs, 1995) and other conditions such as 
depression (Onder et al.,2005).  Research has also reported the incidence of 
skin disorders (45%), tinnitus (40%), thyroid disorders (27%) and vitiligo (15%) 
as co-existing conditions among PA sufferers (PAS, 2012). However, studies 
undertaken have not been able to identify and/or establish a causal 







5.6.2 Positive and negative perceptions of being diagnosed with PA 
When asked about what has been positive and/or negative about the PA 
diagnosis, individuals' positive perceptions were associated to the relief of 
finally being taken seriously by health professionals, after a long struggle of 
trying to understand what was wrong with them. They also hoped that their 
symptoms would eventually get better.  
 
"Finally being diagnosed has been a relief and I feel so much better and 
healthier as a result, having felt under par and struggling for years. Also 
frustrated it took so long to be diagnosed." (Female, 37) 
 
"Relieved that there was a reason for my symptoms and I could begin to 
manage my condition” (Male, 30) 
 
"The only positive was feeling I was not making things up and the initial booster 
injections made me feel a lot better"  (Female, 26) 
 
"The positive thing is that I have regained my self-confidence. I do no longer 
believe that I am a hypochondriac. I know that I correctly can separate 
between mental and physical sensations that can occur in my body, and I do 
not have more or stronger depressions/anxieties than most people, or 
pathological mental symptoms. I’m in hope for the future." (Female, 48) 
 
Negative perceptions revolved around the idea of PA being a lifelong illness, 
the accompanying symptoms, complications that emerged as a result of a late 
diagnosis, being subject to labelling, the perceived lack of knowledge from 





“Negative is not getting enough treatment.  My levels are still very low and I'm 
still very sick, but it's difficult to get more B12 injections" (Female, 60) 
 
“Very little awareness of PA and a perception that it isn't being taken seriously 
by the medical profession" (Male, 39) 
 
“Negative - doctors’ not understanding blood test results is absolutely 
bewildering" (Male, 57) 
 
 “Being labelled hypo, depressed, wished I was diagnosed years ago" (Female, 
55) 
 
"Negatives are feeling lousy for the majority of the time, falling asleep in the 
midst of doing things and the painful injections" (Female, 46) 
 
 
5.6.3 Emotional responses 
Individuals experienced a plethora of emotions when diagnosed with PA. 
These ranged from complete happiness to fear regarding the ability to manage 
PA in the future. For many, being diagnosed meant they could be released 
from the stigma associated to their ‘unknown’ symptoms and finally be 
accepted for their condition, therefore regaining their once lost sense of 
identity. 
 
"I was delighted to have a diagnosis so I could tell people; it is not all in my 
head. I have actual proof and I can now start to get better and get back to the 
person I used to be." (Female, 48) 
 
"It didn't come as a surprise considering my grandmother's history. I was 
concerned about prognosis, and how it would affect my life. As well as my 
training, as it affects the body's ability to break down amino acids and protein, 




“Shocked due to the fact that I had to research the condition myself to find out 
what was wrong with me and relieved it wasn't psychological like doctors had 
told me" (Male, 50) 
 
"Shocked, upset and alone" (Female, 19) 
 
“I am scared for what the future holds and for the unknown damage that has 
been done that could have been prevented if the proper checks were done 6 
years ago. I have a history of type 2 diabetes and dementia in my family and 
believe I am now at a higher risk of getting these with having PA." (Female, 47) 
 
"Relieved but angry that I had suffered needlessly for months” (Female, 60) 
 
 
Despite these mixed emotions, the majority of individuals felt that PA was the 
right diagnosis. Physical and emotional changes started to happen through 
treatment, and for many it meant a new beginning. 
 
"When the injections worked it felt right, despite controversy in the practice" 
(Female, 30) 
 
“It all made sense. All my symptoms were exactly what PA is and I knew it was 
the right diagnosis" (Female, 58) 
 
"On the whole I feel better - nearly all my symptoms have gone, and those that 
remain are mild and easy to cope with. It's not stopping me doing what I want 
anymore." (Female, 48) 
 
"Physically I have improved dramatically but my highest improvement has been 
mentally and psychologically" (Female, 63) 
 




"I feel "normal" again and don't feel like I'm struggling to keep up. I used to 
think it was just me but I never knew why I didn't feel right, so I'm relieved and I 
feel I have a new lease of life." (Male, 50) 
 
Studies have documented individuals’ relief of getting a diagnosis of chronic 
illness. Similar to the statements of PA sufferers, patients reported feeling 
happy and relieved as they had a reason for their unexplained fatigue and 
could finally be freed from the label of being called a hypochondriac. 
Frustration was expressed regarding initial complaints not being further 
investigated by health professionals. 
 
 Feelings of uncertainty were also expressed regarding symptom improvement 
(Sexton & Loflin 2009; Ueland & Malterud, 2007). Illness perceptions of 
individuals play an important role in the psychological adjustment of individuals 
suffering from a chronic illness (Abbey, 1993, as cited by Edwards, Suresh, 
Lynch, Clarkson & Stanley, 2001). A study with clinically diagnosed CFS 
sufferers has established that illness perceptions can explain a significant 
variance in levels of anxiety and depression in this population. Specifically, 
illness identity and perception of illness severity were considerably associated 
with high levels of anxiety and depression (Dejean, Giacomini, Vanstone & 








5.7. B12 therapy  
This crucial theme discusses the effectiveness of B12 therapy, treatment 
disruption and the request for additional B12 therapy. The majority of the 
respondents in this study confirmed receiving B12 therapy (93%) and 88% 
reported starting treatment following the PA diagnosis. Treatment frequency 
information was specified for 93 respondents, being administered on a frequent 
basis, mainly between 1-3 months (34%).  The main forms of treatment 
included injections (56%), and to a lesser extent, oral B12 (3%) and topical B12 
(1%). In 5% of the cases respondents suggested only having received the 
loading doses of vitamin B12 and self-treatment (injections) was recorded for 
1% of the cases (n=162).  
 
5.7.1 B12 effectiveness    
Treatment effectiveness reflects an important element of PA management. 
However, some individuals are still waiting for the PA diagnosis to be 
confirmed before treatment is initiated. A minority of respondents stated 
receiving treatment prior to their PA diagnosis, as a preventative measure from 
their GPs. 
 
"No current diagnosis. I am currently being tested and on my last visit, I 
convinced the haematologist to give me a B12 shot to see how I felt. They have 
booked me in for a follow up visit but I know they are just trying to appease me 
and I felt absolutely stupid for continuing to question why I was diagnosed for 
PA in 2003 and why in 2013, I was being told I don't have it, and I couldn't 
have had it." (Female, 47) 
 




"The GP suggested starting the B12 jabs before the diagnosis came back for 
PA as my B12 levels were borderline" (Female, 26) 
 
"Started a year before 'official' diagnosis" (Female, 47) 
 
 
The majority of respondents felt that treatment was effective, resulting in 
symptom relief and having a life changing impact on their lives. However, they 
also expressed being concerned with worsening symptoms, by the time 
scheduled treatment was due.   
 
"As the injections started I started to feel human, like the old bubbly happy me" 
(Female, 63) 
 
“I’m alive" (Female, 56) 
 
“After my injection last week my balance has been a lot better and my energy 
concentration etc. is improved but I don’t know how long this will last” (Male,57) 
 
"Without treatment, individuals with a true diagnosis of PA would experience 
severe neurological symptoms and eventually the disease is fatal. I feel the 
regular injections are preventing further neurological damage and also alleviate 
the other symptoms, such as lethargy and memory issues." (Male, 50) 
 
"Yes. I can think again, my mood has stabilized, my nerves are working right, 
my fatigue mostly gone, I can eat again without getting sick, and I can lift a 
pencil without fainting." (Female, 48) 
 
"I am feeling much better but I quickly decline in the couple of weeks leading 
up to my injections" (Female, 55) 
 
"Yes, I feel much better after the jab and the symptoms start to come back as I 




“Yes. I have a buzz of energy for about 2-3 weeks after injection. For about 6 
weeks my memory and concentration are better and I don't have sensory loss 
in my arms/ hands and I don't get pins and needles for about 10 weeks.”  
(Female, 31) 
 
Considering individuals’ accounts, it becomes clear the perceived physical and 
psychological improvement of symptoms experienced by individuals' as a 
result of replacement therapy. Some studies have investigated the 
effectiveness of B12 therapy on the treatment of PA. An early study carried out 
over a 40-month period confirmed that the administration of parenteral B12 
every six weeks in patients with PA resulted in satisfactory maintenance of 
clinical and haematological remission (Conley, Green, Hartmann & Krevans, 
1952). These results are also supported by later studies. A prospective study 
using patients with B12 deficiency related to PA, found that cobalamin 
concentration in the blood had increased in 30% as compared to baseline 
levels, therefore suggesting the effectiveness of B12 therapy (Andrès, Loukili, 
Maloisel, Vinzio, Kaltenbach, Caro-Sampara & Blicklé, 2005).  
Nevertheless, some respondents felt that treatment was not working to the 
level that they hoped for, experiencing recurrent and severe symptoms. 
 
"No, it is not working I feel like I am slowly getting worse and keep going to 
doctors but he hasn't a clue and keeps saying I am depressed" (Female, 30) 
 
"No, as I am still having a lot of the symptoms especially the burning pains in 
my arms, legs and feet” (Female, 37) 
 
"No!  I feel lousy, am breathless, ridiculously tired and it is having a detrimental 
effect on me and my life." (Female. 63) 
 
"No, it is not working, I am short of cash so can't afford to pay privately for 




One of the main reasons for treatment effectiveness in PA may refer to the 
individual variability in treatment response (Hooper, 2012; Tudhope, Swan & 
Spray, 1967). Despite regular treatment, B12 stores seem to deplete before 
next treatment is due, which may explain why many patients still remain 
symptomatic (PAS, 2009, as cited by McCaddon, 2013; Stabler & Allen, 2004). 
However, current guidelines do not seem to specify the necessity for 
individualised PA management (Hooper, 2012). 
 
5.7.2 Treatment suspension 
While undergoing treatment some individuals experienced treatment disruption 
(23%; n=162). The main reasons behind this mainly included their doctors' 
judgement based on clinical results. Other reasons included socio-economic 
status and individuals' forgetfulness. 
 
"A few years ago I was given a one off injection and it was never followed up 
after until I became ill and went to doctors myself to ask for a test" (Female, 47) 
 
"Doctor said my last B12 level was too high as I was self-medicating and has 
stopped my injections. Doctor also doesn't think I have PA as my parietal cell 
antibody was negative, but she won't test my intrinsic factor, MMA, active B12 
or homocysteine levels and won't accept my word that my symptoms have 
improved, including measurable hair growth." (Female, 46) 
 
"Now that my B12 levels are 'normal' I'm not getting any injections and have 
been told to stop taking tablets" (Female, 43) 
 
“Dr. happy with my blood results he stopped all vitamin d, calcium, B12 and 




"I was initially given loading doses and 3 monthly injections, but was told I no 
longer needed them as I did not have intrinsic factor antibodies." (Female, 26) 
 
"Doctor insisted I should stop for 2 months to see if my levels dropped, which 
they did." (Female, 58) 
 
"Blood tests showed levels were normal so treatment was stopped. Went 
downhill rapidly. Had to make a fuss to get treatment started again.  This has 
happened on more than one occasion." (Female, 50) 
 
"My treatment was stopped because of lack of health insurance" (Female, 49) 
 
"I literally forget to get the shot” (Female, 47) 
 
Treatment disruption has been documented in the chronic illness literature, 
generally with the reduced likelihood of resuming therapy (Harrold, Andrade, 
Briesacher, Raebel, Fouayzi, Yood & Ockene, 2010). However, this was 
mainly initiated by patients and referred to reasons such as symptom 
intermittence (Yeung et al,2013; Kilinç & Campbell, 2008) side effects, drug 
ineffectiveness, financial problems (Yeung et al,2013; Harrold et al,2010), 
inability to get more treatment and inconvenience of treatment (Yeung et al, 
2013). According to the statements of PA sufferers, the decision to 
suspend/discontinue treatment was initiated by their GPs. Research has 
highlighted the importance of patients' active roles in the decision making 
process (DH, 2001; GMC, 2001); however, investigations of routine practice 
usually report low levels of patient participation (Collins, Drew, Watt & 
Entwistle, 2005). Patients’ perception of not accepting their doctors' decision 
may indicate that future care is compromised (Ziebland, Evans & McPherson, 




5.7.3 Requesting additional treatment and purchasing OTC treatment 
Whilst treatment may help to control symptom frequency and severity, for 
some individuals it may not be the case, as they didn’t find a significant 
improvement in their symptoms since initiating B12 therapy.  The demand for 
more frequent treatment was a common complaint among those that felt that 
the current treatment regime was not tailored to their needs. 
 
A great proportion of the population (69%) requested for more frequent 
treatment and 41% of the respondents confirmed buying OTC treatment 
(n=148). The outcome of requests is summarised below (Table 5.7.3).  
 
Table 5.7.3  
Main observations regarding the request of additional B12 therapy (n=112) 
 




GP agreed 44 29% 
GP refused 28 18% 
GP refused  due to B12 levels being within 
the ‘normal’ reference range 
 
12 8% 
GP reluctant, ordered more tests 3 2% 
Still negotiating with GP 2 1% 
 
While some doctors fulfilled their patients' request, others may have felt 
reluctant to do so. One of the main reasons for denial appeared to be that 
improvement in symptoms would be similar to a placebo effect. Therefore, 




Also, lack of provision in GP practices in case individuals at some point are 
unable to get treatment (e.g. holidays), appeared to be another reason to buy 
OTC treatment. One individual reported that when she told her GP that she 
self-medicated, her treatment was discontinued by her GP. 
 
"In fact I asked for treatment. I experienced the contact with my GP as a 
struggle. In the end, I got what I wanted: injections. Still the GP is not 
convinced it helps me. Well, it does!" (Female, 60) 
 
"Because I need daily shots. I was monitored and the doctor concluded with 
observation that the B12 was needed daily." (Female, 60) 
 
"I was so desperate that I have considered buying injections online but this was 
prior finding the sympathetic GP.  He talked me out of it and agreed to help 
me. I had already started using sublingual Methylcobalamin." (Female, 47) 
 
"Absolute worst thing has been trying to get enough B12 from my doctor - it's 
been like talking to a brick wall and I've had to resort to self-medicating." 
(Female, 63) 
 
"Doctor cannot provide it as doesn't fit with the guidelines apparently"(Male, 
50) 
 
“When I asked for more B12 he turned the monitor towards me with the letter 
from the neurologist, saying that the neurological damage is now irreversible 
and looked to see if I was reading the letter, then he shrugged. I felt so bullied 








"Most GP's in my surgery simply refused.  They spoke to me as though I was 
neurotic. One agreed to give me an additional injection but said any 
improvement would be 'psychosomatic'." (Female, 56) 
 
"Tablets didn't help all the symptoms, so I requested injections, was getting 
worsening symptoms leading up to each injection so requested more frequent 
injections or the loading doses that I should have had initially (but never got). 
Doctor refused so I resorted to self-medication and she has now stopped my 
injections as a result. I cannot even begin to explain how incredibly frustrating 
this has been. I have provided scientific evidence to my doctor on numerous 
occasions but to no avail. I'd have been better off refusing B12 blood tests and 
lying to my doctor about the self-medication." (Female, 48) 
 
"Because I couldn't get it from my doctor and it enables me to live a normal life 
again! Also it's safe as it's not possible to overdose on it." (Female, 37) 
 
"I could not live on 3 monthly injections. Gradually my mind disintegrated. Extra 
has helped moods, at least now." (Female, 62) 
 
"I buy transdermal patches to fill in, after having checked with my GP that it is 
ok to use them" (Female, 49) 
 
"Cyanocobalamin is sold OTC in Canada and is far cheaper than when 
prescribed" (Male, 65) 
 
"When I was going on holiday and didn't have access to injections. I bought 
sub-lingual tablets." (Female, 39) 
 
It may not seem surprising that in many cases individuals' request for 
additional treatment, especially for those who receive quarterly treatment. 
Experts have stated that in case of PA or severe malabsorptive deficiency, 






 It has also been suggested that after the dosing protocol, treatment should be 
administered once monthly for life (CDC, 2009; Stabler & Allen, 2004). As 
previously mentioned, some physicians still rely on ‘the one-size- fits- all’ 
regimen, which negatively affects patients’ care.  
This apparent lack of flexibility within the healthcare system often encourages 
individuals to take the responsibility for their own treatment; this may result in 
health inequalities, when considering those who do not have access to 
treatment (Hooper, 2012; Pacholok & Stuart, 2011). The main source of B12 
supplements derives from internet companies, and some of these supplements 
have not been subject to testing. However, the risks of purchasing OTC 















5.8 Symptom management  
This theme refers to the symptom experience and ways individuals managed 
their symptoms as well as the inability to control their symptoms. In the majority 
of the cases (63%), individuals felt they could not control perceived symptoms. 
The tables below (Fig 5.8.1; 5.8.2) show the frequency and severity of the main 
types of symptoms experienced by individuals. 
 
 Table 5.8.1 
 The frequency of main symptoms experienced by PAS members 
   Symptom  
frequency 








Occasionally Seldom Response 
Count 
       
Shortness of 
breath 
10 9 35 55 38 147 
       
Dizziness 6 11 34 56 38 142 
       
Extreme 
tiredness 
29 33 44 37 7 148 
       
Poor 
concentration 
15 24 47 42 21 149 
       
Confusion 10 11 35 49 42 146 
       
Mood Swings 9 23 37 51 27 147 
       
Pins and 
Needles 
18 21 24 47 35 145 
       
Sleeping 
problems 
26 19 35 43 27 149 
       
Lethargy 33 20 39 41 14 146 
       











Symptom severity of the main symptoms experienced by PAS members 
 
   Symptom 
severity 
   
Main symptoms Not 
severe 





      
Shortness of breath 47 38 45 11 6 146 
       
Dizziness 51 31 42 20 2 144 
       
Extreme tiredness 12 22 45 42 31 149 
       
Poor concentration 29 37 41 34 10 150 
       
Confusion 50 36 37 19 6 146 
       
Mood Swings 39 38 38 22 11 145 
       
Pins and Needles 42 32 41 17 14 145 
       
Sleeping problems 34 36 33 23 25 145 
       
Lethargy 22 27 34 35 30 145 
       
Unusual gait 70 21 27 10 12 138 
       
 
Both tables suggest that the most frequent symptoms perceived by individuals 
were not necessarily the most severe ones, which may suggest that individuals 
may have become habituated to experiencing severe symptoms (Jones, 
Somerville, Feder & Foster, 2010; Turner & Kelly, 2000). 
 
 
Individuals managed the frequency and severity of their symptoms in different 
ways. For some, ways of coping concerned relying on treatment or alternative 
medication, ignoring their symptoms or getting by through lifestyle choices 
such as resting, eating a healthy diet and practicing exercise. Others did not 
allow the symptoms to get the best of them, accepted their condition and 
carried on with their lives.  
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However, some struggled to lead what they would call as a normal life and 
suffered in isolation. Others relied on the support from their families and/or 
support organisations.  
 
"I listen to my body now.  When symptoms increase in frequency/severity, I 
inject more frequently and rest.  I hardly ever need to use pain relief now, 
whereas on the three monthly regime, I took 8 painkillers a day and used a 
tens machine." (Female, 32) 
 
"I am on antidepressant medication" (Female, 48) 
 
"I self-medicate according to my symptoms, it works" (Female, 41) 
 
"I just count down the days until the next jab .... I use holidays and sick days to 
get the rest I need “(Female, 56) 
 
"I do my best to ignore it and my kids have to help me to remember everything" 
(Male, 77) 
 
“Eat healthily, exercise regularly, attempt to sleep well (occasionally with the 
use of sleep aids), allow myself to have a decent rest if I am particularly 
fatigued/worn out." (Female, 49) 
 
"I do not recall much of life before PA. The memory loss makes accepting PA 
easier." (Female, 66) 
 
"I have accepted that this may take a while to sort out so I am looking after 
myself and pushing/paying for more tests when necessary." (Male, 50) 
 
"It is a way of life.  Sometimes I sit here for hours and hours thinking I am 
holding a conversation.  In reality, I sit here in silence and the conversation is 
in my head.  I find it hard to find the energy to talk, to go out, and to actually do 




"Isolation: curl up in a ball in my bed. Stay away from social things." (Female, 
29) 
 
"I've just joined the PA Society and hope to learn from others how to cope.  
Right now, I don't feel as if I'm coping very well at all - I'm just along for the 
roller-coaster ride." (Female, 56) 
 
"Have a loving husband who takes good care of me in my down times and my 
tired times. I also meditate and study Buddhism. I am also about to begin 
graduate school after obtaining my BA. So I put what energy I have into my 
studies." (Female, 32) 
 
Coping strategies have been associated with either a positive or negative 
impact one’s adjustment to chronic illness. Studies that have suggested 
positive predictors of social adjustment have included seeking social support, 
illness acceptance and lifestyle changes (Büssing, Ostermann, Neugebauer & 
Heusser, 2010; Meijer, Sinnema, Bijstra, Mellenbergh & Wolters, 2002; Yuet, 
Alexander &Pak Chun, 2002; Ahlström & Sjöden, 1996; Ray, Weir, Stewart, 
Miller& Hyde, 1993). A study exploring empowerment and perceptions of 
control in patients suffering from various chronic conditions has reported 
individuals recognizing the illness was part of them, yet a distinct part of their 
"selves", therefore feeling a sense of reconciled identity and more control over 
their illness (Aujoulat, Marcolongo, Bonadiman & Deccache, 2008). 
Depression, anxiety and low-self- esteem have been previously reported as 
negative predictors of adjustment to one’s illness (Meijer et al, 2002; Yuet et al, 
2002; Ahlstrom et al, 1996; Ray et al, 1993). Other studies have suggested 
maladaptive coping strategies such as escape-avoidance, to contribute to 
impairments in physical and social functioning (Büssing et al, 2010; Nater, 
Wagner, Solomon, Jones, Unger, Papanicolaou, Reeves & Heim, 2006; 




5.8.1 Inability to control symptoms 
Even though some respondents felt that lifestyle choices could help alleviate 
their symptoms, the majority believed that they had no control over their 
symptoms (63%; n=151), expressing great vulnerability. It may be that in some 
cases individuals felt that PA took control over their lives. 
“It is difficult to do anything when the body gives up on you and hard to stay 
positive when everything causes pain, or you are beyond exhaustion doing 
simple things." (Female, 51) 
 
"You have no control over it, you just have to grin and bear, it's out of your 
hands only the doctor can make you feel better by treating you, but when they 
don't know anything about it, treatment is hard to get." (Female, 58) 
 
"I can't control my symptoms, only the injections can hopefully relieve them. I 
can help matters though by living a healthier lifestyle and making choices that 
won't prevent the injections from working to the full potential." (Male, 50) 
 
"Although my symptoms are greatly improved, I still feel that the condition 
controls me and that I am somewhat helpless." (Female, 49) 
 
 
Some PA sufferers commented on their perceived lack of control over their 
condition, mainly attributing it to external causes. Research has documented 
individuals' experience of powerlessness over their condition, with no 
perceived resources within themselves to act towards a desired goal (Clarke, 
Yates, Smith & Chilcot, 2016; Aujoulat et al. 2008). A study by Horner (1996) 
has found that individuals with an external locus of control were more 
vulnerable to physical illness and were more likely to have maladaptive coping 
strategies (emotion-oriented) as opposed to adaptive coping strategies (task-
oriented), when compared to individuals with an internal locus of control.  
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Illness severity has also been suggested to impact on perceived control 
(Miglioretti, Mazzini, Oggioni, Testa & Monaco, 2008). It has been suggested 
that people who rate their illness as more severe are found to have less 
perceived control (Mazzotti, Sebastiani & Marchetti, 2012; Andrykowski & 
Brady, 1994 ; Helgeson, 1992). These studies imply that the severity of 
symptoms influence perceptions of low control and the experience of 
psychological distress. 
 
5.9 Provision of information and support from local health services 
This theme includes the perceived support provided by health services in 
dealing with B12 deficiency/PA and highlights ways of improving this support, 
from an individuals’ perspective. Once diagnosed, 48% of the respondents did 
not feel they received information from their GP’s. 38% felt they were informed 
about PA and the information provided was perceived as beneficial in 34% of 
the cases. However, 99% of the individuals confirmed seeking for further 
information (n=151).  
 
Individuals predominantly searched for online information (53%). This mainly 
included looking in the PAS website (42%). To a lesser extent, individuals 
looked for information in libraries (12%), another support organisation (B12d.) 
and on the NHS website however, this is not surprising since the sample in the 
current study represents an online sample. 
 
Individuals also thought that healthcare services were somewhat helpful in 
dealing with their condition (22%). However, 20% thought they were not at all 
helpful. Results indicated that healthcare services were very helpful in only 2% 
of the cases.  
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When asked what was the purpose of GP visits in relation to PA, in 72% of the 
cases it was related to scheduled treatment, in 32% of the cases, test 
monitoring, and in 29% of the cases, it was related to PA review. The 
confidence in discussing PA with clinicians was recorded for 49% of the 
population as compared to 51% who felt they could not discuss the condition; 
(n=143). 
 
Respondents provided mixed opinions regarding the quality of support 
provided by local health services and the availability of health professionals to 
discuss PA issues. While some felt that they were well informed and that they 
could trust their doctors, others felt that the information that they have received 
when first diagnosed wasn't enough and lacked clarity. Therefore, many had to 
find out more about their condition. At times, health professionals were 
perceived as being dismissive, resulting in individuals' mistrust and reluctance 
to make further enquiries. According to individuals' opinions, the lack of 
understanding and awareness of PA within the medical profession appears to 
be a detrimental issue. 
 
"My doctor knew how to take care of me" (Female, 66) 
 
“Not old doctor but new doctor starting to trust slowly so being more open with 
him" (Female, 48) 
 
"I was given very little bar a few leaflets which I lost when I ran to the bathroom 
to be sick at the horror of being diagnosed with such an illness at such a young 
age and with no supervision" ( Female, 27) 
 




"It was just the bare bones of PA, i.e. B12 deficiency caused by lack of intrinsic 
factor. I would require loading shots and an injection.” (Female, 56). 
 
"Because as far as they're concerned the symptoms are fully treated by 3 
monthly injections so you feel like a complete fraud questioning it" (Male, 30) 
 
“I can't discuss something that my GP doesn't recognise" (Female, 51) 
 
"My GP has on occasion called me a "silly girl" and has written notes that do 
not reflect our conversations.  The confusion have led me to believe I was not 
remembering things, so from now on I will attend with notes and my husband if 
he is available." (Female, 37) 
 
“I feel as if the doctors don't take PA seriously and try to fob me off with stress 
or depression rather than finding out the cause of all my symptoms" (Female, 
45) 
 
“I am not able to discuss my concerns regarding PA unless I bring medical 
articles (“evidence”) that my symptoms could be/are a possible consequence 
of PA. If I don’t bring such “evidence” I’m often told that there is no reason for 
my concerns." (Female, 58) 
 
“I feel we have reached a limit. I think that she is doing the best she can with 
the limited information that the GPs in Australia get. I don't think she 
understands the severe impact it is having on my life." (Female, 71) 
 
“I queried the reaction to high homocysteine and B12 as this is something my 
sibling has.  Answer: don't know we don't test for homocysteine in the UK." 
(Female, 44) 
 
"I feel Dr. Thinks I am a hypochondriac; I avoid visiting unless I am desperate." 
(Female, 51) 
 
"They don't listen; they don't understand it and I see a different doctor every 






Members of the PA society rated the provision of support in the diagnosis and 
treatment of PA as very poor in the majority of the cases (25%) and 
inadequate (20%). Good support was reported in 10% of the cases and very 
good support in 8% of the cases (PAS, 2011). 
 
 Other studies have also reported individuals’ lack of satisfaction with the 
management of their condition , linked with the lack of perceived social 
support in effective self-management, failure to meet their needs and 
frustration with the provision of care (Murphy, Chuma, Mathews, Steyn & 
Levitt, 2015; Snow, Humphrey & Sandall, 2013). These are some of issues 
also encountered by PA patients. 
 
In some cases, patient satisfaction is evaluated by the provision of 
informational and interpersonal skills rather than the ability to treat (Deale & 
Wessely, 2001).  Complaints revolved around delay and/or dispute over 
diagnosis, misdiagnosis, perceiving doctors as dismissive, sceptical, providing 
inadequate/ conflicting advice, not having enough knowledge about the 
condition and experiencing unhelpful and distressing consultations. These 
complaints are also present in other studies (Hooper, Hudson, Porter & 
McCaddon, 2014; Dickson, Knussen & Flowers, 2007). Patients satisfied with 
the care provided, perceived their doctors as supportive and interested in their 
condition. Annandale & Hunt (1998) reported individuals feeling dismissed by 
their GPs over diagnosis related disagreements and poor doctor-patient 
interactions in terms of not providing enough information or providing 
conflicting advice regarding their condition. 
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 Perceptions of being accurately informed, developing illness related 
knowledge and the meaning attached to the information provided have been 
found to be very important in the management of the disease, whereas the 
opposite has been found to be associated to feelings of helplessness (Aujoulat 
et al.,2008; Kharrazi and Kharrazi ,2005). Implications arise regarding the 
doctor-patient therapeutic alliance, being central to the effective management 
of a complex illness such as PA. 
 
5.9.1 Suggestions for improving the availability and quality of local health 
services 
While some individuals may have felt privileged with the care provided from 
their local health services, the majority felt the need of its improvement. PAS 
members provided suggestions, which they believed, would make a difference 
to the current management of PA. This included training of health 
professionals, treating each patient as unique, developing better protocols to 
ensure an early diagnosis and provide additional care beyond the physical 
aspects of the condition. This could potentially result in improved experiences 
in the clinical encounter as well as reduce health costs at a great level. 
 
"I am extremely fortunate to have an approachable and supportive GP/Practice 
Nurse, and therefore I can't think of any ways of improving the service which I 
have personally received in relation to my diagnosis of PA." (Female, 39) 
 







"GPs' need re-educating in B12, most are dangerously unaware of the facts 
about the illness and the best ways to diagnose/treat it. I have been shocked 
by some things doctors have said to me and I have been very distressed to 
think that others would be blindly following this disaster, lushly wrong advice 
from a person you trust." (Female, 43) 
 
"They could listen to me and how I feel. They should not be adopting the 'one 
size fits all' approach, as this may be the cause of more costly treatment. One 
Hydroxocobalamin injection = a few pence. The results of not having enough 
B12 runs into thousands of pounds, it is false economy! They need to develop a 
blood test for B12 at cellular level, not just test for the amount present in the 
blood. This could potentially save the NHS millions of £'s and they are stupid 
not to do it!" (Female, 51) 
 
"I was never offered any information about pernicious anaemia, I never saw the 
Doctor concerning my PA, and the nurse who gave me the injections seemed 
to have very little knowledge about it. When diagnosed I think the patient 
should be seen by the Doctor to have PA explained and not leave it to his staff 
who have very little or no knowledge of the condition." (Female, 49) 
 
"To use active listening skills and if after repeat complaints of the same 
symptoms over a two year span, that they seek out other areas of diagnosis to 
find out what is going on with their patients." (Female, 58) 
 
"I am in Canada, my health system fails miserably.  Again, this is because PA 
is an orphan illness, there is a (sort of) treatment, it is cheap and sort of does 
the job in keeping one alive. However, it falls through the cracks in every 
sense. There is no PA speciality and PA is not glamorous, will not get anyone 
a great fat grant, etc. Health services should address the issue of these rare 
orphan illnesses generally; there should be protocols for PA sufferers to be 
seen by every speciality involved at least when diagnosed." (Female, 45) 
 





“Listen to me, treat me as an individual and not a statistic in a guideline book." 
(Male, 50) 
 
"It is down to sheer luck of seeing one competent GP that I have been 
diagnosed. Others have sent me away either calling hypochondriac or 
suggesting oral vitamin supplements that do not work. I can't believe that 
something so obvious has been consistently missed." (Female, 42) 
 
" Early diagnosis, better care after diagnosis especially when other conditions 
have developed as a result of undiagnosed PA, better guidelines and clearer 
patients’ rights when GP care falls below acceptable standards; Health service 
should take more responsibility for incorrect/late diagnosis and make sure that 
patients are not left fending for themselves." (Female, 66) 
 
"It would be very beneficial if the GP's surgeries could start running PA clinics 
in the same way that they run other clinics such as asthma and diabetes." 
(Female, 46) 
 
Research has previously reported patients’ perceptions regarding how the 
management of chronic illness may be improved. Barriers to health care 
improvement mainly include lack of knowledge, training and poor 
communication in the medical encounter (Maimela et al., 2015; Houle et al., 
2012; Mirzaei et al., 2012). A qualitative study addressing health professionals’ 
perceptions on the management of hypothyroidism emphasised lack of expert 
knowledge, lack of patient education and over-reliance on clinical tests as main 
contributors to the suboptimal treatment of hypothyroidism in general practice 
(Dew et al., 2018). The need to factor in patient experience is vital to provide a 
holistic approach to the management of chronic illness (Coulter, Roberts & 







Individuals commented on the inability to manage PA on a daily basis, causing 
strains in their personal and social lives. This theme discusses both intimate 
and social relationships. 
 
5.10.1 Intimate and social 
The working lives of these individuals have been negatively affected. Personal 
relationships were transformed and emotions were very fragile. Individuals felt 
they underperformed at work, having to take time off to cope with symptoms 
and restore their energy.  
 
"Struggling to get back to full health and feel no energy to do nothing, it is a 
constant struggle every day." (Female, 49) 
 
"Have had to take time off work with symptoms as unable to carry out duties 
when at worst and I have been turned down for jobs and experienced 
disciplinary due to sickness absence."(Female, 55) 
 
“I cope poorly. I have to take a lot of time off, and perform at very low levels for 
work and in a social capacity. My bedtime is 8:30-9pm." (Female, 47) 
 
"It has affected how I feel on a day to day basis, I get very depressed and 
frustrated, it has affected my job, my career, relationships, social life, starting a 
family, things like going away and doing things...feel like a decrepit old woman, 
not able to live the kind of life most people do at my age, and that I would have 





"Yes in every way - I think my friends all think I'm mad as well they have had 
enough of me moaning about my health. My work has become more difficult; I 
find it hard to concentrate for any length of time." (Female, 37) 
 
“I would like to be able to keep up with my friends and family, but I can't. I am 
tired. I forget things a lot. I have about a week to 10 days each month (right 
after my injection) where I feel great and could conquer the world. Then it 
peters out." (Female, 51) 
 
“I’ve gone down to only working part time, I am unable to go out socially as 
often as I used to, I've drifted away from friends, etc.; and the symptoms 
affected my relationship." (Male, 30) 
 
"My family are affected by the restrictions this has put on me, my mood swings 
and irritability." (Male, 50) 
 
“Concentration affects my school work; my tiredness affects my playfulness 
with my son, and my mood swings make other people unhappy." (Female, 32) 
 
“I fake that I am happy in social settings.  I fake that I am getting my work done 
but I really cannot focus.  It is difficult to be taken seriously at work when you 
literally cannot string a complete thought together in a group setting (makes me 
want to cry).  My memory is so affected that I forget things moments after they 
are spoken about... I laugh along, yeah it's hell getting old, but I know that's not 
the cause." (Female, 42) 
 
"As I am often too tired to socialise I don’t have many close relationships.  I 
recently attended college and found it very hard to retain information when 
sitting exams.  I am finding it hard to find a new job as I don’t think I could 







Ell (1996) has reported the substantial impact that chronic illness places on 
families. Experiencing emotional strain, physical demands, fear, uncertainty, 
altered roles and lifestyles, all may significantly influence marital relationships, 
the family system and alter the social reality of a family.  
 
Studies have documented negative relationship interactions between 
individuals suffering with a long-term condition and their partners, resulting in 
distress (Golics, Basra, Finlay & Salek, 2013; Wittenberg, Saada & Prosser, 
2013; Waxman, Tripp & Flamen Baum, 2008; Rook 1990). 
 Individuals' perceptions of having a caring and supportive relationship also 
reflect the absence of conflict (Robinson, 2017; Luttik et al., 2005; Coyne & 
Bolger, 1990).   Literature has also pointed out the positive effects that social 
support plays on morbidity and psychosocial adaptation. Positive aspects 
relate to increased general well-being and a substantial decrease in depressive 
states (Trief, Sandberg, Greenberg & Weinstock, 2003; Ell, 1996; Revenson et 
al, 1991). Participation in employment has been reported as the main road to 
well-being. Work reflects an important area of an individual's life that gets 
affected with the presence of a chronic illness (van Campen & Cardol, 2009). 
Dealing with the emotional impact of a chronic illness may prove uncomfortable 
for many people. The consequences are withdrawal from social activities and 
professional relationships, resulting in a restrictive life fostered by insecurity 
(Aujoulat et al, 2008). Individual satisfaction is integral to social adjustment 









5.11 The impact of PA on one’s life 
The super ordinate themes mentioned in this study revolve around and seem 
to directly affect sufferers’ everyday lives. The majority of the respondents 
suggested that PA impacted on their daily lives (92%) with 81% experiencing 
lifestyle restrictions as a consequence of having PA (n=136). 
 
The detrimental effect of B12 deficiency/PA has been essentially expressed 
through the severity of symptoms and the inability to manage these. Individuals 
felt they did not have control over their bodies and even the most usual and 
minor tasks were difficult to attain. Furthermore, their sense of identity 
appeared to be fragmented. 
 
“I do not have a quality of life. I am unable to go shopping as I cannot cope in 
busy surroundings and have difficulty with walking." (Female, 58) 
 
"Walking, sleeping, breathing, inability to carry out the simplest of tasks, the 
overwhelming exhaustion, I could go on and on." (Female, 49) 
 
“Working, housework, anything that requires concentration or energy” (Female, 
47) 
 
"I am not me anymore, just a sad old woman." (Female, 63) 
 
"I am not the same person. I can't work or concentrate. My life is forever 
changed." (Male, 50) 
 
“It has been a struggle to lead a normal life and cope with exacerbated 




For individuals who experience chronic illness, maintaining a good quality of 
life is essential for disease management and improved psychosocial outcomes 
(Davison & Jhangri, 2013; (Megari, 2013; McGee, 2001). Studies have found 
impaired HRQOL to be an important predictor of co-morbidity presence (Huber, 
Wacker, Vogelmeier & Leidl, 2015; Kluger et al., 2014; Hussain et al, 2001). 
Impaired quality of life has been associated with frequent and severe 
symptomatology, distress, functional impairment, poor psychological well-being 
and mood disturbances (Blinderman et al, 2009). Living with a chronic illness 
may also influence one's sense of identity (Aujoulat et al, 2008). A study by 
Larun & Malterud (2007) with CFS sufferers has suggested that the experience 
of symptoms and stigma from significant others posed a threat to individual's 
identity. In this study, patients felt blamed and dismissed which in turn led to 
withdrawal and behavioural disengagement, having a detrimental effect on 
HRQoL.  
Nevertheless, studies also report the beneficial role of illness acceptance in 
improving HRQoL (Mroczek, Parzuchowska, Jasińska-Starczewska, Grodzki 
& Kurpas, 2017; Kurpas et al., 2013). In light of this, focusing in improving the 
management of PA may result in the enhancement of the overall quality of life 












5.12 General discussion  
The present study sought to investigate the experience of a B12 deficiency/PA 
diagnosis through the perspective of members of the PAS. The main findings 
of this study highlight issues with diagnosis and treatment that have been 
discussed in previous literature (Devalia, Hamilton & Molloy, 2014; Hooper, 
Hudson, Porter & McCaddon, 2014; Carmel, 2008) as well as in study 1 and 2. 
This relates to the occurrence of misdiagnosis and suboptimal testing and 
treatment. However, the current study adds to existing findings by offering 
more insight in terms of the frequency and severity of symptoms experienced 
by this population, symptom control, the main sources of information pursued 
to aid illness understanding and information regarding OTC treatment. Data 
suggested that the main symptoms of, extreme tiredness, poor concentration, 
pins and needles, difficulty sleeping and lethargy, were experienced more 
frequently and to a moderate degree, however these were not necessarily 
rated as more severe. Inspection of time since diagnosis in relation to symptom 
frequency and severity seemed to indicate that symptoms were rated as more 
frequent and severe in patients with a time since diagnosis between 1 and 5 
years. This was not noticed in patients with a longer time since diagnosis (> 10 
years).  This may indicate that individuals may have become used to deal with 
these symptoms (Jones, Somerville, Feder & Foster, 2010; Katon, Sullivan, 
Walker, 2001). In addition, these symptoms may be related to existing co-






Individuals also suggested that health professionals perceived their symptoms 
as being psychosomatic in nature, resulting in patient distress and resulting in 
problematic medical encounters (Armstrong, Rochnia, Harries, Bundock & 
Yorke, 2017; Banka, Ryan & Thomson, 2011; Devalia, 2006; Deale & Wessely, 
2001).  
The inability to control symptoms was also reported by the majority of the 
respondents (63%). Lack of control over symptoms in chronic conditions has 
also been reported elsewhere, being associated with increased symptom 
severity (Clarke, Yates, Smith & Chilcot, 2016; Aujoulat et al. 2008). In terms of 
searching for PA related information, results suggest that 99% of the 
population searched for information to supplement the information provided by 
their GP’s. Most of this information was pursued online mainly in the PAS 
website.  The increased use of the internet to research health concerns has 
been documented (Armstrong, Rochnia, Harries, Bundock & Yorke, 2017; 
Liddle et al., 2015; Diaz et al., 2002), and this would be expected given the 
nature of the sample in the current study. A study looking at patients’ use of 
online sources (NHS and WebMD websites) to check their symptoms indicated 
that the diagnoses suggested in relation to the presenting symptoms were 
frequently inaccurate (Powley, McIlroy, Simmons & Raza, 2016).  
 
Another study investigated whether the identification of symptoms in online 
sources would provide information for users to seek appropriate health care. 
This study identified several online websites through Google, Yahoo and Bing 
search engines. Findings suggested that these websites provided poor 
information, lacking in prescriptive guidance , therefore not effective to aid 
decisions  about whether symptoms presented required urgent attention (North 
et al., 2012).  
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The results of this study are similar to another study assessing the clinical 
performance and triage accuracy across a large number of symptom checkers. 
These were based in the UK, United States, the Netherlands and Poland, and 
were checked against standardized patient evaluations concerning common 
and uncommon conditions. Deficits were found in listing the correct diagnosis 
and for triage decisions (Semigran, Linder, Gidengil & Methrotra, 2015).  
The overreliance in seeking online information results in the unsuitable use of 
health care services and more importantly influences how patients respond to 
advice.  This has implications for the current study findings, as it is unclear the 
extent to which PA diagnoses are self-diagnoses, which may result in the 
increased self-management of the condition without correct advice (Janevic et 
al., 2014; Schulman-Green et al., 2012; Lessenger, & Feinberg, 2008). A 
significant proportion of the respondents confirmed buying OTC treatment to 
top up their current treatment, when unable to get the treatment they expected. 
However, only 10% of the individuals (n=156) confirmed exclusively self-
managing their condition. 
 
The qualitative component of the present study relates to six superordinate 
themes, which include misdiagnosis, PA diagnosis, B12 therapy, symptom 
management, provision of information and support from local health services 
and relationships. These themes reflected loss of identity as part of individuals’ 
journeys, significantly affecting individuals’ lives. These qualitative findings are 
very similar to study 2 as well as findings from various chronic illness studies 
(Robinson, 2017; Hooper, Hudson, Porter & McCaddon, 2014; Golics, Basra, 




Nonetheless, the current study expands on information regarding the feelings 
experienced because of misdiagnosis, emotional responses from being 
diagnosed with PA, treatment suspension and ways of improving the 
management of PA from a patients’ perspective. Research has previously 
documented feelings of being misdiagnosed (Duck et al.,2015; Barais et 
al.,2014; Aujoulat et al.,2008)  as well as emotional responses associated to 
receiving a diagnosis (Armstrong, Rochnia, Harries, Bundock & Yorke, 
2017;Sexton & Loflin 2009; Lehman et al.,2002).  
Treatment suspension represented an important sub-theme bearing 
implications for clinical practice. It was suggested that patient care was 
compromised when clinicians decided to interrupt treatment, despite PA 
diagnosis. This may reflect lack of understanding regarding the management of 
PA, a common observation of patients with the condition (Hooper, Hudson, 
Porter & McCaddon, 2014). Further, individuals reported not feeling confident 
to question medical decisions regarding treatment. Reasons for this may be 
related to the level of trust placed on the medical profession, resulting in poor 
communication (Maimela et al., 2015; Dickson, Knussen & Flowers, 2007). 
Suggestions to improve the availability and quality of local health services 
reflected the need for training of health professionals, the need to provide 
multidisciplinary support and to manage PA from a holistic point of view. 
Patients felt that healthcare professionals "had little appreciation for those 
aspects of illness beyond the realm of what biomedical science makes rational 
"(Thorne, Nyhlin & Patterson, 2000, p.306). This is not uncommon in the 
management of chronic illness when considering the challenging demands of 




Even though time since diagnosis varied between PAS members’, their illness 
perceptions did not seem to be dissimilar. Challenges faced by individuals as 
documented in previous research, still reflect current issues in the 
management of PA (Devalia, Hamilton & Molloy, 2014; Hooper, Hudson, Porter 
& McCaddon, 2014; Carmel, 2012; PAS, 2008; Devalia, 2006). The themes 
that surfaced from the current study findings highlight perceptions of treatment 
as vital in the improvement of symptoms, influencing positive illness responses 
and contributing to improved quality of life. 
 Alternatively, the lack of perceived support in getting treatment and/or 
receiving tailored treatment contributes to individual psychological distress and 
subsequently illness responses that may not be adaptive and therefore 
detrimental to quality of life. These themes that emphasize the relationship 
between illness perceptions, health status and coping responses will serve as 
foundations to the measurement of the aspects of illness that are meaningful to 
this population group. To address the potential limitations of the current study, 
the forthcoming study (4) will recruit patients from local GP surgeries to ensure 
that the findings are representative of the PA population. Given the central role 
played by clinicians regarding patients’ journeys to diagnosis, future research 
should also include their perspectives regarding the management of B12 
deficiency/PA. 
 
The design of the current study was flexible, allowing for data collection of a 
distinctive population. The PAS members represented a varied sample in 
terms of ethnic background, with varied age groups, being active members of a 
support system. Patient organisations such as the PAS empower individuals 
and help reduce the stigma of being diagnosed with PA (Hooper, 2012). 
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 It may be reasoned that individuals’ belonging to support groups may feel 
more in control of their condition. Therefore, their views may be more assertive 
in comparison to the views of individuals who do not engage with support 
groups (Grande, Myers & Sutton, 2006; Voerman et al., 2006).  However, in 
terms of illness experience, PAS members’ experiences didn’t seem to be that 
dissimilar to the ones of individuals’  with no membership to support groups, as 
in study 2. Perceived lack of control over their illness and the difficulty in 
dealing with everyday life challenges were reported by many individuals in the 
current study.  
Informational support may represent a key factor contributing to the illness 
understanding of PAS members. This may have helped some individuals to be 
more active in terms of developing awareness of the condition, conveying their 
needs to their GP’s and/or making decisions regarding the self-management of 
their condition.  
 
The current study provided a neutral environment for individual responses, 
reducing the potential stigma that individuals may face. However, it may be 
limited by self-selection bias as well as it may have also missed accounts of 
individuals that do not have access to the internet (BPS, 2013; Wright, 2005). 
Nevertheless, this sample provided substantial evidence that is well supported 
by previous research conducted in the area of chronic illness, by existing PA 








The study presented here expands on the growing body of PA knowledge by 
emphasizing the need to measure psychosocial variables. The experience of 
ongoing symptoms and variability in response to treatment may result from 
different factors such as time since diagnosis, the way individuals perceive 
their condition, the way they cope, the potential tendency to somatise 
symptoms and associated risk for anxiety/depression. To date, studies 
presented in this thesis have been of an exploratory nature. Therefore, the 
forthcoming study (study 4) aims to measure illness perceptions, health status, 
coping strategies, locus of control and somatic focus and investigate to what 
extent these variables may form the basis of a patient-centred tool for the 
identification and management of health-related quality of life in this population. 
B12 deficiency constitutes a major public health problem and currently there is a 
lack of awareness within the medical profession to identify and treat PA 
(Carmel, 2008).  
 Further, current guidelines may not be explicit to reflect individual treatment 
needs (Hooper, 2014). Since there is no tool to assess the severity of patients’ 
symptoms, developing a condition-specific tool in a new area of clinical 
research may prove valuable to patients by providing tailored treatment, 
therefore improving health-related quality of life. It may also benefit health 










5.13 Reflexive analysis 
Before the start of the current research, I joined the PAS to access the 
members’ forum.  After the survey was posted online, I have perceived 
members’ defensiveness concerning the nature of the research being 
conducted. I am aware that investigating PA perceptions may have triggered 
prior negative experiences such as patients’ symptoms being addressed by 
clinicians as psychosomatic in nature. This represented a challenge in terms of 
being able to address potential lay understandings regarding the focus of 
research. Hence, any future research conducted with this population 
considered this aspect by using unbiased wording when informing or providing 
feedback regarding the research outcome. 
 
Considering that the present study was a web-based survey, it may have 
reduced the likelihood of the data collection process being affected by the 
presence of the researcher. I have ensured that each involved question 
presented to participants did not represent a theme in its own account. A report 
of the findings of the current research was posted by the Chair of the society in 
the members’ area. Feedback regarding these findings was approached with 
great positivity and it was mentioned that these findings helped strengthen 
preliminary research conducted by the PAS. This feedback has helped to 
ensure that the current study findings provided rich detailed information, being 
reflective of individuals’ experiences. 
Members of the PAS may have had increased expectations of improved 
healthcare from participating in this research. While this is difficult to avoid, I 
ensured that the main purpose of the research was to further the 
understanding of PA. Increasing awareness regarding the issues faced by PA 





Study 4: Investigating illness severity and health-related quality of life in 
patients diagnosed with Pernicious Anaemia 
 
6.1 Study Aims 
The primary endpoint of the present study is to develop a patient-centred 
outcome measure for the identification and management of health-related 
quality of life in patients suffering with pernicious anaemia. The secondary 
endpoint is to identify the best predictors of HRQoL in this population. 
 
6.2 Background 
Existing PA research has primarily approached issues regarding the diagnosis 
and treatment from a medical point of view. Pilot work presented in this thesis, 
highlighted patients experiencing severe symptoms, resulting in major life 
disruptions. For many patients, symptom management through B12 therapy 
appears to be suboptimal (Hooper, Hudson, Porter & McCaddon, 2014). The 
goal of PA treatment is to limit symptoms, delay the progression of disease and 
optimise one’s health-related quality of life. Assessing the impact of PA on 
one’s life is key to establishing the severity of one’s condition. Health-related 
quality of life measures provide an understanding of how an illness impacts on 
one’s daily living. Employing generic measures allows the comparison of 
HRQoL across different conditions. However, generic measures assess quality 
of life independent of condition-specific characteristics; therefore, important 




Condition-specific measures possess the advantage of capturing subjective 
evaluations that are appropriate to the illness under study (De Gutch, 2015). 
Most conditions have a HRQOL measure to assess the illness burden 
(Bradley, Todd, Gorton, Symonds & Plowright, 1999; Wong, Guyatt, Cook, 
Griffith & Irvine, 1998; Juniper, Guyatt, Epstein, Ferrie, Jaeschke & Hiller, 
1992). However, very little is known regarding the HRQoL of patients suffering 
with pernicious anaemia. There is a gap in research addressing the 
psychosocial impact of PA on individual's adjustment. Therefore, it is 
anticipated that developing a patient-centred instrument for the identification 
and management of health related quality of life in patients suffering with PA 
would further the current understanding of this condition. Clinicians’ accounts 
fail to capture the impact of disease from a patient’s perspective (Heijmans et 
al., 2001). To improve one’s quality of life there is a need to identify modifiable 
determinants, and illness representations have been suggested as valuable 
determinants of an individuals’ quality of life (Schoormans et al., 2014). 
Explanations for the variability in responses to a health threat have been put 
forward by the common sense model developed by Leventhal (Leventhal, 
Meyer and Nerenz, 1980). The central principle of this theory refers to the 
impact of illness representations on individual’s coping responses, which in 
turn may influence judgement-based outcomes such as emotional reactions 
and quality of life (Llewellyn, McGurk & Weinman, 2007). According to this 
model there is a consistent pattern in the way individuals’ organise their illness 
perceptions and this refers to illness identity (type of illness and associated 
symptoms), cause of the illness and how long it will last, beliefs regarding 
personal consequences of the illness for both the individual and their family, as 





The Common sense model has been successfully applied in a variety of 
conditions from Irritable Bowel Syndrome (IBS;Rutter & Rutter, 2002) to Cystic 
Fibrosis (Sawicki, Sellers & Robinson,2011), Chronic Fatigue Syndrome 
(CFS;Moss-Morris, Petrie and Weinman ,1996), Multiple Sclerosis (MS; 
Vaughan, Morrison & Miller, 2003) and Congenital Heart Disease 
(CHD;Schoormans, Mulder, Melle, Pieper, Dijk, Sieswerda, Hulsbergen-
Zwarts, Plokker, Brunninkuis, Vliegen & Sprangers, 2012). 
 Illness perceptions, psychological status and quality of life, were explored in a 
sample of 102 outpatients suffering from inflammatory bowel disease. This 
study employed a disease- specific HRQoL measure for this population. This 
questionnaire covers specific symptoms as well as emotional status, activities 
of daily-living, personal interaction and social performance. Findings suggested 
positive associations between dimensions of quality of life (bowel function, 
social function, emotional function and systemic function) with timeline 
perceptions and treatment control. Individuals’ beliefs that their illness would 
last a short time were associated with better HRQoL. Patients’ beliefs that 
medication controlled their condition reported improved quality of life. 
Alternatively, patients who did not perceive that medication controlled their 
illness were more likely to present with depressive symptoms (Rochelle & 
Fidler, 2012). Negative correlations were also found between depression, 
personal control and emotional function. Individuals who felt they did not have 
any control over their illness reported experiencing more depressive 
symptoms. A prospective longitudinal study reported depression and anxiety 
as significant predictors of HRQoL in patients who were admitted to hospital as 
a result of experiencing chronic obstructive pulmonary disease. This study 




Depression was significantly associated with worse psychological and 
environmental health at baseline, and follow-up (at 6 and 9 months), 
(Andenaes et al., 2006).  Another study explored associations between 
defensive coping and HRQoL in patients with chronic kidney disease. 
Defensive coping was assessed using the rationality/emotional defensiveness 
scale and the 36-item short-form survey served as the general measure 
assessing HRQoL. Higher defensive coping was associated with worse mental 
health. A higher score on defensive coping indicated better physical health.  
 
Studies that lend support to previous findings have explored associations 
between illness beliefs, measures of health status, coping and adjustment. 
Rutter and Rutter (2002) measured the illness representations, health status, 
coping and perceptions of quality of life in two-hundred and nine irritable bowel 
syndrome sufferers recruited from an IBS self-help network. Respondents who 
felt that their illness had serious consequences reported less satisfaction with 
health, higher levels of anxiety, depression, and poor quality of life. Individuals 
who had weak control beliefs stated lower satisfaction with health, greater 
depression and poorer quality of life. Individuals who believed that their illness 
was caused by stress reported higher levels of anxiety and depression. In this 
study, serious illness consequences were associated with the coping strategies 
of “venting emotions”, “restraint” and “mental and behavioural disengagement”. 
Acceptance of the illness was associated with reporting fewer illness 
consequences. A belief that the illness would last for a short period of time was 
positively related to “seeking instrumental support” and negatively associated 
with illness acceptance. 
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 Anxiety and depression were both related to a belief in psychological causes 
and serious illness consequences. Depression was also linked with 
perceptions of low control. Another study including ninety-nine Multiple 
Sclerosis (MS) sufferers explored the predictive value of illness beliefs in 
determining outcome as measured by illness intrusiveness, physical 
functioning, depression, anxiety and self-esteem. Findings suggested that 
participants associated MS with a wide range of symptoms that would last for a 
long time, with no specific cause and unlikely to be cured. Participants felt that 
they could not control MS and that it had a detrimental impact on various facets 
of their lives. The belief that MS had serious consequences was associated 
with higher levels of illness intrusiveness, greater impairment in physical 
functioning, reduced self-esteem and higher levels of anxiety and depression. 
An important finding of this study implies that the perception of experiencing 
severe symptoms, perceiving severe consequences for one’s life, perceiving 
the illness to last a long time and experiencing low control over MS, predicted 
high levels of depression (Vaughan, Morrison & Miller, 2003). Leventhal’s 
model has also been useful in describing how individual’s respond to somatic 
symptoms regardless of their aetiology. The model suggests that individuals 
tend to develop a cognitive and emotional representation that elicits behaviours 
to cope with these type of symptoms (Broadbent, Petrie, Main & Weinman, 
2006; Leventhal, Brissette & Leventhal, 2003, as cited by Zhang ,Fritzsche, 
Leonhart, Zhao, Zhang, Wei, Yang, Wirsching, Nater-Mewes, Larisch & 
Schaefert, 2014). A study by Zhang and colleagues (2014) has investigated 
the relationship between somatic symptom severity, quality of life and 







This study aimed to explore how patients with high somatic symptoms differed  
from patients with low somatic symptoms  in terms of illness perceptions  and 
illness behaviour, emotional distress( anxiety and depression) and quality of 
life; High somatic symptom severity was significantly associated with 
catastrophizing and illness vulnerability; low physical quality of life was 
associated with avoidance of physical activity and low mental quality of life was 
associated for the need of immediate medical assistance.  Results also 
suggested that illness worries and dysfunctional illness behaviour (e.g. safety 
seeking, repeated doctor visits and fear avoidance) were associated with high 
somatic symptom severity and poor quality of life (Zhang et al., 2014).  
 
Research studies previously outlined have addressed the importance of illness 
beliefs in the understanding and management of chronic illness; however, 
existing research may not be significant to the PA population since the targeted 
focus of disease-specific investigations is what makes them clinically relevant 
(Razvi, McMillan & Weaver, 2005). The identification of disease-specific factors 
that influence HRQoL and enable health professionals to tailor treatment 
according to individual needs is central in improving the quality of care, 
optimising clinical outcomes. Research has previously suggested that including 
validated measures as basis for the development of HRQoL measures, reflects 
good practice (Kamudoni, Mueller & Salek, 2015). The present study aims to 
administer quantitative measures to participants to validate the psychological 
constructs (illness representations, coping, health status, somatic symptoms, 
locus of control and health-related quality of life) that frequently emerged from 





These measures will ultimately be subjected to data reduction techniques to 
identify meaningful variables that may explain HRQoL and its determinants in 
this population. The study proposed here, being conducted in a 'real-world" 
setting, has the potential for a more effective approach to patient engagement 
and satisfaction with treatment.  
The development of a HRQoL instrument, built from a patients’ perspective, 
will enable clinicians to understand patients' health status, which may result in 
improved PA management. In this way, treatment may be adjusted according 
to patients’ needs, resulting in improved HRQoL. Hence, the present study will 
describe the development of a condition-specific questionnaire for the 
identification and management of health-related quality of life in patients 




















The present study employed a cross-sectional survey design as the basis for 
data gathering and subsequent development of a screening/outcome measure 
for patients with PA. Statistical analyses were performed to establish 
relationships between the variables (Pearson correlation coefficient), to identify 
predictors of adjustment (Multiple Regression methods) and ultimately to 
identify meaningful items (Principal Components Analysis) in the dataset. 
 
Variables recorded included ethnic background, source of patient recruitment, 
marital status, employment, affiliation to support groups, type of diagnosis, 
family history, time since diagnosis, treatment related information and co-
morbidities. Psychological measures included illness representations, health 
status, multidimensional health locus of control, somatic focus, coping 
strategies and health-related quality of life. 
 
6.3.2 Ethical considerations 
The Abertawe Bro Morgannwg NHS Trust, the North-West Lancaster Research 
Ethics committee and the University of South Wales, Faculty Ethics Research 
Sub Group, granted ethical and governance approvals. Regarding the online 
sample, anonymity of potential participants was secured as Survey Monkey did 
not retain or transfer IP data with the provided responses. Informed consent 








The purposeful sample consisted of 184 patients diagnosed with B12 
deficiency/PA (N=184; 144 females, 40 males; Mean age = 56, SD=16.1). It 
included patients registered in two GP surgeries (Bridgend and Port Talbot) as 
well as non-NHS participants, recruited via Social Media websites (PAS and 
subsidiary groups, the University of South Wales intranet and Facebook 
pages). Participants were required to be at least 18 years of age, to have 
received a formal diagnosis of B12 deficiency/ PA from a health professional 
and to be in receipt of regular B12 injections. The same criteria applied to the 
online sample and further asked participants to confirm that they were not 
taking part in this study through their local GP practice. Patient data that did 
not meet the inclusion criteria were excluded. 
 
6.3.4 Sample size 
The current study used an adequately powered sample for conducting the 
analyses. As a rule of thumb, multiple regression analyses require at least 10 
cases per predictor in the model (Field, 2009). It has been recommended that 
when testing the overall model fit, one would look into the sample size for an 
overall model (a sample size of 50+8k, k representing the number of 
predictors) as well as the sample size for each individual predictor(104+k) . By 
calculating both sample sizes, one would select the one with the largest value 
in the regression analyses (Green, 1991). To conduct an Exploratory Factor 
Analysis (EFA), an acceptable sample size may be determined by the nature of 




Authors recommend looking at the proportion of variance of an individual 
variable shared with other variables, and the level of item communality. In the 
present study, most item communalities were greater than .5, indicating the 




Brief COPE Inventory (Carver, 1997)  
The Brief COPE is a validated, multidimensional short-form of the COPE 
inventory (Carver, 1989) which has proven to be useful in health-related 
research possessing good psychometric properties (Tuncay, Musabak, Gok & 
Kutlu, 2008; Lode, Larsen, Bru, Klevan, Myhr & Nyland, 2007; Carver et al., 
1993). Data from the original scale supports the reliability of the reduced scales 
(α>.50). This scale assesses a broad range of coping responses across 14 
coping scales (28 items). Both adaptive and maladaptive coping strategies are 
included (Appendix 4.13). Ways of coping include both cognitive and 
behavioural strategies such as active coping, planning, acceptance, reframing 
and behaviour disengagement. Scores for each subscale range from 2 to 8; 
higher scores indicate more frequent use of a specific coping strategy. 
Cronbach’s alpha for each subscale ranged from acceptable to high (self-
distraction α=.60; active coping α=.81; denial α=.73; substance use α=.92; 
emotional support α=.81; instrumental support α=.72; behaviour 
disengagement α=.66; venting α=.72; positive reframing α=.61; planning α=.85; 





Multidimensional Health Locus of Control Scale (MHLC; Wallston, Wallston & 
Devellis, 1978) 
This scale has been adapted from the general LOC and may be administered 
to individuals with a specific health/medical condition (Basinska & 
Andruszkiewicz, 2012; Nagy & Wolfe, 1983). This scale measures the extent to 
which an individual believes that external factors (i.e. other people and chance) 
and internal factors (i.e. one’s behaviour and thoughts) play important roles in 
determining one’s health. Sample items include: "If I take the right actions, I 
can stay healthy" (internal); "No matter what I do, if I am going to get sick, I will 
get sick" (chance), and "My family has a lot to do with my becoming sick or 
staying healthy" (powerful others), (Appendix 4.14). The MHLC Comprises of 
18 items in a 6- point Likert Scale and possesses acceptable levels of internal 
reliability ranging from .67 to .76. The Cronbach’s alpha values were recorded 
for each subscale (internal α=.65; chance α=.68; powerful others α=.75) 
 
Patient Health Questionnaire (PHQ-15; Kroenke, Spitzer & Williams, 2002) 
The PHQ-15 measures the extent to which patients are bothered which 
symptoms during the previous 4 weeks. It consists of 15 somatic symptom 
clusters measured in a 3-point Likert scale (0 “not bothered at all”, 1 “bothered 
a little” or 2 “bothered a lot”), (Appendix 4.15). Scores range from 0 to 30 
representing the grading of somatisation disorder. Scores of ≥5, ≥10, ≥15 
represent mild, moderate and severe levels of somatization. The PHQ-15 
possesses high levels of reliability and validity and is proposed to aid clinical 
judgement and reflect the illness experience of individual patients (Kroenke et 




Validation studies have reported the internal reliability (.80) and test-retest 
reliability (.83) of this scale (van Ravesteijn et al., 2009; Kroenke, Sptizer & 
Williams, 2002). The internal reliability of the scale (α=.83) was recorded for 
the PA population. 
 
The Brief illness perception Questionnaire (Brief IPQ; Broadbent, Petrie, Main 
& Weinman, 2006) 
The Brief IPQ represents a shorter version of the IPQ-R (Moss-Morris et al., 
2002), a widely used scale to assess patients' representations of their illness 
(Broadbent, Wilkes, Koschwaneza, Weinman, Norton & Petrie, 2015; Afshar et 
al.,2011;Dalbeth et al.,2011;Broadbent, Ellis, Thomas, Gamble & 
Petrie,2009;Dickson, Toft& O’Carroll,2009). The Brief IPQ provides the option 
to adapt question wording to the specific illness being investigated. This scale  
includes a total 8 components in which 5 of these assess cognitive illness 
representations (consequences, timeline, personal control, treatment control 
and identity); 2 items that represent emotional representations (concern and 
emotions); 1 item assessing illness understanding and 1 item assessing causal 
representations (Appendix 4.16). Identity refers to the label individuals use to 
describe their illness and the symptoms they view as being part of the 
condition; consequences refers to the expected effects and outcome of the 
illness; timeline relates to how long the patient believes the illness will last, and 
control the extent to which individuals believe that they can recover or control 
the illness.  The emotional representation includes negative reactions such as 
distress and fear. Items are rated on a 0-10 response scale except for the 
“causal” component where items may be grouped into categories determined 
by the specific illness and a categorical analysis may be performed.  
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A total score may also be computed, representing the degree to which the 
condition is perceived as threatening or benign. A higher score will indicate a 
more threatening view of the illness.  
Test-retest reliability was assessed with renal patients at 3-week and 6-week 
intervals (e.g. illness consequences r=.70, p<.001, 3-week and r=.71, p<.001, 
6-week). Concurrent validity was assessed through comparison with equivalent 
scales of the IPQ-R in asthma, diabetes and renal patients and significant 
correlations were reported between items of equivalent scales (e.g. 
consequences, r=.62, p<.001). Discriminant validity showed significant 
differences between illnesses (e.g. diabetes and asthma). Predictive validity 
was shown with patients recovering from myocardial infarction. Illness 
consequences were associated with mental health functioning (r=-.58, p<.001), 
measured by the SF-36 and illness identity was associated with physical 
functioning (r=-50, p<.001), measured by the Seattle Angina Questionnaire. 
The internal reliability for the overall scale in PA patients was α=.60. 
 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) 
This scale has been widely used as a measure of health status in clinical 
populations, measuring symptoms of depression and anxiety (Bock, 
Bendstrup, Hilberg & Lokke, 2017; Peltzer & Pengpid, 2016; O’Connor et al., 
2010; Mclaughlin et al., 2005; It is comprised of fourteen non-somatic 
symptoms of depression and anxiety, rated according the degree to which 
these have been experienced over the past two weeks, on a 4-point Likert 
scale (Appendix 4.17). Total scores are calculated for the two subscales, 




 Scores between 0-7 reflect scores within the normal range, scores within 8-10 
indicate the presence of state depression and/or anxiety and scores above 11 
reflect caseness of mood disorder. The HADS has good psychometric 
properties. In the original scale, HADS scores were associated with clinical 
ratings (r=0.54 for anxiety and r=.79 for depression). Concurrent validity was 
assessed with the beck depression inventory and reported correlations for 
anxiety ranged from .61 to .83 and for depression correlations ranged from .62 
to .73 (Bjelland et al., 2002). Discriminant validity was assessed in a few 
studies were independence from anxiety and depression were supported 
(Clark & Watson, 1991; Aylard et al., 1987). Internal reliability of the measure 
of anxiety in the PA population was α= .87 and for the depression scale α=.84. 
 
 
The World Health Organization Quality of Life Assessment (WHOQOL-BREF; 
Skevington, Lofty, O’Connell & WHOQOL group, 2004) 
The 26-item version of the WHOQOL-100 scale (Skevington, 1999) has good 
to excellent psychometric properties of reliability and validity measuring across 
four domains, physical health, psychological health, social relationships and 
environment. Responses are rated on a 5-point Likert scale.  Raw scores in 
each dimension are converted to transformed scores in a linear 0-100 scale. 
Higher scores denote improved HRQoL. It also includes two general questions 
that relate to life satisfaction and general quality of life. It has been employed in 
different areas such as medical practice, research and audit, policy making as 
well as assessing the effectiveness of different treatments (Gholami, Jahromi, 
Zarei & Dehghan, 2013;Shavro, Ezhilarasu, Augustine, Betchel & Christopher, 
2012;Skevington & McCrate, 2012; Chachamovich, Trentini & Fleck, 2007; Van 
Heck & de Vries,2003). 
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 It may also be used to assess cross-cultural variation, to compare sub-groups 
within the same culture and to measure change across time in response to 
change in life circumstances. The HRQoL dimensions possessed good internal 
reliability for the PA population (physical health α=.68; psychological health 
α=.88; social relationships α=.69; environment α=81).  
 
6.3.5.1. Comparison of the validity scores of the WHOQOL-BREF in the 
PA population with the original WHOQOL-BREF scale 
 
The psychometric properties of reliability and validity of the WHOQOL-BREF 
were examined in the PA population and compared with the original validity 
scores of the WHOQOL-BREF (Skevington, Lofty & O’connell, 2004). In the 
original WHOQOL-BREF study, participants were recruited from various 
settings, which included in-patient and outpatient healthcare facilities and well 
samples in different study centres (including the UK). Considering that the 
present thesis refers to the administration of the WHOQOL-BREF in a PA 
population, comparison of validity scores with the original scale is limited. 
Given the absence of similar methodology with the original study (Skevington, 
Lofty & O’connell, 2004) it was only possible to compare the reliability 
(cronbach’s alpha) and construct validity with the original scale. The criterion 










A reliability analysis was carried out on the four dimensions of the WHOQOL-
BREF. For the physical dimension (7 items), the Cronbach’s Alpha reached 
marginal reliability (α=.68). Most items present in this scale were worthy of 
retention, resulting in a decrease in reliability if deleted.  
The one exception to this was item 16 (sleep), which would increase the 
reliability to α=.86. The psychological dimension scale (8 items) reached good 
levels of reliability (α=.88) and all items were worthy of retention.  The 
dimension of social relationships (α=.69) and environment (α=. 61) reached 
marginal reliability scores. These reliability scores are partly consistent with the 
scores found for the original WHOQOL-BREF data set where only one item 
(negative feelings) was considered to have low reliability (α=. 56).  
 At this point, reliability of the dimensions of psychological health and 
environment in the PA population have similar levels of reliability in comparison 
with the total population used to test the WHOQOL-BREF scale (physical 
health α=.82; psychological health α=.81; social relationships α=.68; 
environment α=.80). Reliability scores are also similar with the ones reported 
for the UK centre (physical health α= .87; psychological health α=. 74; social 











Construct validity  
Construct validity was assessed to investigate if items were clearly identified 
with the intended domain. Analysis of the correlations concerning the scores in 
the PA population showed that eleven items had strong correlations (>.50) with 
domains other than their intended domain (Skevington, Lofty & O’Connell, 
2004).  
These items were part of the psychological dimension (enjoyment, meaning, 
concentration, personal satisfaction and negative feelings) strongly correlating 
with items from the physical, environmental and social dimensions. Items from 
the physical dimension (energy, activities of daily living and work) strongly 
correlated with the psychological and environmental dimensions. Items from 
the social dimension (personal relationships) strongly correlated with items 
from the psychological dimension. Lastly, items from the environment 
dimension (safety and leisure) strongly correlated with the physical, 
psychological and environmental domains. Whilst cross-domain correlations 
may be expected, the majority of items did not correlate more strongly with 
items from other domains. Only occasionally, the item of safety was more 
strongly correlated with the physical (energy and activities of daily living) and 
psychological domains (concentration). 
 
 In the original WHOQOL-BREF data set, seven items had strong correlations 
with other domains (Skevington, Lofty & O’Connell, 2004). These items were 
reflected in the physical domain (energy, activities of daily living and work), 
strongly correlating with the psychological domain. The self-esteem item from 
the psychological dimension correlated highly with all of the other dimensions. 
Other items included positive feelings (psychological) relationships (social 
relationships) and safety (environment). 
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In the PA population, item-domain correlations ranged from 0.37 (treatment) to 
0.74 (activities of daily living) for the physical domain, to 0.59 (body 
appearance) to 0.81 (personal satisfaction) for the psychological domain, to 
0.47 (transport) to 0.62 (safety) for the environmental domain, to 0.47 
(friendship support) to 0.54 (personal relationships) for the social relationships 
domain. Pearson correlations (2-tailed) were strong and statistically significant 
(p<.001), ranging from 0.42 (physical vs. social) to .78 psychological vs. 
environmental). These results are somewhat similar to the item-domain 
correlations for the items of activities of daily living and personal relationships 
in the original WHOQOL-BREF data set. Pearson correlations were strong and 
statistically significant (p<.001), ranging from 0.46 (physical vs. social) to .67 
physical vs. psychological). 
 
Considering the initial comparison between the validity scores from the 
WHOQOL-BREF in the PA population with scores derived from the original 
data set, it appears that the instrument performs well in terms of reliability and 
construct validity. However,  as pointed out by the authors of the WHOQOL-
BREF (Skevington, Lofty & O’Connell, 2004) item identification would require 
further attention as specific items (e.g. safety, more strongly associated with 
the psychological domain) could be improved to reflect their intended domain 








Two surgeries from different areas within the ABMU health board were 
purposively selected for participation in the present study. Both GP surgeries 
are engaged with the primary care research incentive scheme (PiCRIS), an 
initiative developed to offer support, mentorship and funding to general 
practices across Wales to become research active and embed research 
activity in their daily practice. Patients who met the inclusion criteria were 
invited to participate in the study through their local GP surgeries. Participants 
were sent out a postal survey with a covering letter from their attending 
surgeries explaining the reason why they were being contacted,  the patient 
information sheet (PIS; Appendix 4.7) and consent form (Appendix 4.8) 
explaining the study aims and procedures. It was made plain to participants 
that they had time to think whether to participate in the research study (PIS). 
The principal investigator provided participants with her contact (PIS) in case 
they had any issues completing the survey. Participants were required to 
complete the survey and return it back to the surgery in a pre-paid envelope. 
Reminders to follow-up from voluntary participation were sent out 
approximately 3 weeks after the initial contact was made .The practice nurse 
also raised awareness of the study when patients attended their surgeries for 
scheduled injections. This included asking patients if they were aware that the 
study was taking place and giving them a copy of the survey in case they were 
interested in participating. The data collection period started in October 2016 
and ended in January 2017. The researcher collected the surveys at the end of 
the data collection period. To ensure that a broader population was targeted, 
the survey was also posted online (via Survey Monkey). Participants were 
recruited via Social Media websites (PAS and subsidiary groups, the University 
of South Wales intranet and Facebook pages.  
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The online survey, information and consent forms were identical to the postal 
survey administered to NHS patients. The data collection period started in 
January 2017 and ended in March 2017.Participants were informed that a 
summary of study results would be made available once all the research 
related tasks were completed. 
 
6.3.7 Instrument development  
Meaningful items within the validated measures served as basis for the HRQoL 
prototype (PA-HRQoL). Additional items were generated from findings from the 
pilot studies in the present thesis, and a comprehensive literature review to 
ensure relevant items captured the perspective of PA sufferers. The draft 
measure includes 43 items measured across seven dimensions (physical 
functioning; psychological health; illness management behaviours; illness 
controllability and support; maladaptive coping; illness understanding and 
adjustment; distraction). 
 
Thirty-nine items were generated through Principal Component Analysis, and 
four items relate to the experience of specific symptoms (poor concentration, 
pins and needles, numbness of extremities, and  shortness of breath) that 
emerged from existing PA literature and qualitative accounts of PA sufferers, 
outlined in the present thesis (study 1, 2 and 3). These additional symptoms 
were integrated within the first dimension (physical functioning) due to the 
apparent similarity with items in the same dimension. Where appropriate, and 
kept to a minimum, item phrasing was reworded to ensure consistency with the 
response categories (Gu, Cavanagh, Baer & Strauss, 2017; Patrick et al., 
2011). This included changing items worded as questions to statements and 
removing frequency terms (e.g. ‘how much’). 
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Instructions for completing the questionnaire were provided and responses are 
measured in a 5-point Likert scale format (no, not at all; a little; moderately; 
very much; extremely), Miller (1956).  
A 4-week time frame was selected (WHO, 1996) in line with many well-
established HRQoL measures, such as the 36-Item Short Form Survey 
Instrument (SF-36; McHorney, Ware, Lu & Sherbourne, 1994) and the 
WHOQOL-BREF (Skevington, Lofty, O’Connell & WHOQOL group, 2004). 
Validation of the PA-HRQoL instrument is not part of the present thesis and it 
is yet to be established. Content validity will be assessed through the patient 
perspective, in terms of providing critical feedback once the instrument is 




















The aims of the present study are to investigate the best predictors of overall 
quality of life and to develop a patient-centred outcome measure for the 
identification of health-related quality of life in patients suffering with PA. Prior 
to addressing these aims, descriptive statistics were computed for the sample. 
 
6.4.1 Descriptive analyses 
Information recorded included demographics and clinical data. Information 
recorded included ethnic background, source of recruitment, marital status, 
employment, affiliation to support groups, type of diagnosis, family history, time 
since diagnosis, treatment related information and co-morbidities. 
Psychological measures will include illness representations; health status; 
locus of control; somatic focus; coping strategies; quality of life. Data was 
checked for normality prior to computing descriptive analyses. Patients’ 
demographics and clinical characteristics were summarised by frequencies 
and percentages, and means and standard deviations, where appropriate. 
 
6.4.1.1 Normal distribution 
The Shapiro-Wilk test was employed as numerical means of assessing 
normality for the variables of ‘age and ‘gender’. This test is appropriate to use 
in small sample sizes (Field, 2009).  
The observed value of the Shapiro-Wilk (W=0.976) and the exact probability of 
the outcome was not statistically significant (p=0.528).  
Therefore, the observed distribution for the variable ‘age’ in males fits the 




The observed value of the Shapiro-Wilk (W=0.987, p= 0.191), with skewness 
of 1.41 (SE=0.20) and Kurtosis of -0.511 (SE=0.40). The observed distribution 
for the variable ‘age’ in females fits the normal distribution.  
 
Normality was further explored for the remaining variables in the study to 
investigate potential data skewness. The data deviates from normality for the 
other recorded variables. The sample (N=184; 144 females, 40 males; M = 
56.2, SD=16.1) included patients from two GP surgeries in the area of 
Bridgend (37%) and Port Talbot (17%) and patients recruited online (46%), 
from various areas in the UK. Tables 6.4.1.2 display the survey response rates. 
 
Table 6.4.1.2 


















220 121 68 53 99 55% 68 
GP surgery 
Port-Talbot 
206 56 32 24 151 27% 32 
Total 426 177 100 77 250 41% 100 
 
The table above highlights that the study achieved an overall response rate of 
41%, regarding the recruitment of patients through GP surgeries. In light of 
this, sample representativeness may be questioned (Draugalis, Coons & 








6.4.2 Characteristics of the population 
Patient data indicated that the majority of the population was White British 
(97.3%). Only a small proportion of the population were from any other 
background (2.7%). The sample included patients from two GP surgeries in the 
area of Bridgend (37%) and Port Talbot (17%). It also included patients 
recruited online, from various areas in the UK (46%). The majority of the 
sample was married (57.1%) and the highest level of education recorded was 
higher education (44.7%) followed by GCSE/O level (24.7%) and further 
education (21.2%).  Employment information indicated that the largest single 
group was employed (44%). In 36.8% of the cases, individuals were retired. 
Affiliation to support groups was recorded for 38% of the cases (n=69), mainly 
including the PAS. 
 Eighty-four individuals (46%) received the diagnosis of B12 deficiency and one-
hundred individuals reported receiving a PA diagnosis (54%). These diagnoses 
were delivered by their GPs in the majority of the cases (84%). Family history 
of PA was recorded in 30.4% of the cases, compared to 46.2% of the cases 
where there was no family history and in 23.4% of the cases, individuals were 
not sure. Time since diagnosis varied in the population, from newly diagnosed 
to 50 years since diagnosis, the most frequent being one year (18.5%). 
Treatment was administered every 3 months for 63.2% of the cases, followed 
by every 2 months (12.6%) and every month (6.6%). Treatment request was 
recorded for 50.5% of the population as compared to 49.5% who did not 
request more frequent treatment. Requests were refused for the large majority 




Other outcomes included pending decisions (3.5%) or receiving additional 
treatment on occasion (3.5%). B12 additional treatment was recorded for 32% 
of the cases and mainly included purchasing over-the–counter injections. 
 A small proportion of the population reported having their treatment 
suspended (13%) and self-injecting (13%). 55% of the population confirmed 
being diagnosed with other chronic conditions, mainly conditions related to the 
endocrine system, musculoskeletal system and connective tissue, and 
gastrointestinal system. 
6.4.3 Findings for the psychological measures included in the current 
study  
 
Coping strategies  
 
Table 6.4.3.1  
Means and standard deviations of the measure of coping strategies 
administered to B12/PA deficiency patients 
 
 
Variable M SD Range N 
BC self-distraction 3.70  1.92 2-8 179 
BC active coping  4.39  2.27 2-8 179 
BC denial 2.70  1.45 2-8 179 
BC substance use 2.54  1.37 2-8 179 
BC emotional support 3.48  1.79 2-8 179 
BC instrumental support 3.72  1.85 2-8 179 
BC behavioural disengagement 2.88 1.34 2-8 179 
BC venting 3.45  1.72 2-8 179 
BC positive reframing 3.31  1.60 2-8 179 
BC planning 4.34  2.21 2-8 179 
BC humour 3.21  1.73 2-8 179 
BC acceptance 5.67  2.19 1-8 179 
BC religion 2.51  1.24 1-8 179 
BC self-blame 3.12  1.70 2-8 179 
 
Note: M= mean; SD= standard deviation; N= number of participants. 
 
 
The table shows the variables that represent coping strategies, higher mean 
scores represent proactive ways of coping, including active coping, planning 






Means and standard deviations of the measure of multidimensional 
health locus of control administered to B12/PA deficiency patients 
 
 
Variable M SD Range N 
MHLC internal 22.08  5.81 2-36 182 
MHLC chance 18.68  6.18 5-33 182 
MHLC powerful others 17.06  6.80 5-36 182 
 
Note: M= mean; SD= standard deviation; N= number of participants. 
 
The table suggests that individuals perceived having higher an internal locus of 
control in dealing with their illness in comparison to chance or powerful others. 
 
Table 6.4.3.3  
Means and standard deviations of the measure of somatic focus 
administered to B12/PA deficiency patients 
 
 
Variable M SD Range N 
PHQ-somatic focus 13.20  7.54 0-71 182 
 
Note: M= mean; SD= standard deviation; N= number of participants. 
 
The table shows that somatisation appears to fall within moderate levels for 





















Means and standard deviations of the measure of illness representations 
administered to B12/PA deficiency patients 
 
Variable M SD Range N 
BIPQ total 42.49  13.20 5-72 184 
BIPQ consequences 5.67  3.09 0-10 184 
BIPQ timeline 9.47  1.59 0-10 181 
BIPQ treatment control 7.53  2.51 0-10 183 
BIPQ personal control 4.16  3.15 0-10 183 
BIPQ identity 6.38 2.85 0-10 184 
BIPQ coherence 6.41  3.33 0-10 184 
BIPQ concern 6.09  3.28 0-10 184 
BIPQ emotional representation 3.52  4.16 0-10 184 
 
Note: M= mean; SD= standard deviation; N= number of participants. 
 
The table shows that illness threat appears to fall within moderate levels for 
this population. Individuals seemed to have a very good understanding of 
illness chronicity (timeline) and believed that treatment would be beneficial to 
their condition. Individuals seemed to experience symptoms (identity) and 
worry about their illness (concern) to a moderate degree. Results also suggest 
that individuals may have a reasonable illness understanding (coherence). 
 
Table 6.4.3.5 
Means and standard deviations of the measure of health status 
administered to B12/PA deficiency patients 
 
Variable M SD Range N 
HADS anxiety 8.68  5.23 0-21 184 
HADS depression 7.50  4.68 0-19 184 
 
Note: M= mean; SD= standard deviation; N= number of participants. 
 
 
Psychological distress measures indicate the presence of anxiety state (8-10) 







Means and standard deviations of the measure of health-related quality 
of life administered to B12/PA deficiency patients 
 
Variable M SD Range N 
Perceived QOL 3.51  1.05 1-5 183 
Perceived life satisfaction 2.67  1.10 1-5 182 
WHOQOL-BREF physical health 48.55  14.03 6-81 183 
WHOQOL-BREF psychological health 52.88  17.41 0-88 183 
WHOQOL-BREF social relationships 56.67  25.14 0-100 182 
WHOQOL-BREF environment  68.01  19.24 19-100 183 
 
Note: M= mean; SD= standard deviation; N= number of participants. 
 
Perceived quality of life seems to be neither poor/nor good for most of the 
individuals. Results indicate that most of the individuals seem to be slightly 
dissatisfied with their lives. Regarding the dimensions of HRQoL, results seem 
to point that social relationships and environment contributed to a better 
HRQoL. 
 Findings from the current study suggest acceptance and planning as ways of 
dealing with one’s illness. Literature has previously identified these strategies 
as adaptive (Uchmanowicz, Jankowska-Polanska, Motowidlo, Uchmanowicz & 
Chabowski, 2015; Kostova, Caiata-Zufferey & Schulz, 2014; Pierobon, 
Giardini, Callegari & Majani, 2011; Büssing, Ostermann, Neugebauer and 
Heusser, 2010). The engagement in coping styles that have been suggested 
as less adaptive such as self-blame, venting and behavioural disengagement 
have also been highlighted in the currently study and documented in previous 
research (Cameron & Wally, 2014; Kaltsouda et al., 2011; Büssing, 
Ostermann, Neugebauer & Peter Heusser, 2010). 
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Patients seemed to have a reasonable understanding regarding the chronicity 
of their illness. However, the majority seemed to experience symptoms to a 
moderate degree and express concern toward their condition. Most individuals 
seemed to believe they could control their illness to a moderate extent. These 
findings are similar with studies conducted with other populations (Clarke, 
Yates, Smith & Chilcot, 2016; Moss-Morris et al., 2002). The levels of 
depression and somatisation (Patel, Morgan, Bercik & Ford, 2015) seemed to 
be moderate for this population. However, it also indicated the presence of 
state anxiety as opposed to trait anxiety. Psychological distress seems to be a 
common occurrence in patients experiencing chronic illness (Tselebis et al., 
2016; Clarke & Currie, 2009). Perceptions of better social relationships and 
environmental health seemed to be the most meaningful aspects of HRQoL in 















6.5 Aim 1 
To investigate the best predictors of health-related quality of life.  
 
This aim will be addressed by computing multiple regression analyses for the 
four dimensions of health-related quality of life (physical health, psychological 
health, social relationships and environment). The WHOQOL-BREF was used 
as a measure of adjustment, reflecting the HRQoL of PA sufferers. Prior to 
conducting multiple regression analyses, investigations were carried out to 
check for outliers, collinearity of data, independent errors, homocedascity and 
linearity of data, and non-zero variances. Correlation coefficients between the 
variables were determined prior to conducting multiple regression analyses 
(Field, 2009). Only items with acceptable levels of correlations (r>.3) and items 
that did not correlate too highly (r<.9) were included in the multiple regression 
analyses. The variables that satisfied the above criteria derived from the Brief-
Cope (venting, behaviour disengagement; emotional support; denial and self-
blame) HADS (anxiety and depression) and Brief-IPQ (consequences, 
treatment, concern, identity, emotional representation) scales.  
 
6.5.1 WHOQOL physical health 
An analysis of standard residuals showed that the data contained one outlier. 
This was removed to reflect no outliers (Std.Residual Min=-2.87, Std Residual 
Max = 2.79). Tests to check if the data met the assumption of collinearity 
indicated that multicollinearity was not a concern. The data met the assumption 
of independent errors (Durbin-Watson value =2.08). The scatterplot of 
standardised residuals showed that the data met the assumptions of 





In order to assess the contributions of the variables in predicting the physical 
health dimension of health-related quality of life, a forced entry multiple 
regression was performed, previously reported as an appropriate method for 
theory testing (Studenmund & Cassidy, 1987). The results of this analysis 
indicated that all the variables that represent coping, illness representations, 
anxiety and depression, explained a reasonable amount of the variance in 
physical health to a statistically significant level (F (9,166) = 10.02, p <.05, R2 = 




Regression coefficients of each predictor using physical health as the 
criterion variable (n=176) 
 
Predictor Beta t Sig Tolerance VIF 
BIPQ consequences -.309 -2.423 P<.05 .332 3.014 
HADS depression -.353 -3.259 P<.05 .332 3.016 
 
Results from the analysis show that from all the predictors in the study, only 
illness consequences (r=-.467, p<.01) and depression (r=-.531, p<.01) made a 
significant individual contribution in predicting physical health. 
 
6.5.2 WHOQOL Psychological health 
 
An analysis of standard residuals showed that the data contained one outlier. 
This was removed to reflect no outliers (Std.Residual Min=-2.46, Std Residual 
Max = 2.44). Tests to check if the data met the assumption of collinearity 
indicated that multicollinearity was not a concern. 
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The data met the assumption of independent errors (Durbin-Watson value 
=2.00) .The scatterplot of standardised residuals showed that the data met the 
assumptions of homogeneity of variance and linearity. The data also met the 
assumption of non-zero variances.  
In order to assess the contributions of the variables in predicting the 
psychological health dimension of health-related quality of life, a forced entry 
multiple regression was performed. The results of this analysis indicated that 
the variables that represent coping, illness representations, anxiety and 
depression explained an acceptable amount of the variance in psychological 
health to a statistically significant level (F (12,163) = 18.31, p <.05, R2 = .57, 




Regression coefficients of each predictor using psychological health as 
the criterion variable (n=176) 
 
Predictor Beta  t Sig Tolerance    VIF 
 
HADS depression -.575 -6.381 P<.05 .326 3.064 
BIPQ identity  .246 2.386 P<.05 .272 3.682 
BIPQ treatment control .197 3.601 P<.05 .877 1.140 
BIPQ consequences -2.34 -2.189 P<.05 .241 4.144 
 
Results from the analysis show that from all the predictors in the study, 
treatment control (r=.360, p<.01), illness identity(r=-.349, p<.01), illness 
consequences(r=-.471, p<.01), and depression (r=-.680 p<.01) made 






6.5.3 WHOQOL social relationships 
 
An analysis of standard residuals showed that the data contained no outliers 
(Std.Residual Min=-2.90, Std Residual Max = 2.92). Tests to check if the data 
met the assumption of collinearity indicated that multicollinearity was not a 
concern. The data met the assumption of independent errors (Durbin-Watson 
value =2.08) .The scatterplot of standardised residuals showed that the data 
met the assumptions of homogeneity of variance and linearity. The data also 
met the assumption of non-zero variances. 
In order to assess the contributions of the variables in predicting the dimension 
of social relationships of health-related quality of life, a forced entry multiple 
regression was performed. The results of this analysis indicated that the 
variables that represent coping, illness representations, anxiety and 
depression, explained an acceptable amount of the variance in social 
relationships to a statistically significant level (F (5,171) = 10.08, p <.05, R2 = 
.22, R2 adjusted=.20). Table 6.5.3.1 displays the regression coefficient for the 
variable that emerged as the only significant predictor of social relationships. 
 
Table 6.5.3.1 
Regression coefficients of each predictor using social relationships as 
the criterion variable (n=176) 
 
Predictor Beta t Sig Tolerance VIF 
HADS depression -.312 -2.881 P<.05 .384 2.604 
 
Results from the analysis show that from all the predictors in the study, only 
depression (r=-5.57, p<.01) made a significant contribution in explaining the 






6.5.4 WHOQOL environment 
An analysis of standard residuals showed that the data contained three 
outliers. These were removed to reflect no outliers (Std.Residual Min=-2.87, 
Std Residual Max = 2.27). Tests to check if the data met the assumption of 
collinearity indicated that multicollinearity was not a concern. The data met the 
assumption of independent errors (Durbin-Watson value =1.93). The 
scatterplot of standardised residuals showed that the data met the 
assumptions of homogeneity of variance and linearity. The data also met the 
assumption of non-zero variances. 
In order to assess the contributions of the variables in predicting the 
environment dimension of health-related quality of life, a forced entry multiple 
regression was performed. The results of this analysis indicated that all the 
variables that represent coping, illness representations, somatic focus, anxiety 
and depression explained an acceptable amount of the variance in 
environment to a statistically significant level ( F(10,164) = 15.99 ,p <.05, R2 = 




Regression coefficients for each predictor using environment as the 
predictor variable (n=175) 
 
Predictor Beta t Sig Tolerance VIF 
HADS anxiety -.321 -3.632 P<.05 .396 2.528 
BIPQ identity .203 1.820 P<.05 .231 4.320 




Results from the analysis show that from all the predictors in the study, only 
anxiety (r=-.563, p<.01), illness identity (r=-.352 p<.01) and illness 
consequences (r=-.471, p<.01) made significant contributions in explaining the 
environment dimension of health-related quality of life. 
 
Outcomes from the multiple regression analyses were presented according to 
the best predictors in each HRQoL dimension (physical health, psychological 
health, social relationships and environmental health). Findings suggested that 
the best predictors of physical health were illness consequences and 
depression. The best predictors of psychological health were illness 
perceptions that relate to illness identity, illness consequences, treatment 
control and depression. Social relationships were better explained by health 
status (depression). The variables that were better at explaining environmental 
health were anxiety and illness perceptions (identity and consequences). 
Results from the present study have significant implications in terms of 
highlighting the importance of psychosocial factors in the management of B12 
deficiency. Studies that may provide support for the current findings have 
explored the relationship between illness perceptions, psychological distress 
and different facets of health-related quality of life in patients presenting with 
various chronic conditions. Faller and colleagues (2009) investigated the 
simultaneous influence of heart failure severity and comorbid depression on 
the physical function and psychological domains of HRQoL. This study 
recruited 206 outpatients suffering from chronic heart failure.  Depression was 
measured using the patient health questionnaire (PHQ-9) and HRQoL was 




The New York heart association functional class ratings assessed the impact 
of symptom severity on activities of daily living. The aim of this study was to 
examine whether both HRQoL dimensions were affected by comorbid 
depression considering symptom severity. Results from this study suggested 
that depression had an impact on both physical and psychological HRQoL 
domains.  However, the severity of patient’s symptoms only had an impact on 
the physical HRQoL domain. These findings may highlight the significance of 
illness perceptions, since patients that experience depression may appraise 
their health status in a more negative way.  
Another study investigating health-related quality of life and disability in 
patients with chronic obstructive pulmonary disorder has found that 
psychological factors such as depression and perceived illness threat were 
important predictors of low HRQOL and high disability in these patients. 
However, in these patients, co-morbid somatic symptoms were the most 
important predictors of physical health (Mewes, Rief, Klenn, Ried & Stenzel, 
2015). While somatisation did not emerge as a significant predictor of HRQoL 
in the PA population, it had low negative associations with all dimensions of 
HRQoL. A longitudinal cohort study investigated the predictors of health-
related quality of life in people with chronic conditions presenting with 
multimorbidity, over a 12-month period.  The variables assessed included 
demographics, disease, intervention factors and psychosocial factors. Results 
suggested that the most significant predictors included the impact of illness on 
activities of daily living, the number of co-morbidities, health functioning and 





A systematic review of 11 independent published studies showed a significant 
association between depression and subsequent physical aspects of HRQoL in 
patients suffering with coronary heart disease. This association was reported 
independently of the severity of the condition and impairment of physical 
HRQoL at baseline. Depression was mostly assessed using the HADS and the 
Beck Depression Inventory and HRQoL was mostly assessed using generic 
measures such as the SF-36. Results suggested that nine of the studies 
reported a strong association between depression and physical HRQoL. These 
findings may suggest that individuals may negatively appraise physical health 
due to lack of motivation and experienced fatigue (Dickens, Cherrington & 
McGowan, 2012). The relationship between illness perceptions and quality of 
life was explored in a sample of 100 patients suffering with chronic obstructive 
pulmonary disorder. This study indicated that the perception of negative illness 
consequences and more physical complaints were associated with poorer 
HRQoL (Tiemensma, Gaab, Voorhaar, Asijee & Kaptein, 2016). 
Another study looking at health-related quality of life predictors in patients with 
rheumatoid arthritis has found that pain, functional disability and depression 
were the main predictors of HRQoL (Wan et al., 2016). In other studies, 
negative affect has been inversely associated with all dimensions of quality of 
life (Vilhena et al., 2014; Graydon, Bubela, Irvine & Vincent, 1995). 
  
Literature has suggested psychological factors as important predictors of 
outcome, influencing one’s illness and treatment control, having significant 
implications in terms of managing disease severity (Rochelle & Fidler, 2012; 




The fact that treatment control emerged as a significant predictor of 
psychological health is supported by existing literature suggesting that 
perceptions that treatment will benefit one’s condition may be associated with 
improved quality of life (Rochelle & Fidler, 2012). Alternatively, the perceived 
experience of severe symptoms has also been linked to the experience of 
psychological distress subsequently affecting one’s adjustment. Morgan, 
Villiers-Tuthill, Barker and McGee (2014) have documented the contribution of 
illness perceptions to depression and anxiety indices in patients experiencing 
heart failure. Although patients seemed to have a good illness understanding 
and perceived treatment to be effective, they perceived greater illness 
consequences and negative emotional responses. These negative influences 
on one’s psychological well-being may contribute to a reduced health-related 
quality of life. Alternatively, patients did not attribute most of their symptoms to 
their condition. The same may not be suggested for PA patients, which 
attributed a somewhat higher proportion of symptoms to their illness identity 
(mean score=6.38). This may also be related to illness co-morbidity in the PA 
population (55%).  
A study by Le Grande and colleagues (2012) has examined different illness 
perception profiles in cardiac patients and its association with quality of life and 
depression. Illness perceptions were measured using the BIPQ, depression 
was assessed using the Beck Depression Inventory II and quality of life was 
measured by the MacNew HRQoL instrument, designed for cardiac patients. 
Findings from this study demonstrated that cardiac patients developed a 
structured pattern of beliefs about their existing condition leading to different 
outcomes. In example, patients identified as being highly focused on the 
consequences of their condition as well as perceiving little control over the 
same presented with high levels of depression and poor HRQoL.  
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Alternatively, patients who felt in control over their illness perceiving lower 
illness consequences reported experiencing mild depression and improved 
HRQoL (Le Grande et al., 2012).  
Depression emerged as the only significant predictor of social relationships 
HRQoL.  The functional limitations resulting from experiencing chronic illness 
may result in increased psychological distress. Subsequently, this may affect 
one’s ability to form meaningful relationships and benefit from social support 
(Turner, 2000).  The predictive value of social support on HRQoL has been 
investigated in conditions such as multiple sclerosis. In a  cross-sectional 
design and a sample of 150 patients, social support was assessed  using the 
medical outcomes study social support survey (emotional and informational 
support, tangible, affectionate, positive social interaction) and quality of life was 
assessed using the health status questionnaire (SF-36v2). Regression 
analyses indicated that social support was positively associated with HRQoL. 
However, in this study, the dimension of emotional support emerged as a 
significant predictor for all dimensions of HRQoL. These findings highlight the 
importance of social relationships in illness adjustment (Costa, Sá & Calheiros, 
2011).  
 The investigation of the relationship between individual dimensions of illness 
representations and anxiety provides an insight into the dimension of 
environmental HRQoL. Research has documented the reported negative 
effects of type 2 diabetes such as the experience of symptoms and increased 
anxiety and its relationship with poor environmental HRQoL, where patients felt 
unsafe and perceived lack of facilities to exercise (Chew, Mohd-Sidik & Shariff-
Ghazali, 2015). Similar findings have been documented in other conditions 
such as rheumatoid arthritis (Wan et al., 2016; Iversen, Scanlon, Frits, Shadick 




6.6. Aim 2 
To develop a patient-centred outcome measure for the identification and 
management of health-related quality of life in patients suffering with PA. To 
address this aim, factor analysis (PCA) was performed to identify factors in the 
data that form the basis of the patient-centred outcome tool. Individual item 
scores were normalised prior to conducting PCA. 
 
6.6.1 Principal Components Analysis 
In total, there were six scales. These scales measured illness perceptions 
(BRIEF-IPQ), anxiety and depression (HADS), coping strategies (Brief-Cope), 
somatic focus (PHQ-15), locus of control (MHLOC) and health-related quality 
of life (WHOQOL-BREF). Overall, the scales consisted of 107 items. 
Negatively worded items were reverse-coded prior to analysis. Prior to 
conducting exploratory factor analysis and to ensure there were no issues with 
data multicollinearity, the correlation matrix was examined to check the pattern 
of relationships between the items. Items with low correlations(r<.3), items that 
did not correlate with any other variables or correlated highly (r>.9) with other 
variables, were eliminated from the analysis (Field, 2009). Subsequently, 
measures of sampling adequacy (Kaiser-Meyer-Olkin; KMO) were examined to 
check that the patterns of the correlations yielded reliable factors.  As per 
recommendation (Kaiser, 1974) any items with values below the acceptable 
level of .5 were removed. This was the case for forty-eight items. A principal 
components analysis (PCA) was conducted on the remaining 59 items with 
orthogonal rotation (varimax), as suggested in case factors are expected to be 




The KMO measure indicated a high value (Hutcheson & Sofroniou, 1999), 
verifying the sampling adequacy for the analysis (KMO=.88). All KMO values 
for individual items were above .5. Bartlett’s test of sphericity, which tests the 
overall significance of correlations between all the variables, was highly 
significant (2 (1711) = 6025.95, p <.001), indicating that factor analysis is 
appropriate for the data. An initial analysis was conducted to obtain 
eigenvalues for each data item. Thirteen factors were initially obtained, 
meeting Kaiser’s criterion, eigenvalues greater than 1. However, four of these 
had no substantial loadings (only two items or less). An examination of the 
factor structure and the convergence of the scree plot, as recommended to aid   
decisions regarding the number of factors to retain (Costello & Osborne,2005) 
,justified running the analysis looking at a 9-factor solution and subsequently 
an 8-factor solution. Both failed to converge in a significant number of 
iterations. Subsequently, a 7-factor solution was carried out and it seemed to 
have better described the data, producing cleaner loadings across the factors, 
with a total variance of 56.37%.  
These factors loaded at higher than .4. This suppression value was chosen to 
assist with the interpretation of the factor structure (Field, 2009). Items in the 
factors were retained on the basis of having strong factor loadings (.4 or 
greater) and at least .2 difference between the highest loading and loadings 
onto other factors (Davies et al., 2000; James et al., 2004, as cited by West & 
Roderique-davies, 2008), since the goal of FA is to explain the variance 
between the common factors (Child, 2006). Factors were also retained if they 
included a minimum of three items per factor, to ensure that factors were well- 




Items were removed if they didn’t appear to make significant contributions to 
the overall factor, such as not being theoretically related to the highest loading 
items in a specific factor. Table 6.6.1.1 .presents the factor structure and 
loadings of items to specific factors. 
Table 6.6.1.1 
Summary of the results from exploratory factor analysis 
 
Factor Eigenvalue % of variance 
1 18.59 30.47 
2 4.48 7.35 
3 2.60 4.26 
4 2.50 4.10 
5 1.87 3.07 
6 1.77 2.90 
7 1.64 2.70 
 
Table 6. 6.1.1 shows the 7 factors that were identified and retained in the final 
analysis. These factors possess moderate to high reliabilities with Cronbach’s 
α values ranging from .46 to .82. Factor 1 consists of seven items and 
represents physical functioning. Factor 2 comprises of ten items and suggests 
the impact of illness on psychological health.  Factor 3 consists of seven items 
and outlines different ways of dealing with PA. Factor 4 consists of three items 
and relates to illness related control and support. Factor 5 includes 3 items and 
represents maladaptive coping. Factor 6 consists of 5 items and suggests 
illness understanding and adjustment. Factor 7 comprises of four items 




Table 6.6.1.2  
Summary of exploratory factor analysis results from the HRQOL, Somatic symptoms, Brief-IPQ and HADS scales 











and support  
Maladaptive 
coping  
illness understanding  
and adjustment   
Distraction 
I feel as I have slowed down .69       
During the past 4 weeks, how much have you 
been bothered with feeling tired or having little 
energy? 
.56       
During the past 4 weeks, how much have you 
been bothered with chest pain? 
.56       
How much does your illness affect your life? .55       
During the past 4 weeks, how much have you 
been bothered with constipation, loose bowels or 
diarrhoea? 
.51       
I look forward with enjoyment to things .51       
During the past 4 weeks, how much have you 
been bothered with trouble falling or staying 
asleep or sleeping too much? 
.49       
I get sudden feelings of panic  .80      
I get a sort of frightened feeling like ‘butterflies’ in 
the stomach  
 .79      
I get sort of a frightened feeling as if something 
awful is about to happen 
 .77      
Worrying thoughts go through my mind  .69      
I feel tense or ‘wound up’  .67      
How often do you have negative feelings such as 
blue mood, despair, anxiety, depression?  
 .-60      
I have been giving up trying to deal with it  .47      
I can laugh and see the funny side of things  .45      
 I can enjoy a good book or radio or TV 
programme 
 .44      
I have been getting help or advice from other 
people 
 .41      
 I have been getting emotional support from others   .73     
I have been concentrating my efforts on doing 
something about the situation I am in 
  .70     



















and support  
Maladaptive 
coping  
illness understanding  
and adjustment   
Distraction 
I have been getting comfort and understanding 
from someone 
  .67     
I have been thinking hard about what steps to take   .67     
I have been trying to get advice or help from other 
people about what to do 
  .62     
I have been expressing my negative feelings   .45     
I have been making fun of the situation   .41     
How much control you feel you have over your 
illness? 
   .51    
How much do you think your treatment can help 
your illness?  
   .50    
How satisfied are you with your personal 
relationships? 
   .43    
I have been using alcohol or other drugs to help 
me get through it 
    .61   
I have been saying things to let my negative 
feelings escape 
    .57   
I have been refusing to believe that it has 
happened 
    .56   
I have been learning to live with it      .67  
I have been accepting the reality of the fact that it 
has happened 
     .62  
How available to you is the information you need 
in your day-to day-life? 
     .44  
How well do you feel you understand your illness?      .42  
How healthy is your physical environment?      .41  
I have been trying to find comfort in my religion or 
spiritual beliefs 
      .72 
 I have been praying or meditating       .71 
I have been doing something to think about it less, 
such as going to movies, watching TV reading 
,daydreaming, sleeping, or shopping 
      .59 
I have been turning to work or other activities to 
take my mind off things 
      .53 
Eigenvalues 18.59 4.48 2.60 2.50 1.87 1.77 1.64 
% of variance  30.47 7.35 4.26 4.10 3.07 2.90 2.70 
Α .82 .81 .86 .46 .66 .63 .70 
 
Note: Factor loadings above.4 appear in boldface 
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Factor 1: Physical functioning  
This factor is composed of seven items and reflects physical functioning. This 
factor combines two items from the HADS measure that relate to the 
experience of depression, illness consequences and four somatic symptoms 
included in the PHQ-15 (tiredness, chest pain, bowel and sleeping problems). 
Existing literature supporting this factor has established the association 
between depression and illness consequences in determining health-related 
quality of life in patients suffering with rheumatoid arthritis. In this way, worries 
about the consequences of disease were important correlates of physical 
dimension of HRQoL (Hyphantis et al., 2013). Another study has found that 
patients' perceived illness consequences and emotional representations 
mediated symptom severity and overall health-related quality of life in patients 
with irritable bowel syndrome (De Gutch, 2015). The present study may partly 
support the presence of moderate somatisation for the majority of the 
population. Although PA sufferers don’t perceive some of their symptoms as 
psychosomatic, pilot work has previously reported their symptoms being 
labelled as psychosomatic, by health professionals. The experience of four 
additional symptoms that significantly emerged from pilot work and PA 
research (Hooper, Hudson, Porter & McCaddon, 2014; Springhouse, 2005; 
Sethi, Robilotti & Sadan, 2004) were included in this factor, due to the similarity 
with the items included in this factor. These items were numbness, pins and 
needles, poor concentration and shortness of breath. The first two symptoms 
may indicate neurological abnormalities, resulting from the delayed diagnosis 
of PA/B12 deficiency, an important element that has emerged from narrative 





Factor 2: Illness impact on psychological health 
Factor 2 represents the impact of pernicious anaemia on psychological health. 
This factor comprises of ten items and combines the emotional representation 
of illness with five symptoms of anxiety, two items that relate to depression, 
one item that relates to the experience of negative mood (psychological 
HRQoL), one item that reflects behaviour disengagement and one item that 
relates to instrumental support. Previous studies have documented the impact 
of chronic illness in one's psychological health. This includes the experience of 
depression, anxiety and response to illness, being detrimental to one’s HRQoL 
(Finnegan-John & Thomas, 2013; Major & Glass, 2013). Behaviour 
disengagement has been associated with more depressive symptoms 
(Kaltsouda et al., 2011) and poorer HRQoL (Cartwright, Endean & Porter, 
2009). Research in a population suffering with diabetes has suggested the 
negative association between experiencing anxiety and seeking instrumental 
support (Tuncay, Musabak, Engin, Gok & Kutlu, 2008). 
 
 In another study, seeking instrumental support has been linked with lower 
scores in depression (Arran, Craufurd & Simpson, 2013). Inspection of the 
factor loadings confirm that the items that possess higher loadings relate to 
symptoms of anxiety and psychological HRQoL when comparing with items 
that relate to depression, coping and emotional representation of illness. It may 
be the case that anxiety is a significant facet of psychological health in this 
population. This may be supported by analyses in the present study that may 






Factor 3: Illness management behaviours 
This factor integrates seven items that reflect a combination of illness 
management behaviours indicating good internal reliability (.86). The 
importance of coping and its strategies (e.g. active coping, planning , emotional 
support, instrumental support,venting and humour, have been  cited throughout 
the thesis, and widely cited in the chronic illness literature (Kaltsouda et 
al.,2011; Büssing, Ostermann, Neugebauer & Peter Heusser, 2010;Endler, 
Kocovski & Macrodimitris, 2001 ; Rutter and Rutter ,2002; Carver,1997).  The 
present study indicates that PA sufferers may have engaged more in adaptive 
coping when compared to maladaptive coping. 
 
Factor 4: Illness controllability and support 
This factor consists of three items reflecting illness controllability and support. It 
includes two items from the Brief-IPQ, personal control and treatment control, 
as well as one item that represents satisfaction with personal relationships in 
the WHOQOL-BREF. Previous literature has suggested the importance of 
illness beliefs about controllability in the management of disease (Weldam, 
Lammers, Heijmans & Schuurmans, 2014; Taylor, 2009). Studies have 
suggested patients feeling that their illness was controllable, both personally 
and through treatment (Morgan, Villiers-Tuthill, Barker & McGee, 2008). Other 
research has found that perceptions of personal control over one’s illness have 
been found to be lower than perceptions of treatment control (Hopman & 
Rijiken, 2015).  In other studies, weaker beliefs about one’s illness control was 
associated with lower HRQoL (Rutter & Rutter, 2002). Higher perceived control 
regarding one’s condition has also been linked with support in assisting with 
the same (Joseph, Neeraj & William, 2014). 
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Individuals’ perceptions of absence of support have also been linked to higher 
perceived need of treatment. Pilot studies in the present thesis have suggested 
that PA sufferers being dissatisfied with PA management and seeking online 
support to help them deal with the life disruptions posed by PA.  
 
Even though the internal reliability for this factor may be relatively low (.46), it 
highlights the importance of patients’ perceived control, how treatment may 
help control the severity of symptoms, and support through personal 
relationships. Examination of the factor loadings indicated that personal 
relationships had the lowest loading onto the overall factor. The examination of 
correlation coefficients indicated low non-significant associations of personal 
control with both perceived control and treatment control. Previous studies 
looking at support provided by a significant other suggested that in some 
cases, the type of support provided may inhibit the sense of control and 
adjustment of the patient. This may be explained through the display of 
overprotective behaviours which may increase psychological distress in the 
person receiving the support (Meier, Bodenmann, Mörgeli, & Jenewein, 2011; 
Schokker, Links, Luttik & Hagedoorn, 2010). Perceived control and treatment 
control shared similar loadings and significant moderate correlations. Higher 
perceived control has also been associated with better self-management of 
illness (Kaptein, Klok, Moss-Morris & Brand, 2010). This may be the case for 
PA patients who may not get treatment according to their needs and resort to 
self-treatment. The cognitions included in this factor reflect crucial themes that 
emerged from qualitative pilot work and existing research (Hooper, Hudson, 






Factor 5: Maladaptive coping  
Factor 5 comprises 3 items from the Brief-Cope (substance use, denial and 
venting) and the internal reliability for this factor was moderate (.66). These 
coping styles are well documented in the literature, reflecting the challenges of 
dealing with a diagnosis of chronic illness (Cameron & Wally, 2014). Tuncay, 
Musabak, Gok & Kutlu (2008) have reported the use of denial and substance 
use in patients suffering with diabetes. This study also reported the use of 
venting, however this was perceived as an effective way to promote 
psychosocial wellbeing in this patient group. Alternatively, in patients 
experiencing chronic fatigue syndrome venting was associated with greater 
disability and poorer psychological well-being (Moss-Morris, Petrie & Weinman, 
1996). The detrimental use of venting has also been reported in other 
population groups (Kaltsouda et al., 2011; Büssing, Ostermann, Neugebauer & 
Heusser, 2010). Freeman et al., (2016) have associated patient denial with 
worse visual field, when assessing the progression of glaucoma. The 
experience of heart failure was associated with denial in a narrative review of 
qualitative studies (Jeon, Kraus, Jowse & Glasgow, 2010). Qualitative research 
reported patient engagement in substance use as a way of dealing with 
different chronic conditions. The use of alcohol and prescription medications to 
deal with the associated stress has been reported by Jacobs, Ownby, Acevedo 





Research has also suggested that patients with rheumatoid arthritis self-
managed their illness by buying over-the- counter medication to relieve their 
perceived symptoms (Townsend, Backman, Adam& Li, 2016).  
Other studies with other patient groups reported increased substance use at 
the time of diagnosis and denial as barriers to treatment entry (Kuchinad et al., 
2016). In the present study approximately 80% of the population reported 
‘substance use’  72% reported using ‘denial’ and the use of ‘ venting’ was 
recorded for 42%, all to a lower extent. This may be linked to self-management 
in PA patients that are unable to get additional treatment, however only a small 
percentage (13%) of PA sufferers reported self-managing their condition. 
 
Factor 6: Illness understanding and adjustment 
Illness understanding and adjustment represents factor 6, comprising of five 
items. These items include acceptance coping, illness coherence and 
environmental HRQoL (availability of information and healthy physical 
environment). Literature has previously emphasized illness understanding as 
an important cognition through the course of one’s illness, facilitating one’s 
adjustment (Kostova, Caiata-Zufferey & Schulz, 2014; Pierobon, Giardini, 
Callegari & Majani, 2011; Morgan, Villiers-Tuthill, Barker & McGee, 2008; 
Sharpe & Curran, 2006). Illness responses such as acceptance are common in 
patients suffering with long-term conditions and may be explained by positive 
experiences of diagnosis, treatment and appropriate social support (Spessotto 







Factor 7: Distraction 
This factor is composed of four items that reflect spirituality and self-distraction. 
Spirituality has been suggested as a resourceful way of dealing with a chronic 
condition, being a key component of holistic care.  Seeking meaning through 
spirituality has been suggested as a resourceful way of coping with chronic 
illness, being associated with improved health-related quality of life (Büssing & 
Koenig, 2010; Cohen et al, 2007). A qualitative study based on descriptive 
phenomenology have suggested that engaging in  faith, prayer and  seeking 
related sources of support,  reflected  patients’ lived experience with their 
chronic illness (Narayanasamy, 2013; Büssing & Koenig, 2010;Cohen et al, 
2000). Self-distraction has been reported to be one of the most used strategies 
by diabetic patients (Tuncay, Musabak, Gok & Kutlu, 2008). Self-distraction 
and spirituality have been used as a meaningful way of diverting attention from 














The Pernicious Anaemia health-related quality of life questionnaire (PA-HRQoL) 
The following statements relate to the extent to which your life has been affected by your Pernicious Anaemia (PA), your experience of symptoms and how 
you may have dealt with it, in the past four weeks. Please select the most appropriate answer that fits your personal situation.  There are no wrong answers. If 







No, not at 
all 
  1. My illness has affected my life       
  2. I have had comfort and understanding from someone      
  3. I have found comfort in my religion or spiritual beliefs      
  4. I have felt as if I am slowed down       
  5. I have experienced  a frightened feeling as if something awful was about to happen      
  6. I have felt tense or ‘wound up’      
  7. I have made fun of the situation      
  8. I have had constipation, loose bowels or diarrhoea       
  9. I have  felt that treatment controlled my Illness      
10. My physical environment has been healthy      
11 .I have felt tired or had little energy       
12. I have given up trying to deal with my illness      
13. I have thought hard about what steps to take      
14. Worrying thoughts went through my mind      
15. I have  learnt  to live with it      
16. I have looked forward with enjoyment to things      
17. I have used alcohol or other drugs to help me get through it      
18. I have had emotional support from others      








No, not at 
all 
20. I have prayed or meditated      
21. I had trouble falling or staying asleep or sleeping too much       
22. I have been able to laugh and see the funny side of things      
23. I have felt pins and needles      
24. I have felt that the information I need is available in my day-to day- life      
25. I have felt numbness (extremities)      
26. I have turned to work or other activities to take my mind off things      
27. I have experienced sudden feelings of panic      
28. I have felt I am able to control my illness      
29. I have refused to believe that it has happened      
30. I have been satisfied with my personal relationships      
31. I have had negative feelings such as blue mood, despair, anxiety, depression       
32. I have felt chest pain       
33. I have felt  that I have a good understanding of my illness      
34. I have experienced  a sort of frightened feeling like ‘butterflies’ in the stomach       
35. I have had help or advice from other people      
36. I have said things to let my negative feelings escape      
37. I have accepted  the reality of the fact that it has happened      
38. I have expressed my negative feelings      
39. I have been able to enjoy a good book or radio or TV programme      
40. I have done something to think about it less, such as going to movies, watching TV, reading 
,daydreaming, sleeping, or shopping 
     
41. I have concentrated my efforts on doing something about my illness      
42. I have had memory problems, such as difficulty in concentrating      
43. I have tried  to get advice or help from other people about what to do      
 
Table.6.6.1.3 The preliminary version of the PA-HRQoL questionnaire© with 43 items 
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The PA-HRQoL questionnaire  
 
Please take the time to describe the ways PA affects your life (in case this 


































Please check that you have answered all the questions 






Table 6.6.1.4  












Domain Items  Range  
Domain 1 Physical functioning 1,4,8,11,16,19,21,23,25,32,42 0-44 
Domain 2 Illness impact on psychological 
health 
5,6,12,14,22,27,31,34,35,39 0-44 
Domain 3 Illness management behaviours 2,7,13,18,38,41,43 0-28 
Domain 4 Illness controllability and support 9,28,30 0-12 
Domain 5 Maladaptive coping 17,29,36 0-16 
Domain 6 Illness understanding and 
adjustment 
10,15,24,33,37 0-16 






6.7 General discussion 
 
The present study aimed to investigate the impact of illness severity on 
patients’ health-related quality of life. These investigations helped to identify 
the best predictors of HRQoL in the PA population and specifically served as 
basis for the development of a patient-centred instrument for the identification 
and management of health-related quality of life for patients suffering with 
pernicious anaemia, the PA-HRQoL questionnaire. PA poses a considerable 
impact on individuals’ lives and these impacts have not previously been 
assessed. The present study has described the development of a new patient-
centred instrument to identify and assess the health-related quality of life of 
patients suffering with PA (PA-HRQoL). The PA-HRQoL is a novel measure 
based on patient-reported outcomes and it has the advantage of potentially 
identifying issues that may not be assessed in generic HRQoL instruments or 
during the clinical consultation (Heijmans et al., 2001). Its content resulted from 
the initial generation of factors from existing validated measures, and pilot 
work, ensuring that items included were pertinent to the PA population. This 
measure consists of 43 items measured across seven domains (physical 
functioning, illness impact on psychological health, adaptive management 
behaviours, illness controllability and support, maladaptive coping, illness 
understanding and adjustment and distraction) and it appears to be reasonably 






Findings from the present study demonstrate the important relationship 
between health status, illness representations and coping as important 
determinants of HRQoL. In the PA population, HRQOL seems to be 
determined by patients’ beliefs about their condition, which in turn motivate 
behaviours consistent with disease management and as a result, may elicit 
anxiety and depression responses. 
 Nevertheless, these findings lend support to the common sense model 
described by Leventhal and colleagues (1980). However, it also becomes 
difficult to identify the cause of poor or improved functioning. Using these 
constructs as central determinants of outcome is warranted in future 
longitudinal research (Petrie & Weinman, 2012). 
 
Measures of health status (anxiety and depression) emerged as significant 
negative predictors of physical, psychological and environmental health. 
Investigation of the levels of anxiety and depression in this sample indicated 
the possible presence of a depressive and anxious state in this population. 
One may argue that this may not seem surprising since negative affect is 
common among all disease groups, compared with the general population 
(Yuan, Yu, Shi, Ke & Zhang, 2015; Katon, 2011; Clarke & Currie, 2009). 
Nonetheless, this emphasizes the need of identifying patients that may 
experience troubles dealing with the impact of PA, so that appropriate 







The current study has also presented statistically negative associations 
between illness consequences and physical, psychological and environmental 
HRQoL. The experience of symptoms and psychosocial difficulties as part of 
the chronic aspect of one’s condition may have resulted in psychological 
distress and therefore impaired HRQoL (Nabosi, Wardam & Al-Halabi, 2013). 
Alternatively, significant positive associations were found between illness 
identity and the psychological and environmental dimensions of health-related 
quality of life. In this way, PA sufferers’ illness understanding may be a 
contributing factor to an improved HRQoL. Environmental HRQoL includes 
items that cover health care and informational support. Pilot work and existing 
PA research, however limited (Hooper, Hudson, Porter & McCaddon, 2014), 
has previously emphasized the lack of satisfaction with the current provision of 
support. These findings have also been documented elsewhere in other 
population groups (Kaltsouda et al., 2011; Cartwright, Endean & Porter, 2009; 
Dickson, Knussen & Flowers, 2007). Intervention studies aiming to help 
patients develop effective coping strategies would be valuable for this 
population. Previous research has reported the beneficial effects of a psycho-
educational intervention programme addressing health-related quality of life in 
patients experiencing symptom burden.  Improved health status, better illness 
understanding and feeling less isolated were reported as the main benefits of 
this intervention (Lindell et al., 2010). The results discussed here highlight the 
importance of measuring health–related quality of life in populations suffering 
from chronic conditions such as the one under investigation (Rawlings, Brown 





One significant finding related to the potential impact of illness controllability 
and support on HRQOL. This finding may imply that improvements in one’s 
perceived personal control may improve PA management, resulting in 
improved relationships and better HRQoL. Research may also focus on 
assessing the provision of health care support in this population. Assessing 
patients’ needs in relation to their expectancies of support has been suggested 
as an important part of disease management (Bonevski et al., 2000; Girgis, 
Boyes, Sanson-Fisher & Burrows, 2000). Findings from a needs assessment 
with patients suffering from renal complications has found emotional, physical, 
psychological, social and existential burdens. These findings served as basis 
for the future development of a health psychology service in concurrence with 
a renal counselling support within hospital services as ways of improving 
services to renal patients (Finnegan-John & Thomas, 2012). Future research 
may also implement prospective studies to investigate whether illness 
representations mediate symptom severity. 
 
Coping styles have emerged significantly in the factor structure, being included 
in different factors. It is important to note that there appears to be an overlap 
regarding the coping styles that emerged in factor 3 (illness management 
behaviours) and factor 5 (maladaptive coping). An example, the two items that 
represent venting, one loaded in factor 3 (‘I’ve been expressing my negative 
feelings’) and one loaded in factor 5 ( I ‘ve been saying things to let my 
unpleasant feelings escape’). Even though these items represent the same 
coping style, it may be the case that these items may have been perceived 




The design employed in the present study may be a possible explanation. 
Factor analysis of different set of items, may have reduced coping styles into 
apparently different concepts. This is shown on factor 3, 5 and 7 (e.g. religion 
and self-distraction). Previous psychometric assessments of the COPE 
questionnaire (Carver et al., 1989) have documented this issue (Lyne & Roger, 
2000; Ingledew et al., 1996). 
 
Co-morbidity presence remains an issue in this population. More than half of 
the sample (55%) reported being diagnosed with another chronic condition. 
This may impact on the present findings, as it is not clear whether patients 
differentiated PA symptoms from existing co-morbidities. Previous research 
has suggested co-morbidity presence to result in poor psychological health and 
increased symptom severity, resulting in impaired HRQOL (Huber, Wacker, 
Vogelmeier & Leidl, 2015 Blinderman et al, 2009). It would be useful to 
investigate PA patients with no other existing conditions. However, this may 
prove difficult regarding the likelihood of co-morbidity in chronic conditions 
(Katon, 2011) and in PA (Hooper, Hudson, Porter & McCaddon, 2014; 
Alkhateeb et al, 2003; Zelisseen et al, 1995). Therefore, firm conclusions may 
not be drawn regarding the HRQoL of these patients. 
 
Limitations of the measures included in the present study refer to the fact that 
illness perceptions’ dimensions’ were only measured by using one item. This 
may lack clarity in terms of the underlying explanations for specific dimensions 





Employing the previous version of the same measure (IPQ-R; Moss-Morris, 
Weinman, Petrie, Horne, Cameron & Buick, 2002) where dimensions consist of 
more items, would have possibly been more precise (Fuchs & 
Diamantopoulos, 2009). Qualitative investigations into illness consequences 
would also prove useful in terms of potentially overcoming this limitation. This 
will be addressed in further studies, specifically when piloting the PA-HRQoL 
questionnaire. 
 
The multidimensional locus of control scales only produced significant marginal 
correlations with the other variables in the present study. Even though the 
scale possessed acceptable internal reliability in this population group, it failed 
to capture perceptions of control in the analyses conducted. However, these 
were captured by the control dimensions in the Brief-IPQ. This may be 
explained by the population group and design used. Nonetheless, these scales 
are used to supplement other locus of control measures. It has been 
suggested that for specific population groups, investigation of only one 
dimension would possibly yield better results.  
Further, this scale may produce better findings when applied to the 










Limitations of the present study refer to the cross-sectional nature of the study 
design in which arguments about causality may not be drawn. Further, since 
no objective data regarding illness severity was gathered, further discussion of 
the impact of psychological factors is not possible. Although the current study 
used an adequate powered sample for conducting the required analyses, the 
sample size was potentially limited to conduct comparisons between sub-
groups of patients in different stages of their condition. 
 
 Exploring these psychological variables longitudinally may have produced 
different results, if the effect of treatment was considered in these patients. 
Research with patients suffering from comorbid depression and diabetes 
receiving treatment for depression, were part of an intervention aimed at 
improving diabetic outcomes. The intervention was based on providing 
education, problem-solving treatment and support for managing antidepressant 
medication. Functional impairment and diabetes self-care behaviours were 
assessed at baseline, 3, 6 and 12 months. Patients presented with less severe 
depression and improved on their overall functioning (daily activities’ 
performance) at 1-year post-intervention, as compared with individuals 
receiving usual care (Williams et al.,2004). 
 
Due to a low response rate in the clinical population, the findings of the present 
study are limited to infer generalizability. Nevertheless, part of the sample 
included non-NHS patients. This has both advantages and disadvantages.  
The online simple recruited from patient support groups, was a diverse one 




However, it may also bias the results of the study, meaning that individuals that 
are affiliated to support networks may express more illness concern. 
Advantages of using an online social networking population means that the 
experience of both clinic and non-clinic individuals is reflected in the developed 
instrument. 
 
HRQoL has been suggested as an important health indicator in clinical 
outcomes. Some of the studies presented in this section used disease-specific 
measures of HRQoL, which in a way may have provided better support for their 
findings. However, it has also been suggested that the combined application of 
both generic and disease-specific measurements may result in more accurate 
investigations of both global aspects and specific dimensions of HRQOL, 
covering all areas of functioning (Engstrom, Persson, Larsson & Sullivan, 
2001; Milligan et al., 1993). Taking this into account, since there is no current 
validated measure of HRQoL for the PA population, the only way of assessing 
HRQoL at this point in time was to use a well-established generic measure like 












6.8 Conclusion  
 
The current study emphasizes the interrelationship between the dimensions of 
HRQoL and mainly indicates the contribution of illness identity, treatment 
control, illness consequences and depression to explaining psychological 
HRQoL, and the influence of illness consequences and anxiety in explaining 
environmental HRQoL. Research findings recognize the importance of 
considering the impact of a chronic condition such as pernicious anaemia on 
psychological health and reinforce the knowledge that improved psychological 
health may predict improvements in HRQoL (Blakemore et al, 2014).   The 
present study contributes to a growing body of literature emphasising the 
importance of investigating patients’ beliefs regarding their overall illness 
experience, when developing patient-centred treatment pathways. The 
preliminary version of the PA-HRQoL questionnaire was developed for the PA 
population. However, this only represents the early stages of instrument 
development. Further research will focus on the validation of this instrument in 
a sub-sample of PA sufferers to establish appropriate psychometric properties. 
Subsequent instrument refinement will allow items to be added or removed in 
subsequent versions. The outcome of the research presented in this thesis 
may represent significant advances in the PA care by supplementing existing 














7.1 Summary of findings 
The work presented in the current thesis was carried out to address the 
limitations in the existing research concerning the psychosocial impact of 
pernicious anaemia on individuals’ health-related quality of life. The primary 
endpoint reflected the development of a patient-centred outcome measure to 
identify and manage HRQoL in patients suffering with this condition, the PA-
HRQoL questionnaire. This objective was achieved through conducting four 
exploratory studies to further understand why patients still experience severe 
symptoms and perceive the need for additional B12 therapy, despite frequent 
treatment. The findings of these studies align with empirical evidence and 
highlight the contribution of illness representations, coping styles and health 
status to the understanding of health-related quality of life in this population. 
Study 1 (investigating the demographic profile of patients suffering with B12 
deficiency) investigated the progression of patients from diagnosis through 
treatment and clinical management of this condition. There were gaps 
identified in the patient records mainly relating to specific diagnostic testing, 
which may not have been carried out consistently for this population. Further, 
information regarding clinical variables such as family history and the reason 
why treatment was discontinued for some patients despite a PA diagnosis is 
lacking for the majority of cases.  
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This study highlighted the diagnosis of comorbidities, in particular, depression, 
contributing to the experience of psychological distress in this patient group.  
These findings indicate that PA screening may not be routinely performed, 
having significant implications for the effective management of PA. 
Study 2 (investigating individuals’ perceptions of their PA experience) was 
carried out to explore specific questions of diagnosis and treatment that 
emerged from the findings of study 1. The themes that surfaced from this study 
included transitions to PA diagnosis, PA beliefs, B12 therapy and symptom 
experience and management. This study suggested poor practices in the 
management of PA, resulting in misdiagnosis in many cases. This contributed 
to exacerbated symptoms, illness progression, and social isolation resulting 
from the lack of perceived clinical support. The severity of symptoms and the 
inability to control these represented key factors in the way individuals coped 
with PA. Pernicious anaemia imposed restrictions on activities of daily living, 
impacted on the ability to establish social relationships, contributing to the 
experience of psychological distress and resulting in less confidence in the 
ability to deal with this condition. Nevertheless, for some individuals, lifestyle 
changes such as exercising and changing one’s diet, helped to cope with the 
severity of symptoms. Findings from this qualitative study highlighted locus of 
control, coping, quality of life and social support as meaningful variables to be 








Subsequently, study 3 (A study of the PA experiences of members of the 
Pernicious Anaemia Society) delved into the diagnostic and treatment 
perceptions of members of the PA society. The themes that emerged from this 
study included misdiagnosis, PA diagnosis, B12 therapy, symptom 
management, provision of information and support from local health services 
and relationships. Findings suggested that patients’ subjective experiences 
were trivialized and that reported symptoms were attributed to psychosomatic 
causes, by GP’s. This resulted in increased patient anxiety, influencing coping 
responses such as ignoring symptoms, suffering in isolation and buying OTC 
treatment to alleviate perceived symptoms. 
 Although individuals expressed the relief and regained sense of self from 
finally receiving a PA diagnosis, lack of confidence in the medical profession, in 
terms of effectively identifying and treating pernicious anaemia was also 
expressed. Treatment suspension reflected an important sub-theme, 
compromising individual care. Some patients reported treatment being 
interrupted by their GP, despite PA diagnosis, resulting in poor clinician-patient 
encounters and influencing decisions for the self-management of their 
condition. Some patients also expressed worry concerning the prognosis of 
their condition. An area of future research may be to explore the significance of 
prognosis over time and its potential association with the development of 
gastric cancer, a significant concern in this population. Treatment 
dissatisfaction and the lack of healthcare support represented common 
complaints of many PAS members’. Results of this study highlighted the 





The outcomes of study 1, 2 and 3 provided the foundations for selecting the 
psychosocial constructs measured in study 4 (investigating illness severity and 
health-related quality of life in patients diagnosed with Pernicious Anaemia), 
which included illness perceptions, health status, coping strategies, locus of 
control, somatic focus and health-related quality of life. Investigations into 
these variables suggested health status, illness representations and coping as 
key determinants of HRQoL in this population. Findings indicated that 
depression and anxiety responses were elicited by patient’s beliefs about their 
condition resulting in specific illness responses.  
 
 Key findings from these investigations indicated that treatment control and 
depression significantly explained psychological HRQoL and anxiety and 
illness consequences explained environmental HRQoL. These findings support 
the idea that improvements in the management of PA may predict 
improvements in psychological health and subsequently improvements in 
HRQoL.  The variables in this study were ultimately subjected to data reduction 
techniques and provided meaningful factors that formed the basis of the PA-
HRQoL questionnaire. This prototype is comprised of 43 items across seven 
dimensions (physical functioning, psychological health, illness management 
behaviours, illness controllability and support, illness understanding and 
adjustment, maladaptive behaviours and distraction), measured on a 5-point 
Likert scale. Physical functioning was associated with perceived illness 
consequences, symptom severity and depression. The dimension of ‘illness 
impact on psychological health’ explains the association between behaviour 
disengagement and its association with the perceived experience of anxiety 
and depression.  
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This relationship appears to be mediated by instrumental support. Illness 
management behaviours reflect the importance of different types of coping 
strategies used to deal with PA. These include active coping, planning, 
emotional support, instrumental support, venting and humour. The dimension 
of ‘illness controllability and support’ reflects the link between personal control, 
treatment control and the provision of support. Patients’ beliefs of being 
supported and that their illness may be controllable, both personally and 
through B12 therapy, contribute to improved HRQoL. Maladaptive coping 
reflects the challenges faced by PA sufferers in dealing with their condition, 
such as engaging in denial and substance use. Illness understanding and 
adjustment are associated with illness acceptance, resulting in improved 
HRQoL. 
 Lastly, distraction highlights the use of coping styles that may help the 
individual cope with illness demands, such as self-distraction and seeking 
meaning through spirituality. These dimensions substantiate the themes that 
emerged from the studies already described here, strengthening the content 
validity of this instrument, and highlight the importance of psychological 
constructs in the development of patient-centred pathways.  Each dimension 
taps into specific areas of HRQoL that are meaningful to PA sufferers,  may be 
assessed individually, or evaluated in a therapeutic context on an item by item 
basis (Lambert and Shimokawa, 2011; Harmon et al., 2007). The PA-HRQoL 
was developed to complement existing physiological approaches through 
highlighting poor functioning on a wider level potentially informing the 




7.2 Potential limitations 
The literature suggesting a higher prevalence of PA diagnosis in females is 
mixed (Lahner & Annibale, 2009; Zittoun, 2001; Carmel, 1996). The fact that 
the sample used was predominantly female, may have influenced the outcome 
of the research. This may be partly explained by gender differences in seeking 
health behaviour (Thompson et al., 2016; Schetzer & Florcken, 2012; Regitz-
Zagrosek, 2012; Zandman-Goddard et al., 2012). Research suggests that in 
comparison with men, women seek health care more frequently for both 
physical and mental health complaints (Mackenzie, Gekoski & Knox, 2006, 
Verhaak et al., 2005).  Gender may indirectly influence health care utilization 
through factors such as a higher propensity to seek health care services, the 
experience of somatic morbidity and poor perceived health status (Nabalamba 
& Millar, 2007; Koopmans & Lamers, 2006; Carriere, 2005).  
A strength of the current research refers to the recruitment of both clinic and 
non-clinic samples with a varied age range and a broad range of educational 
attainment, which may have helped strengthen the findings. However, 
accounts of individuals that do not have access to the internet (BPS, 2013; 
Wright, 2005), and the potential tendency of individuals overstating or 








7.3 Implications of research findings  
The results of the studies that form the current thesis provide a better 
understanding of this condition and contribute to the development of a novel 
instrument based on patient-reported outcomes. This has further implications 
for the management of PA.  Currently, the provision of healthcare support may 
be poor for PA patients in general and most specifically for the ones that 
perceive the need for additional treatment. These patients report experiencing 
dismissive attitudes from their clinicians, resulting in increased psychological 
distress, influencing decisions to withdraw their current care and opt for the 
self-management of their condition. By identifying patients that may be 
experiencing difficulties in managing their symptoms, the PA-HRQoL has the 
potential of adjusting treatment according to individual needs.  
 
7.4 Directions for further research  
In further research, the PA-HRQoL questionnaire will be tested in a sub-
sample of PA sufferers to establish validity and reliability. According to Patrick 
et al (2011), assessing patient understanding represents a key feature on the 
development of patient-centred instruments. This iterative process includes 
ensuring that the content is clear and meaningful to the population under study 
and that respondents understand how to complete the instrument. This will 
allow for subsequent instrument refinement, establishing the content validity of 
the final version of the instrument, and extensive psychometric testing will be 
undertaken, which will include reliability analyses and sensitivity testing. 
Predictive validity refers to the extent to which results of a measure predict 




Since there is no gold standard measure for HRQoL in patients suffering with 
PA, other validation strategies will be considered, such as construct validity 
(Guyatt et al., 1993). Subsequently, further studies including a large number of 
patients will need to be carried out to ensure external validity. Once validated, 
the PA-HRQoL may be useful to identify and target individual patients that may 
be experiencing symptom burden and therefore be used as an outcome 
measure in clinical trials and in the assessment of illness progression. This 
instrument may be used to monitor individual patients and highlight patients in 
need of direct referral to other services to facilitate prompt and effective 
treatment. 
Illness perceptions are not static, these may change according to individual 
circumstances. The research presented here may provide the starting point for 
developing interventions that integrate psychosocial support in the routine care 
of PA. This may be achieved by providing education and support in the 
management of PA.  
Strengthening PA beliefs may result in better illness understanding.  This may 
result in the improvement of symptoms and therefore improved health status, 
benefiting both the patient and physician in achieving optimal management and 
therefore improved HRQoL. Hence, interventions focusing on increasing 
patients’ agency and health-related quality of life that can be rolled out across 






7.4.1. Validity and reliability testing of the PA-HRQoL instrument  
The development of health-related quality of life measures considers the 
examination of the psychometric properties of i) reliability and ii) validity. 
Therefore, instruments must be reliable, valid and sensitive to change. 
7.4.1.1 Reliability  
Reliability is a prerequisite for validity and refers to the ability of a specific 
measure to produce consistent results under the same conditions. Reliability 
may be demonstrated by assessing the internal reliability (Cronbach’s alpha) 
and by assessing test-retest reliability. The internal reliability assesses item 
homogeneity and it is determined by the Cronbach’s alpha. Test-retest 
reliability is an important indicator of the stability of an instrument. It consists in 
the administration of the instrument to the same population, in two separate 
occasions. Since it is likely that symptom reporting fluctuates over time, 
intervals of four weeks are generally used to ensure that a change in true score 
is minimal. The correlation between the scores in two occasions will provide an 
estimate of the reliability of an instrument. 
7.4.1.2 Validity  
The validity of an instrument refers to its ability of measuring what is designed 
to measure. Fundamentally, there are four aspects to validity, face validity, 
content validity, criterion validity and construct validity (Field, 2009). 
 Face validity refers to the subjective assessment of the relevance of a specific 
instrument. It refers to whether items in a questionnaire appear to make sense 
and can be easily understood. Face validity of the PA-HRQoL was initially 
established in previous stages of this research, informed by the experience of 
PA sufferers, leading to the development of the PA-HRQoL.  
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Content validity examines the degree to which individual items represent the 
construct being measured and capture the concepts that reflect the experience 
of individuals (Patrick et al., 2011).  
Criterion validity tests for the ability of an instrument to correspond with other 
valid measures (concurrent validity) as well as it tests for the ability to predict 
future outcomes (predictive ability).  
Construct validity refers to the ability of an instrument to confirm expected 
hypotheses. It reflects the patterns of the relationships of a specific instrument 
with well-established measures. Construct validity may be divided into two sub-
types, convergent validity and discriminant validity.  Convergent validity reflects 
the agreement among ratings of measures, reflecting that they are theoretically 
related. Discriminant validity reflects the lack of a relationship between 
concepts that are not theoretically related, ensuring that measures can 
discriminate between different population groups (Ware et al., 1993; Brazier et 
al., 1992). 
Responsiveness 
Sensitivity to change constitutes an important criterion of HRQoL measures 
aiming to evaluate the impact of interventions. The depiction of change may 
vary according to different measures. This may be related to the content of a 
specific measure as well as its primary objective, such as evaluation of 







 Validity and reliability testing of the PA-HRQoL instrument (ctd’) 
The psychometric properties of reliability and validity of the PA-HRQoL 
instrument will be tested in three different stages. In stage 1, content validity 
will be assessed through language clarity and respondent understanding. The 
measure will be administered to a sub-sample of PA sufferers recruited from 
the Pernicious Anaemia Society. Since there is no gold standard measure of 
HRQoL for patients suffering with PA, stage 2 will determine criterion validity of 
the instrument by testing the same with another well-established generic 
measure of HRQoL, in a cross-sectional study. The Short-form Health Survey 
(SF-36; Brazier et al., 1992; Ware & Sherbourne, 1992) has been widely and 
extensively used across different population groups due to its high 
psychometric properties of validity and reliability and therefore appears to be 
one of the best available instruments for the assessment of criterion validity of 
the PA-HRQoL instrument.  In this stage, relationships between the scales will 
be examined through correlations (Pearson). Item correlations with scale totals 
will be investigated and the internal reliability of the scales will be determined 
(Cronbach’s alpha).  In stage 3, further validation will be carried out to establish 
reliability, construct validity and responsiveness. It is anticipated that 
responsiveness will be tested in a longitudinal study, by assessing change in 







Stage 1: Piloting and modification of the PA-HRQoL to inform subsequent 
developments of the instrument. 
Method  
Design 
Initial validation of the PA-HRQoL instrument will employ a cross-sectional 
survey design to test the psychometric properties of the PA-HRQoL instrument.  
This instrument will be administered online to PA sufferers. This will ensure 
that respondents will have enough time to complete the measure and provide 
appropriate feedback allowing the refinement of the instrument in subsequent 
stages of its development. 
Ethical considerations  
Ethics for the stage 1 (pilot testing of the PA-HRQoL) have already been 
granted by the University of South Wales Faculty Ethics Research Sub-Group. 
Participants will be informed about the study purpose and will be able to 
withdraw for the study at any time (Appendix 4.2). Informed consent will be 
obtained via Survey Monkey, according to BPS guidelines (2010). Responses 
of potential participants will remain anonymous, as Survey Monkey does not 
retain IP data.   
Sample 
The sample will consist of PA sufferers recruited online from the PA society 
website. For inclusion, participants will be required to be at least 18 years of 
age, to have received a formal diagnosis of PA from a health professional, to 
confirm that they have not participated in phase 1 of the research study and to 
have an adequate understanding of the English Language. Exclusion criteria 




Sample size calculation  
According to Baker (1994), a sample size of 10-20% of the original sample 
recruited for the study which led to the development of the PA-HRQoL 
measure (Study 4; N=184), constitutes a reasonable number of participants to 
consider enrolling in a pilot study. Since the primary objective of this study will 
be to pilot test the instrument, a sample calculation was based on the 
expectation that 37 reflects the minimum number of participants required for 
this pilot study. 
Materials 
The PA-HRQoL has been developed in Phase 1 of this research (study 4). 
Procedure 
Participants will be required to complete the measure online and provide 
written feedback on the content and format of the measure to ensure 
acceptability and practicality.  
Data analysis 
Descriptive statistics will be computed to identify frequency distributions and 
dispersion of scores. The reliability of the instrument (PA-HRQoL) will be 
determined by using the Cronbach’s alpha statistic and validity. Item-total 







7.5 Contributions to the PA literature  
Despite potential clinical advances that may inform a more effective approach 
to the management of PA, such as the issue of new guidelines (Devalia, 
Hamilton & Molloy, 2014) , and new ways of interpreting test results (Fedosov, 
Brito, Miller, Green & Allen, 2015) , the current management may not be 
effective in the control of PA.  The current thesis represents advances in the 
PA literature and is the first to effectively address individuals’ perceptions of 
their PA experience. PA research has been extended in terms of  i) developing 
a better understanding regarding the pathway from diagnosis through 
treatment and management of PA, ii) highlighting the centrality of psychological 
variables in determining HRQoL, iii)  creating a  greater awareness of PA, 
calling for clinicians’ willingness to adopt a holistic approach to the 
management of pernicious anaemia, therefore strengthening the doctor-patient 
relationship, iv) developing a patient-centred measure for the identification and 
management of HRQoL in PA patients. The PA-HRQoL is a novel measure 
based on patient-reported outcomes, emphasising meaningful aspects of ones’ 
illness and has the potential of i) complementing existing approaches to the 
management of PA ii) assessing the severity of patients’ symptoms, therefore 
providing tailored care subsequently improving patients’ health status ,  
 iii) identifying issues that may not be assessed in generic HRQoL instruments 
or during the clinical consultation, iv) targeting individual patients’ needs and 
improving coping strategies through the development of interventions, v) 
assessing HRQoL changes over time, and, vi) reducing the economic costs 








General conclusion  
 
The current thesis has demonstrated the crucial impact of PA in influencing 
beliefs regarding illness controllability and eliciting coping responses 
subsequently determining one's health status and HRQoL. Hence, illness 
management that addresses PA sufferers’ needs from a biopsychosocial 
perspective may contribute to higher satisfaction with treatment, resulting in 
improved health-related quality of life. The current thesis has generated 
discussion on how current practices may be improved and described the 
development of the PA-HRQoL, a novel patient-derived health-related quality 
of life measure intended to assess and manage symptom severity in a complex 
condition such as pernicious anaemia. It includes domains that tap into 
interconnected areas of HRQoL including physical functioning, coping styles, 
illness controllability and support. Despite the potential limitations, the PA-
HRQoL questionnaire is the first attempt to identify and manage HRQoL in this 
population group, reinforcing the growing body of literature in this topic area. 
The goal of the current thesis was achieved, and following appropriate stages 
of instrument refinement, the timely implementation of the PA-HRQoL is called 
for. It is anticipated that the PA-HRQoL may be used in routine clinical practice 
and provide health professionals with a further understanding of the health 
care needs of this population, serving  as guidance for decision-making and 








Adenosylcobalamin One of the active forms of B12. As a supplement, only available 
in the form of tablets, not injections. 
Anaemia A reduction in the haemoglobin in the blood cells. The most 
common form of anaemia is iron-deficiency anaemia resulting 
in fatigue symptoms and small red blood cells. Fatigue is also 
common symptom in pernicious anaemia. 
Antibody Also known as, immunoglobulin is a large, Y-shaped protein 
produced mainly by plasma cells. This protein is used in the 
immune system to neutralize pathogens such as bacteria and 
viruses. 
Atrophic gastritis Chronic inflammation of the stomach mucosa, impairing the 
secretion of essential substances such as the intrinsic factor, 
resulting in digestive problems. 
Cobalamin The term used to describe vitamin B12, due to the presence of 
mineral cobalt in the B12 molecule. Cobalamin exists in 
different chemical forms. 
Cyanocobalamin Represents a synthetic form of B12, being produced from 
hydroxocobalamin and cyanide. This form is mostly produced 
in France and it is mainly added to fortified foods. 
Hydroxocobalamin The purest form of B12, being produced by fermenting bacteria 
and it represents the main form of B12 found in most foods. It 
converts to methylcobalamin in the body and it is widely used 
as a standard treatment for pernicious anaemia. 
Intrinsic factor A glycoprotein secreted by the parietal cells. It is essential for 
the absorption of vitamin B12. Failure to secrete the intrinsic 
factor leads to depletion of vitamin B12 and results in pernicious 
anaemia. 
Methylcobalamin Represents the most active form of B12 in the body and 
effective in protecting the nervous system 
Parietal cell Cells present in the stomach lining that produce intrinsic factor 
as well as hydrochloric acid. This acid is essential for breaking 
down proteins in the stomach, enabling the release of vitamin 
B12 from food. 
Pernicious anaemia Also known as autoimmune metaplastic atrophic gastritis, 
occurs when the individual produces antibodies that destroy 
the parietal cells in the stomach. 
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Study 1  








































































Medication: B12  1mg every 3 months, 
loading doses every 2 days/2 weeks, 
regular since diagnosis(rg) 
Consultations since diagnosis 
7(4 years) app 2/year 
Reason for B12 therapy: PA Referrals: 
Orthopaedics 
Request for B12: NS Observations: 
Medication review on a regular basis. 















Appendix 1.3 – Example of classification of diseases and signs and 
symptoms (ICD-10) 
 
Table 1. Disease classification 
Classification  Examples 
Blood and immune system Iron deficiency anaemia 
Circulatory system Angina; Cardiac failure 
Digestive system                                                            Atrophic gastritis; Irritable bowel syndrome 
Ear and mastoid process  Tinnitus 
Endocrine, nutritional and metabolic Folic acid deficiency 
Eye and adnexa  Blurred vision; Cataracts 
Genitourinary system Chronic kidney disease; 
Mental and behavioural disorders  Anxiety disorder; Dementia 
Musculoskeletal system and connective 
tissue                           
Arthritis; Fibromyalgia 
Nervous system  Cerebral atrophy; Epilepsy 
Respiratory system Asthma; Chronic obstructive pulmonary 
disorder 
Skin and subcutaneous tissue Alopecia; Eczema 
 
Note: table devised according to the international classification of diseases (ICD-10). 
 
 
Table 2. Signs and symptoms classification 
Signs and symptoms Examples 
Circulatory and respiratory                                                              pleurisy; shortness of breath 
Cognition, perception, emotional state and 
behaviour                     
memory problems; hallucinations   
                                   
Digestive system and abdomen                                                        bowel problems; nausea 
General signs and symptoms                                                  abnormal weight loss; extreme tiredness 
Nervous and musculoskeletal system    gait problems; tremors 
Speech and voice                                                                       
  
slurred speech; voice hoarseness 
Skin and subcutaneous tissue                                                      pins and needles; numbness 
Urinary      dysuria; nocturia 
 








Study 2  




I am undertaking research in the School of Psychology to explore the experiences of 
Pernicious Anaemia (PA) sufferers and to create a better understanding of the illness 
in order to improve treatment experiences. If you suffer from PA or if you know 
someone that would like to share their PA experience, and you can spare an hour of 
your time, please contact me to arrange an interview. Your views will be of great help 




Lenira Semedo (e-mail: lsemedo@glam.ac.uk) 
 
 
Appendix 2.2 – Development of interview schedule   
 
Interview Schedule: Exploring individuals’ perceptions according to their PA experience 
There is a lack of empirical evidence concerning the nature of psychological factors 
implicated in PA and questions regarding the understanding of the condition, its 
symptoms and variations in individual differences remain unanswered. Therefore, in 
order to create a better understanding of the illness and to be able to offer treatment 
regimes that meet the individual needs of each patient, the present interview soughs to 
explore the experiences of these individuals regarding disease management. 
Psychological aspects in terms of coping with the illness, symptom perception and 
severity, locus of control, self-efficacy, illness beliefs and how these might guide 
symptom interpretation and the way patients adapt and cope with the condition, and 





1. Locus of control and chronic illness 
Research has documented that individuals who exert control over their illness, 
experience the reduction of the side effects of their treatment (Carlson, 1977).  
People with an internal locus of control (LOC) may be more likely to be more 
motivated, therefore engaging actively in efforts to gain control over their illness. 
However, it has been reported that this doesn’t apply to chronically ill patients (e.g. 
cancer) who may experience frustration due to the inability to change their present 
health status. In contrast, individuals with an external LOC maintain a positive 
psychological state since they do not try to control the environment, therefore, 
frustration in less likely to occur (Wortman & Dunkel-Scheffer, 1979). 
1.  Quality of life and chronic illness 
 Coping with life changes and disease management often impairs quality of life 
(Sprangers et al, 2000).The impact of chronic illness threatens the quality of life of 
sufferers and consumes health care resources, therefore, information regarding the 
impact of chronic illness in the health related quality of life is crucial for obtaining 
patient-centred health services (Rice & Sung, 1996, as cited by Lam and Lauder, 
2000). Quality of life is subjective, including domains of physical, psychological, daily 
role, social functioning and general health-perception (Department of Health and 
Human Services, 2000). One important aspect of quality of life refers to co-morbidity, 
where demographic factors such as time since diagnosis and age affect health 
perceptions (De-Bock et al, 1996, as cited by Lam & Lauder, 2000).  
2.  Illness beliefs and coping strategies 
Illness beliefs and coping strategies are crucial factors in both the onset and 
progression of an existing condition as well as its outcomes. Patients beliefs about 
effective ways to manage their own illness may lead to a negative illness schema 
which may encourage processing of symptom- relevant information leading to 
misperception of the significance of these which may help to maintain negative illness 
beliefs (Moss-Morris, 2005).  
Positive beliefs such as sense of internal control have been associated to coping 
strategies, which are generally considered more adaptive such as seeking social 
support and actively trying to tackle the problem. Converse strategies would be 
disengagement, avoidance and venting emotions. Research conducted with patients 
with CFS has reported that individuals normally exhibit emotion focused coping by 
adopting a defensive style.  
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However, it remains unknown if contribution to illness is due to a defensive style of 
coping or to suppression of emotion (Moss-Morris, 1996).  Also, coping strategies were 
characterized as all-or–nothing erratic pattern of behaviour, being related to disability 
and fatigue (Moss-Morris, 2005). 
3. Self-efficacy and chronic illness 
Self-efficacy maintains that processes of psychological change operate through 
alteration of an individuals´ sense of mastering efficacy (Bandura,1982).Patients who 
believe in their ability to master a situation look at challenges to control their illness,  
and these may be accomplished through mastering of situations, observing others and 
social persuasion .McCathie, Spence and Tate(2002) assessed coping strategies, 
levels of Self-efficacy regarding symptom management ,social support and 
adjustment(depression, anxiety and quality of life) in a sample of 92 individuals 
suffering from COPD . Controls used were: symptom severity, socioeconomic status, 
duration of disease and age and it was reported that high levels of withdrawal were 
associated to low levels of coping and self-efficacy and to high depression, anxiety and 
reduced quality of life. 
General questions 
1. Demographics (age, gender, background, status, family history of PA) 
2. May you please confirm that you have been diagnosed with PA.? How 
many years since your diagnosis? 
3. Do you have any other conditions? Please expand. 
4. Do you believe that you have been misdiagnosed prior to your PA 
diagnosis? Please explain 
5. Have you been tested?  Which tests were performed?  Please explain. 
6. Regarding PA, how often do you visit your GP? 
7. Are you undergoing any treatment? For how long? Frequency? Please 






Questions regarding Illness perceptions (understanding of the condition, beliefs 
regarding testing/treatment, coping) 
8. How knowledgeable would you say you are regarding your illness? Please 
expand (sources of information). 
9. When diagnosed did you feel you were informed by your GP about your 
illness? 
10. Did you look for a second opinion? Why/not? 
11. What do you think is the cause of your illness? (i.e. genetic, stress)? 
12. What do you think are the consequences of having PA? Do you think that 
it affects the way others see you or causes difficulties for those close to 
you? 
13. Do you believe that your treatment regime is effective? 
14. Did you ever have a break on the course of your treatment? 
15. Have you ever asked requested for more (or less) treatment? How did 
your GP respond? 
16. How does treatment affect your health? Please expand. 
17. In relation to PA, do you think that it influences your lifestyle? What makes 
you feel better/worse? 
18. How do you manage your symptoms? Please describe. 
19. Are you aware of any support group for individuals with PA? Are you a 
member? If so, how helpful do you think it is? 










Questions regarding symptoms (perception and severity) 
21. What symptoms do you experience as consequence of having PA? 
22. How would you describe the nature of your symptoms 
(frequency/severity/duration)? 
23. Have you looked for information regarding your symptoms? If so, what 
have you found out? Did you find it helpful? Was it any different than you 
thought?  
24. Would you say that your symptoms have changed (to better or worse) 
since time of diagnosis? How? 
Questions regarding LOC and Self-Efficacy  
25. In your opinion, what do you think has caused your illness? Please 
expand. 
26. Do you think that you may have an effect on the control of your 
symptoms? Is there anything you do that makes you feel better? 
27. Are you able to discuss your condition with your GP? If not, why (i.e. time 
constraint)?  
 
Quality of Life and well-being 
28. Do you think PA affects your quality of life? 
29. Has PA changed the way you feel in any way? Please explain. 
30. Have you experienced any limitations for doing your usual activities or 
tasks (inside or outside the home) because of your physical or emotional 
health? (Including social activities with family, etc.)? 
31. Any other issues regarding your overall health? 
Closure 
32. To summarise, is there anything else that you would like to discuss that 







Appendix 2.3 – Revised interview schedule 
 
 Introductory Note: 
First, I would like to thank you for agreeing to participate in this interview. The purpose of this 
interview is to explore and understand the experiences of individuals with PA, as part of PhD 
research with the University of Glamorgan and ABMU NHS trust. All the information will be 
recorded remain confidential and will only be used by the research team for the purposes of 
dissemination. We would like you to answer the following questions as accurately as possible 
and to the best of your knowledge. The interview will last for about one hour. Should you wish to 
receive any feedback regarding the project; the research team will be able to respond to your 
request of information whenever possible. 
My role is to help you to speak freely so you can share your views.  I have some questions that 
will guide us through. Please note that these questions were designed for information only and 
do not intend to judge your answers in any way. If there are any questions that you do not wish 
to answer, I will respect that. I am not here to express my own views so please do not assume 
that my silence or nodding means I agree/disagree with you. Please let me know if you need a 
break or anything else that will help you feel more comfortable. Do you have any questions 
before we begin? 
1. Demographics (age, gender, background, status, family history of PA) 
2. May you please confirm that you have been diagnosed with PA? How long since your 
diagnosis? 
3. Can you please explain the process leading up to the diagnosis? (Have you been 
tested?  Which tests were performed?) 
4. Do you believe that you have been misdiagnosed prior to your PA diagnosis? Please 
explain. 
5. Can you please describe the process from one diagnosis to the other? 
6. Are you undergoing any treatment? For how long? Frequency? Please expand. If not, 
have you ever been treated? If discontinued, why? 
7. Regarding PA, how often do you visit your GP? 
8. Do you have any other conditions? Please expand. 
9. How knowledgeable would you say you are regarding your illness? Please expand 
(sources of information). Did you know anything about it prior to diagnosis? 
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10. When diagnosed did you feel you were informed by your GP about your illness? Was 
this beneficial? 
11. Did you look for a second opinion? Why/not? 
12. Do you feel you are able to discuss your condition with your GP? If not, why (i.e. time 
constraint)?  
13. What do you think is the cause of your illness? (i.e. genetic, stress)? 
14. What symptoms do you experience as consequence of having PA? Can you please 
describe the physical/emotional symptoms experienced? 
15. How would you describe the nature of your symptoms (frequency/severity/duration)? 
16. Have you looked for information regarding your symptoms? If so, what have you found 
out? Did you find it helpful? Was it any different than you thought?  
17. Would you say that your symptoms have changed (to better or worse) since time of 
diagnosis? How? 
18. How do you manage your symptoms? please expand 
19. Do you think that you may have an effect on the control of your symptoms? Is there 
anything you do that makes you feel better? 
20. Are you aware of any support group for individuals with PA? Are you a member? If so, 
how helpful do you think it is? 
21. Regarding family/friends support, do you feel that you are supported? Please expand. 
22. Do you believe that your treatment regime is effective? Please expand. 
23. Did you ever have a break on the course of your treatment? 
24. Have you ever asked requested for more (or less) treatment? How did your GP 
respond? 
25. How does treatment affect your health? Please expand. 
26. In relation to PA, do you think that it influences your lifestyle? What makes you feel 
better/worse? 
27. Do you think PA affects your quality of life? 
28. What do you think are the consequences of having PA? Do you think that it affects the 
way others see you or causes difficulties for those close to you 
29. Has PA changed the way you feel in any way? Please explain. 
30. Have you experienced any limitations for doing your usual activities or tasks (inside or 
outside the home) because of your physical or emotional health? (Including social 
activities with family, etc.)? 
31. Any other issues regarding your overall health? 
32. How has the PA experience been like for you? 
Closure  
33. To summarise, is there anything else that you would like to discuss that hasn’t been 
touched upon 





Appendix 2.4 – Interview extracts 
 
Interview 1 
Y: And me I had it diagnosed for 7 years but it had started off with my hand swelling up, turning burgundy 
and clawing up. I would have been about 41-42 years old when that started maybe and nobody could sort it 
out, nobody understood what was happening and then they started to do B12 injections with me and 
immediately it improved. It still aches but no longer swells up. 
I: ok, so you were diagnosed 7 years ago and prior to that was there a different diagnosis? 
Y: well, they have started treating me for a nervous breakdown, they have put me on antidepressants which 
were terrifying  and I even didn’t  know my son when he came home from school one day and I didn’t have 
the idea of where I was or what was happening and when I realised that they have told me what happened 
that I had this kind of blackout, which I didn’t remember, I thought I will be troubled on my own and I didn’t 
want any more tablets doing it, at least you know that is you. 
I: ok, how long did it take from the diagnosis of nervous breakdown to the diagnosis of PA? 
Y: oh, I would say it would be about 3 months and it was purely by chance because my sister had gone 
feeling very tired and they checked her B12 and my sister had explained how I was and then they told her to 
tell me to get checked and that was it, and just under a 100 when they checked. 
 
Interview 2 
I: Ok then, so, shall we start then with... just tell me a little bit about the time when you were diagnosed and 
how long ago it was, just some of the things if you can remember around that time? 
Y: Hum... I Think it was about 13 or 14 years ago, I have been suffering from what I thought was a really bad 
depression and that even it is really difficult to remember because my memory was affected prior to my 
diagnosis. I think that I have been feeling really rough for about four or five years and I went to the GP and 
said I wasn’t coping with life very well , I was tired, I was sleeping all the time, it was getting on the top of me. 
I wasn’t coping with stressful situations very well, and with all fairness to the doctor, there was a lot going on 
with my life at the time, but at that time he diagnosed me with depression and he prescribed Prozac. I took 
that for about another year I suppose, because I think that I was just coming to the end of the Prozac, from 
what I can vaguely remember, I think that you have to take it for about that length of time. When I went back 
to him, I had an incident, I was driving the car, I was driving through town, I was driving at Newport road and 
I was going somewhere and I couldn’t remember how to get there and I pulled over in the car and I started to 
cry, because I couldn’t in my mind... you know how you sort of mentally map out a route... 
I: yes, to somewhere that is familiar... 
Y: Somewhere familiar and I was pulled in Newport road and I got really upset and I thought, obviously these 
Anti-Depressants aren’t working. I went back to the doctors and at that point the doctor offered me a blood 
test.I got a call from the doctor about a week later saying please would I go in and see him, and he asked me 
if I was drinking. 
I: drinking alcohol? 
Y: drinking alcohol... and I think I would say 98% of the rest of the world. I do drink alcohol but I don’t think 
that I never drank to excess... and said to me “do you drink?” and I said” yes” and then he said that he 
thought that I have been drinking too much and this might be  something that I could consider getting out of 








I: Ok, what do you think are the consequences of having PA? Do you think that if affects the way others see 
you or it causes difficulties for the ones around you? 
Y: I don’t really think that it impacts on my life that much, I suppose people are aware of it because... 
sometimes I find it very hard to concentrate before my injection so my productivity in work may drop and I 
think that the only person noticing it is my partner, because when I come home i just want to sleep, and I am 
laid on the settee and it might be a bit lonely for him because I am  not that involved in the conversation, but I 
don’t really think people consider it to be an illness like cancer or anything and they don’t treat me differently 
I: Do you believe that your treatment regime is effective? 
Y: I have asked for more frequent injections in the past because there are some times when I feel I need 
more energy, I feel I need injections every two or two and a half months rather than the three -monthly 
I: And what was the outcome of your request? 
Y: I have asked for 3 times now and every time I got the same thing which is that they are not willing to give 
it to me more frequently because you can become dependent, according to the GP, the more frequently I get 
an injection, the more frequently I need one, they think it is psychological, I have been told that because my 
Folate levels and B12 levels are so high that the symptoms I experience are psychological, so they are not 
willing to give me more injections. 
I: Ok, after they have refused to give you more treatment you have stopped asking for more treatment? And 
did it have an impact on the way you felt? 
Y: Hum... it’s not very nice being told by a GP... for example normally my feet and toes go numb and they 
say it might be a psychosomatic side effect, not to worry about it, but it doesn’t make you feel very nice... I 
know how GPs are like sometimes, they have certain opinions and i just take it with a pinch of salt and get 


















Study 3  
Appendix 3.1 – Advert to recruit PAS’ members  
  
 
A research student from the University of South Wales, Lenira Semedo, is 
conducting research on the diagnostic and treatment experiences of Pernicious 
Anaemia. Lenira would appreciate your help. Please follow the link below in 
case you would like to take part. 
 
 
Appendix 3.2 – PAS survey (posted online on survey monkey) 
 
 Welcome 
Welcome and thank you for taking part in this research project. It aims to create a 
better understanding of Pernicious Anaemia, aiming to create awareness of the 
condition and potentially improve patient experiences .All the answers will remain 
completely confidential and will only be used by the research team. If you wish to 
withdraw from the research at any time you may do so with no further consequence. 
This survey will take approximately 20 minutes to complete. 
Consent to take part in the research project 
 Yes, I consent to participate in the research study 
 Demographics 













Family History of Pernicious Anaemia (PA) 
6. Do you have family history of PA? 
 
Symptoms (pre-diagnosis) 
This section refers to your symptoms before you were diagnosed with PA. Please try 
to answer these questions to the best of your knowledge. 
7. What symptoms did you experience and how often? 
 
 









The following questions relate to the treatment that you are currently taking to 
alleviate your PA symptoms. Please answer as accurately as possible. If any of these 
questions do not apply to you please just answer "No". 
9. Are you being treated for PA? 
 
10. What kind of treatment are you receiving? How often? Please provide details. 
 
11. Did you start treatment following PA diagnosis? 
 
.  
If "no ",  why? 
Yes 
No 





12. Have you ever had a break or discontinued treatment? 
 
13. Did you ever request for more frequent treatment? 
 
14. Did you ever get over - the - counter treatment? 
 
15. Do you feel that the treatment is working? How? Please explain. 
 










If "yes" ,please explain 
Yes 
No 









This section refers to your symptoms after the PA diagnosis. Please answer the 
following questions as accurately as possible. If any of these do not apply to you 
please just answer "No". 
 
 






18. On a scale of 1-5, can you please indicate how severe are your symptoms? 
 
 
19. How do you cope with your symptoms? Please explain. 
 
20. Do you feel better since being diagnosed with PA? 
 
21. If "no", please give details. 
 
22. How do you perceive this change? Please explain. 
 
 





23. Do you feel that you can control your symptoms? 
 
Co-Morbidities 
This section refers to other conditions that you may have in addition to PA. Please 
answer to the best of your knowledge. If any of these do not apply to you please just 
answer "No". 















If "Yes", can you please explain how? 
Yes 
No 
If "Yes", please provide details 
Yes 
No 





PA impact on daily life 
The following questions refer to the impact of PA on your daily life. If any of these do 
not apply to you please just answer "No". 
26. Would you say that PA impacts on your daily life? 
 















If "Yes", how? 
Yes 
No 
If "Yes" , what kind of limitations? 
Yes 
No 






This section refers to the provision of Health services in terms of dealing with your 
condition and providing adequate support. Please answer these questions to the best 
of your knowledge. 
29. When diagnosed with PA, did you feel that you were informed by your GP regarding 
the condition? 
 
30. Was this information beneficial for you? 
 
 
31. Did you look for information elsewhere? 
         Yes 
         No 
If you have answered "yes" to the previous question, where did you look for information? Please give details. If 










If "No", would you have wanted to be informed? 
Yes 
No 







33. In your opinion, what is the purpose of your visits to your GP? 
 
 
34 .Do you feel that you are able to discuss with your GP about any concerns that you 
may have regarding 
PA? 
 
35. On a scale of 0-10, how helpful do you think that Health Services have been in dealing 
with your condition? 
Not at all                                                                                                                                                          Very 
Helpful (0)                                                                                                                                                helpful (10) 
 
36. In your opinion, how could your doctor/ health services improve the help they give 
you? 
 














Appendix 4.1 – Gp surgeries brief  
 
THE RESEARCH TEAM 
My name is Lenira Semedo and I am based at the University of South Wales, Treforest. The proposed study is part of an educational project 
(PhD) in collaboration with the departments of Haematology (Dr. Vinod Devalia) and Health Psychology (Dr. Linda Speck; Ms. Michele Williams) 
in the ABMU Local Health Board and The University of South Wales Health Psychology Research Group (Dr. Bev John; Dr. Faulkner; Dr. Gareth 
Roderique-Davies). 
AIM                             PA is a severe chronic condition that poses serious implications for sufferers and medical management. This research 
group has already conducted an audit of patient’s records (GP surgery) as well as interviews and a survey assessing the experience of living with 
PA in members of the Pernicious Anaemia Society. There is a lack of objective tests to assess B12 status (Devalia, Hamilton & Molloy, 2014; 
Hooper, 2012; Pacholok & Stuart, 2011; Devalia, 2006). Furthermore, patients vary in their responses to B12 therapy with no demonstrated 
physical benefit from more frequent treatment. In the absence of physiological parameters of patient’s experience, it is crucial to consider patient-
reported outcomes to evaluate how individuals make sense of their overall illness experience and how this may be related to the variability in 
treatment response. The key aim of the present study is to develop a patient-centred outcome measure for the identification and management of 
Health Related Quality of Life (HRQOL) for patients suffering from B12 deficiency/Pernicious Anaemia. This tool will be subject to extensive 
testing to establish validity and reliability. The development of this tool will benefit patients as it will potentially enable clinicians to select 
treatment strategies according to individual patient needs which may reduce diagnostic delay, symptom severity and illness progression. Further 
benefits may accrue to GP’s and NHS medical practitioners in terms of the reduction in both the frequency and length of consu ltations, as a 
consequence of the outcome measure and the improved adjustment of patients. 
RECRUITMENT  This research team aims to conduct a multi-centre study by recruiting patients from several GP surgeries within the 
ABMU area. The Ethics Research Proposal regarding this study is at the process of being submitted; however, ensuring the access to patients 
once Ethics is granted is paramount. The proposed procedure process will involve the administration of psychological measures including illness 
perceptions, coping strategies, locus of control and quality of life. We will require help from each GP surgery participating in this research in 
identifying patients with B12 deficiency/PA who take B12 injections. Then, a postal survey will be sent out to these patients with a covering 
letter from the surgery, the patient information sheet and informed consent attached in a pre-paid envelope (provided by the Sponsor: University 
of South Wales). 
However, this may be discussed in terms of finding the best procedure for the recruitment process, in line with the requirements of each 
individual surgery, as to minimise disruption within each surgery by strictly following ethical guidelines when accessing vulnerable individuals. 
The collaboration with Riverside would be invaluable for both patients suffering from PA/B12 deficiency as well as health professionals. 
CONSIDERATIONS                When considering research that may potentially enhance patients’ experiences and subsequent quality of life, one 
must consider patients’ expectations of improved health services. Therefore, it will be made plain to participants that the research being carried 
out aims to further understand the experience of PA sufferers and that their participation in research is crucial to aid this understanding. Further, 
findings from this research may potentially inform decisions of service improvement from a patient’s perspective. 
RESEARCH DISSEMINATION        The research team is prepared to engage with the practice administration team as well as GPs in case there 
is a need to further discuss the research study. The research team is also willing to disseminate the outcome of the research study at audit 
sessions/ GP monthly meetings.   
 In case you need any specialist input please contact Dr. Vinod Devalia (Consultant Haematologist; Telephone n.02088692742; E-mail: 
Vinod.Devalia@nhs.net 












Re: Investigating illness severity and health related quality of life in patients 
diagnosed with Pernicious Anaemia 
 
I am pleased to report that your application for ethical approval has now been 
approved by the Faculty Ethics Sub Group.  
  
Please note if you intend on deviating from the approved protocol or documentation 
you will need to request approval for any changes. I’ve attached the documents that 
are approved. 
  




Research Governance Officer, 
Research and Innovation Services (RISe) / Gwasanaethau Ymchwil ac Arloesedd, 
Research and Business Development Office / Swyddfa Datblygu Busnes ac Ymchwil, 




Re: Investigating illness severity and health-related quality of life in patients 
diagnosed with Pernicious Anaemia (FESG1702) 
  
I am pleased to report that on the 20 February 2017 your low risk application for ethical 
approval was approved via chairs action.  
  
Please note this approval is valid for 2 years from the date of issue. Upon the 
expiration of this approval you may apply for an extension of ethical approval. If you 
intend on deviating from the approved protocol or documentation you will need to 
request approval for any changes. I’ve attached the documents that are approved.  
  




Research Governance Officer, 
Research and Innovation Services (RISe)  
Research and Business Development Office  














North West - Lancaster Research Ethics Committee  
Barlow House  
3rd Floor  
4 Minshull Street  
Manchester  
M1 3DZ  
  
Telephone: 020 71048008  
  
05 August 2016  
Dr. Bev John  
University of South Wales  
Faculty of Life Sciences and Education  
Trefforest, Pontypridd  
CF371DL   
Dear Dr. John  
Study title:  Developing a patient-centred outcome measure for the identification and 
management of health related quality of life in patients suffering with 
Pernicious Anaemia  
REC reference:  16/NW/0582  
Protocol number:  N/A  
IRAS project ID:  181272  
  
Thank you for responding to the Proportionate Review Sub-Committee’s request for changes to the 
documentation for the above study. The revised documentation has been reviewed and approved 
by the sub-committee.  
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on 












Approved documents  
  
The documents reviewed and approved by the Committee are:  
  
Document    Version    Date    
Copies of advertisement materials for research participants [Advert (phase 2)]   Version 0.2   01 August 2016   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance 
indemnity]   
      
Letters of invitation to participant [Surgery letter template(phase 1)]   0.2   03 May 2016   
Letters of invitation to participant [Surgery letter reminder template(phase 1)]   0.2   03 May 2016   
Other [Provisional opinion response]   Version 0.1   02 August 2016   
Other [clarification on access to medical records]      03 August 2016   
Participant consent form [Consent form(phase 1)]   Version 0.2   01 August 2016   
Participant information sheet (PIS) [Participant Information Sheet (phase 1)]   Version 0.4   01 August 2016   
Participant information sheet (PIS) [Particiant information sheet and consent 
form(phase 2)]   
Version 0.2   01 August 2016   
REC Application Form [REC_Form_18072016]      18 July 2016   
Research protocol or project proposal [Protocol]   V1   14 November 2012   
Summary CV for Chief Investigator (CI) [CV]         
Summary CV for student [Student CV]         
Summary CV for supervisor (student research) [CV]         
Validated questionnaire [Survey ]         
  
 


















Dyddiad/Date: 14th October 2016 
ABMU Health Board Research & Development 
Swansea University 
Miss Lenira Semedo  Floor 1, Institute of Life Science 2 
PhD (Health Psychology)  Singleton Park 
University of South Wales  Swansea 
Faculty of Life Sciences and Education  SA2 8PP 
Trefforest   01792 530888 
Pontypridd  abm.rd@wales.nhs.uk 
CF371DL 
 
Dear Miss Semedo, 
Re:  Developing a patient-centred outcome measure for PA patients IRAS Ref: 181272 Sponsor: University 
of South Wales 
 
Thank you for submitting the above named research proposal to ABMU Health Board for NHS R&D 
permission.  The attached listed documents were reviewed. 
 
Health Board R&D Governance checks have been completed and passed.  Please accept this letter as 
confirmation of local NHS R&D Health Board permission. 
 
May I take this opportunity to wish you well in undertaking the research.  We will write to you in the future to 
request updates on the progress of the research and look forward to receiving outcomes of the study. 
 
Yours sincerely,  
 
Professor JW Stephens  
Deputy Assistant Medical Director (R&D)  
 
  
Re:  Developing a patient-centred outcome measure for PA patients IRAS Ref: 181272 Sponsor: 










Application Documents Received  
  
Document:  Subtitle:  Version:  
Evidence of insurance or indemnity (non-NHS 
sponsors only)   Insurance Certificate Expiry 31.07.2017       
Other (please specify)   Confirmation of protocol review email        
Research participant consent form - local 
version   Consent Form 01.08.2016     v0.2  
Other (please specify)   Advert 01.08.2016     v0.2  
REC favourable opinion letter and all 
correspondence   Validation Letter     19 Jul 2016  
REC favourable opinion letter and all 
correspondence   
Favourable Opinion with Additional Conditions     
05 Aug 2016  
Research protocol       v1.0, 14 Nov 2012  
Summary CV for Chief Investigator  
(CI)   B John        
Site-Specific Information form checklist   
ABM UHB        
Summary CV for Principal Investigator  
(PI)   L J M Speck        
Summary CV for local researchers and research 
nurses   V Devalia        
Summary CV for local researchers and research 
nurses   M Gray        
Other (please specify)   E-mail evidence ABMU     23 Aug 2016  
Summary CV for  
student(signed/authorised copy)   L Semedo        
R&D Form (Parts A-D)  
(signed/authorised pdf or hard copy)       13 Sep 2016  
Site-Specific Information Form  
(signed/authorised pdf or hard copy)   ABM UHB     16 Aug 2016  
Research participant information sheet (PIS)   
    v0.4, 01 Aug 2016  
Research participant information sheet (PIS)   
PIS/ICF - Phase 2 (via Survey Monkey)     v0.2, 01 Aug 2016  
R&D Application checklist          
Summary CV for Academic Supervisor  S Faulkner     07 Jan 2015  
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Evidence of insurance or indemnity (non-NHS 
sponsors only)   
Employers' Liability & Public And Products Liability 
- 31 Jul 2016     15 Jul 2016  
Other (please specify)   
Reminder Letter to Potential Participants     
v0.2, 03 May 2016  
Letters of invitation to participant       v0.2, 03 May 2016  













Appendix 4.5 – Advert for recruiting online participants 
 
PERNICIOUS ANAEMIA PARTICIPANTS WANTED 
 
We are a research team from the University of South Wales conducting a research 
study to investigate illness severity and health-related quality of life in patients 
diagnosed with Pernicious Anaemia(PA). The information provided in this study will 
aim to support tailoring treatment to individual needs.  
 If you have been diagnosed with Pernicious Anaemia by a health professional, if 
you are receiving regular B12 injections, if you are not taking part in this study via 
your GP surgery and if you are ≥18 years old, we would really appreciate your 
contribution to this research in order to develop a better PA understanding. 
The present research has received ethical approval from the University of South 
Wales. Taking part in this study is voluntary, and all information provided by you will be 
confidential and anonymous.  
If you would like to participate, please follow the link below and answer the 
questionnaire to the best of your knowledge. 
Survey link: https://www.surveymonkey.co.uk/r/PA_HRQoL 
Thank you very much 
The research team 
In case you have any queries please contact the researcher 
(lenira.semedo@southwales.ac.uk) 
 






Appendix 4.6 – Participant information sheet and consent form for 
online population  
 
 
Phase 1 information and consent (via Survey Monkey) 
Investigating illness severity and health-related quality of life in patients suffering with 
Pernicious Anaemia 
Welcome and thank you for considering taking part in this research study. You are invited to participate in 
this research study because you have a diagnosis of Pernicious Anaemia (PA) and you receive regular B12 
injections to alleviate your symptoms. This study is part of an educational project (PhD) with the University of 
South Wales in collaboration with the Abertawe Bro Morgannwg NHS Trust. The North West-Lancaster 
Research Ethics Committee and the University of South Wales Faculty Ethics Sub Group have approved this 
study. 
Before you provide your consent to participate or not it is important for you to understand the purpose of this 
research and what it will involve. Please take time to read this information carefully and discuss it with others 
if you wish. 
The purpose of the present study is to investigate the impact of PA on health-related quality of life. This 
study aims to further knowledge concerning PA. The information provided by you may help improve future 
treatment and care of people diagnosed with PA. 
By taking part you will be required to provide information regarding how PA is affecting your daily life, how 
you deal with your symptoms and how treatment is working for you.  
Your participation in this study is voluntary. It is completely up to you whether or not to participate. Either 
way, you will not be penalized. 
This survey will take approximately 30 minutes to complete. Please answer this survey to the best of your 
ability. 
All your answers will remain completely anonymous. Data generated from this study will only be accessed by 
the research team and the study findings may be disseminated through peer-reviewed journals, 
presentations at conferences or other professional forums. In any publication, your individual contribution 
cannot be identified. 
Once the study has ended, a summary of the findings will be available from the website were you accessed 
this survey. 
Since there is no way of identifying your individual contribution you may not be able to withdraw your 
responses if you have exited the survey. In case you wish to erase your responses you will need to 
backtrack through the survey before you exit the same.  
Disclosing health related information may cause distress for some individuals. If you perceive yourself to be 
in this situation, please contact the director of studies Dr. Bev John (bev.john@southwales.ac.uk; telephone 
n. 01443 654145). 
If you wish to complain about this research you may do so with no further consequences. Please contact the 




After reading the information above you are encouraged to contact the researcher Lenira Semedo regarding 
any queries regarding the research study (lenira.semedo@southwales.ac.uk; telephone n. 01443 484517). 
Before you provide your consent to participate in this study please confirm your diagnosis by a health 
professional, that you are receiving regular B12 injections and that you are not currently taking part in this 
study through your local GP practice. 
  I can confirm that I have been diagnosed with Pernicious Anaemia by a health professional, I receive 
regular B12 injections and I am not currently taking part in this study through my local GP practice. 
Clicking on the "agree" button below indicates that:  
• I have read and understood the above information. I have had the opportunity to consider the information, 
ask questions and have had these clarified to my satisfaction. 
• I voluntarily agree to participate in the study 
• I am at least 18 years of age 
• ’I consent to the processing of my personal information for the purposes of this research study. I 
understand that such information will be treated as confidential and handled in accordance with the Data 
Protection Act 1998’ 
• I agree to my anonymised data being used in study specific reports and subsequent articles that will appear 
in academic journals 
  I agree to take part in this study 
If you do not wish to participate in this research study, please decline participation by clicking on the 
"disagree" button. 






Appendix 4.7– Participant information sheet for clinical population 
 
                                                                                   
PARTICIPANT INFORMATION SHEET  
Investigating illness severity and health related quality of life in patients diagnosed  
with Pernicious Anaemia 
  
You are invited to take part in this research study because you have a diagnosis of B12 
deficiency/Pernicious Anaemia and you receive regular B12 injections to alleviate your 
symptoms. This study is part of an educational project (PhD) in the University of South 
Wales in collaboration with the Abertawe Bro Morgannwg NHS trust. 
Before you decide whether to participate or not it is important to you to understand the 
purpose of this research and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. 
The purpose of the present study is to investigate the impact of Pernicious Anaemia 
severity on quality of life. We want to know how Pernicious anaemia is affecting your 
daily life, how do you deal with your symptoms and how treatment is working for you.  
This study aims to further knowledge concerning Pernicious Anaemia. The information 
provided by you may help improve future treatment and care of people diagnosed with 
Pernicious Anaemia. 
The participation in this study is voluntary. It is completely up to you whether or not you 
participate. Either way, it will not affect the standard of care you currently receive.  
Please take time to consider your participation and if you agree to participate in this 
study, please sign the enclosed consent form. 
By participating, you also have the right to withdraw from the study at any time without 
providing a reason. In case you wish to withdraw, your data will be removed from the 
study. 
Disclosing health related information may cause distress for some individuals. If you 
perceive yourself to be in this situation please contact the director of studies Dr. Bev 
John (Bev.john@southwales.ac.uk; telephone n. 01443654145). 
352 
  
This study involves filling up a survey regarding your Pernicious Anaemia experience. 
The survey will take approximately 30 minutes to complete. In case you have any 
issues completing this survey please contact the researcher (contact details available 
on the back of this form). After completion you are required to return it in the post with 
the consent form by using the pre-paid envelope provided to you.  
Any information provided by you will be kept confidential and anonymous. If you 
provide your consent to participate we are planning to publish the results in peer-
reviewed journals, presentation at conferences or other professional forums. In any 
publication, information will be provided in such a way that your individual contribution 
cannot be identified.  
Once the study has come to an end, a summary of the findings will be available from 
your surgery website as well as the Pernicious Anaemia website. In case you don’t 
have access to a computer and you are interested in a summary of the study findings, 
paper copies will be available to collect from your surgery. 
In case you don’t have access to a computer, would you like a paper copy of the 
summary of the study findings to be available to collect from your surgery?  
Please circle the word that applies to your choice          YES          NO 
After reading this information you are encouraged to ask or to contact the researcher 
regarding any queries about the research study. 
In case you wish to complain about the present research you may do so, with no 
further consequences. Please contact Dr. Bev John (bev.john@southwales.ac.uk; 
telephone n.01443654145)  
Thank you very much for taking the time to consider your participation in this study. If 
you wish to take part, please sign the attached consent form. This information is for 
you to keep.  
Alternatively, if you do not wish to take to take part please sign and date below and 
post this form as well as the information pack in the pre-paid enveloped provided to 
you. 
I do not wish to participate in this research study 
Signature: -----------------------------------------------------        Date: ------------------------------- 
The researcher 




Appendix 4.8 – Consent form  
 
 (Form to be on headed paper) 
Centre Number:  
Study Number: 
Participant Identification Number for this trial: 
CONSENT FORM 
Title of Project: Investigating illness severity and health related quality of life in patients diagnosed  
with Pernicious Anaemia 
Name of Researcher: Lenira Semedo 
                                                                                                                                  Please initial box 
1. I confirm that I have read the information sheet dated 5th April 2016 (version.0.3) for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. (If appropriate) I understand that relevant sections of my medical notes and data collected during 
the study, may be looked at by individuals from [company name], from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records.  
 
4. (If appropriate) I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other researchers. 
 
5. (If appropriate) I agree to my General Practitioner being informed of my participation in the study. 
 
6. (If appropriate) I understand that the information held and maintained by the Health and Social 
Care Information Centre and other central UK NHS bodies may be 
used to help contact me or provide information about my health status. 
 
7. I agree to take part in the above study. 
 
           
Name of Participant  Date    Signature 
           









                                                                                   Long date letter merged 
                                                                                                              NHS Number  
Title Calling Name Surname 
Home Full Address (stacked) 
Dear Title Surname, 
We are writing to you on behalf of Lenira Semedo (University of South Wales) who is conducting 
a research study investigating illness severity and health related quality of life in patients 
diagnosed with PA/B12 deficiency. As care providers, we are involved in treating our patients 
and promoting research that may advance knowledge on medical conditions. 
It is important for you to know that this letter is not to tell you to join this study.  It is your 
decision.  Your participation is voluntary. Whether or not you participate in this study will have no 
impact on the care you currently receive.  
Please review the enclosed information and take time to consider your participation. In case you 
wish to participate please fill in the attached questionnaire and the consent form and post it back 
to the surgery in the pre-paid envelope enclosed with this letter. 
If you are not interested in the study please circle your option in the attached information sheet 
and post the information pack back to the surgery in the pre-paid envelope provided to you. 
















                                                                                   Long date letter merged 
                                                                                                              NHS Number  
Title Calling Name Surname 
Home Full Address (stacked) 
 
Dear Title Surname, 
We have recently contacted you to provide you with information regarding Pernicious 
Anaemia/B12 deficiency research being carried out by Lenira Semedo in the University of South 
Wales. 
We are contacting you again because we haven’t yet received the questionnaire pack. If you 
wish to participate in this research please fill in the questionnaire and sign the consent form that 
was sent to you in the previous letter. 
If you do not wish to participate, please circle your option in the information sheet previously sent 
to you and post the information pack back to the surgery in the pre-paid envelope that was 
provided to you in the previous letter. 
You will not receive any more letters from the surgery regarding this research. 
 In case you have any queries regarding this research, please contact the researcher (Lenira 
Semedo; lenira.semedo@southwales.ac.uk; telephone n: 01443 484 517). 
 













 Level 4, Brackla House, Brackla Street,  
 BRIDGEND CF31 1BZ 





Re. Research Project:  
Investigating illness severity and health-related quality of life in patients 
suffering with PA. 
 
I’m delighted that this society fully supports the above study and I confirm that we are 
happy for our members to access the study through the Pernicious Anaemia Society’s 
website and via our network of local Support Groups. 
 
I am also pleased to confirm that the Pernicious Anaemia Society agrees to offer 
support to any participant in the study should they experience any discomfort from 
disclosing health-related information to members of the research team as a 
consequence of participating in the above study. 
All of us at the Pernicious Anaemia Society wish you well with your project. 
Yours sincerely 









Appendix 4.12 – Survey  
 
 





PERNICIOUS ANAEMIA SURVEY 
Investigating illness severity and health related quality of life in patients diagnosed with 









                                                                                                                                     









Thank you for taking part in this survey. It aims to create a better understanding of B12 
deficiency /Pernicious Anaemia (PA) and potentially improve PA management from a patient’s 
perspective. Therefore, ensuring that your views are represented is paramount. Please answer 
this survey to the best of your ability. All the answers will remain completely confidential and will 
only be used by the research team. If you wish to withdraw from the research at any time you 
may do so and this will not affect the quality of care you currently receive. This survey will take 
approximately 30 minutes to complete.  
Before you begin, we would like you to answer a few general questions about yourself and your 
PA experience, by ticking the option that best applies to you or by filling in the space provided. 
 
1. DEMOGRAPHICS 
1.1 What is your age?  
 
 
1.2 What is your gender? 
 Male 
 Female 
 Other, please specify 
 
 
1.3 What is your ethnic group? 
White 
 Welsh/English/Scottish/Northern Irish/British 
 Irish 
 Gipsy or Irish Traveller  
 Any other White background, please describe 
 
 
Mixed/ Multiple ethnic groups 
 White and Black Caribbean 
 White and Black African 
 White and Asian 










 Any other Asian background, please describe 
 
 
 Black/African/ Caribbean/ Black British 
 African 
 Caribbean 
 Any other Black/African/ Caribbean background, please describe 
 
 
 Other ethnic group 
 Arab 
 Any other ethnic group, please describe 
 
 
1.4 What is your postcode? 
 
 
1.5 What is your current marital status? 
 Single 
 Living as married 
 Married 







1.6 What is the highest degree or level of school you have completed? If currently enrolled, mark 
the previous grade or highest degree received. 
 GCSE’s\O levels 
 A-levels 
 Further education 
 Higher Education 
 
1.7 What is your employment status? 
 Employed 
 Self-employed 
 Not currently employed 
 Retired 
 Unable to work 
 Other 
 
2. B12 DEFICIENCY/PA RELATED INFORMATION 
2.1 What is your diagnosis? 
 B12 deficiency 
 PA 
 
2.2 Do you have a family history of B12 deficiency/PA? 
 Yes 
 No 
 Not sure 








2.4 Where was this diagnosis made? 
 GP surgery 
 Outpatient clinic 
 Inpatient 
 Other, please specify 
 
 







2.6 How often do you receive B12 treatment? 
 Every 3 months 
 Every 2 months 
 Every 6 weeks 
 Every month 
 Other, please specify 
 
 
2.7 Have you ever requested for more frequent B12 treatment? 
 No 
 Yes 






2.8 Do you supplement your B12 treatment? 
 No 
 Yes 






2.9 Have you ever discontinued treatment? 
 No 
 Yes 
 If ‘yes’, why? 
 
 
2.10 Are you a member of any support organisation to help you deal with PA? 
 No 
 Yes 
 If ‘yes’ please specify 
 
 
2.11 Have you been diagnosed with another chronic condition besides PA? 
 No 
 Yes 





Appendix 4.13 BRIEF-COPE (FORM A) 
 
These items deal with ways you have been coping with your condition. There are many ways to try to 
deal with problems. These items ask what you have been doing to cope with the fact you that suffer from 
B12 deficiency/ PA. Obviously, different people deal with things in different ways, but we are interested 
in how you have tried to deal with it. Each item says something about a particular way of coping. We 
want to know to what extent you have been doing what the item says. How much or how frequently. 
Don't answer on the basis of whether it seems to be working or not—just whether or not you are doing 
it. Use these response choices by ticking the item that applies to you. Make your answers as true FOR 
YOU as you can.  
 
1. I've been turning to work or other activities 
to take my mind off things. 
I haven't 
been doing 




a little bit 
I've been doing 





2. I’ve been concentrating my efforts on doing 
something about the situation I’m in. 
I haven't 
been doing 




a little bit 
I've been doing 





3. I've been saying to myself “this isn't real." I haven't 
been doing 




a little bit 
I've been doing 





4. I've been using alcohol or other drugs to 
make myself feel better. 
I haven't 
been doing 




a little bit 
I've been doing 














a little bit 
I've been doing 





6. I've been giving up trying to deal with it. I haven't 
been doing 




a little bit 
I've been doing 














a little bit 
I've been doing 














a little bit 
I've been doing 





9. I've been saying things to let my 








a little bit 
I've been doing 













a little bit 
I've been doing 







11. I've been using alcohol or other drugs to 
help me get through it. 
I haven't 
been doing 




a little bit 
I've been doing 





12. I've been trying to see it in a different light, 








a little bit 
I've been doing 





13. I’ve been criticizing myself. I haven't 
been doing 




a little bit 
I've been doing 





14. I've been trying to come up with a strategy 
about what to do. 
I haven't 
been doing 




a little bit 
I've been doing 





15. I've been getting comfort and 
understanding from someone. 
I haven't 
been doing 




a little bit 
I've been doing 





16. I've been giving up the attempt to cope. I haven't 
been doing 




a little bit 
I've been doing 





17. I've been looking for something good in 
what is happening. 
I haven't 
been doing 




a little bit 
I've been doing 





18. I've been making jokes about it. I haven't 
been doing 




a little bit 
I've been doing 





19. I've been doing something to think about it 
less, such as going to movies, watching 









a little bit 
I've been doing 





20. I've been accepting the reality of the fact 








a little bit 
I've been doing 





21. I've been expressing my negative feelings. I haven't 
been doing 




a little bit 
I've been doing 





22. I've been trying to find comfort in my 








a little bit 
I've been doing 





23. I’ve been trying to get advice or help from 








a little bit 
I've been doing 





24. I've been learning to live with it. I haven't 
been doing 




a little bit 
I've been doing 













a little bit 
I've been doing 















a little bit 
I've been doing 





27. I've been praying or meditating. I haven't 
been doing 




a little bit 
I've been doing 





28. I've been making fun of the situation. I haven't 
been doing 




a little bit 
I've been doing 































Appendix 4.14 The multidimensional health locus of control scale (FORM 
B) 
Instructions: Each item below is a belief statement about your B12 deficiency/PA with which you 
may agree or disagree. Beside each statement is a scale which ranges from strongly disagree 
(1) to strongly agree (6). For each item, we would like you to circle the number that represents 
the extent to which you agree or disagree with that statement. The more you agree with a 
statement, the higher will be the number you circle. The more you disagree with a statement, the 
lower will be the number you circle. Please make sure that you answer EVERY ITEM and that 
you circle ONLY ONE number per item. This is a measure of your personal beliefs; obviously, 
there are no right or wrong answers. 
1=STRONGLY DISAGREE (SD) 
2=MODERATELY DISAGREE (MD) 
3=SLIGHTLY DISAGREE (D) 
4=SLIGHTLY AGREE (A) 
5=MODERATELY AGREE (MA) 










1 If I get sick, it is my own behaviour which determines how soon I get well again. 1 2 3 4 5 6 
2 No matter what I do, if I am going to get sick, I will get sick. 1 2 3 4 5 6 
3 Having regular contact with my physician is the best way for me to avoid illness. 1 2 3 4 5 6 
4 Most things that affect my health happen to me by accident. 1 2 3 4 5 6 
5 Whenever I don't feel well, I should consult a medically trained professional. 1 2 3 4 5 6 
6 I am in control of my health. 1 2 3 4 5 6 
7 My family has a lot to do with my becoming sick or staying healthy. 1 2 3 4 5 6 
8 When I get sick, I am to blame. 1 2 3 4 5 6 
9 Luck plays a big part in determining how soon I will recover from an illness. 1 2 3 4 5 6 
10 Health professionals control my health. 1 2 3 4 5 6 
11 My good health is largely a matter of good fortune. 1 2 3 4 5 6 
12 The main thing which affects my health is what I myself do. 1 2 3 4 5 6 
13 If I take care of myself, I can avoid illness. 1 2 3 4 5 6 
14 
Whenever I recover from an illness, it's usually because other people (for example, doctors, 
nurses, family, friends) have been taking good care of me. 
1 2 3 4 5 6 
15 No matter what I do, I 'm likely to get sick. 1 2 3 4 5 6 
16 If it's meant to be, I will stay healthy. 1 2 3 4 5 6 
17 If I take the right actions, I can stay healthy. 1 2 3 4 5 6 



















Appendix 4.15 Somatic symptom scale (FORM C) 
 
Instructions: Your answers to the following questionnaire will help in understanding problems 
that you may have. Please answer every question to the best of your ability by putting a cross in 























During the past 4 weeks, how much have you been bothered by 







1.Stomach pain    
2.Back pain    
3. Pain in your arms, legs or joints (knees, hips, etc.)    
4.Feeling tired or having little energy    
5.Trouble falling or staying asleep or sleeping too much    
6.Menstrual cramps or other problems with your periods(Women only)    
7.Pain or problems during sexual intercourse    
8.Headaches    
9.Chest pain    
10.Dizziness    
11.Fainting spells    
12.Feeling your heart pound or race    
13.Shortness of breath    
14.Constipation, loose bowels or diarrhoea    




Appendix 4.16 The Brief Illness Perception Questionnaire (FORM D) 
 
For the following questions, please circle the number that best corresponds to your views in 
relation to your B12 deficiency/PA: 
How much does your illness affect your life? 
          0  1 2 3 4 5 6 7 8 9 10 
severely 
affects my life 
         no affect 
         at all 
 
 
How long do you think your illness will continue? 
 0  1 2 3 4 5 6 7 8 9 10 
forever a very 
short time 
   
 
 
How much control do you feel you have over your illness? 
 0  
absolutely 
  1 2 3 4 5 6 7 8 9 10 
extreme amount 
of control no control 
 
 How much do you think your treatment can help your illness? 
 0  
not at all 





 How much do you experience symptoms from your illness? 














How concerned are you about your illness? 
 0  
not at all 
concerned 




How well do you feel you understand your illness? 




  1 2 3 4 5 6 7 8 9 10 
understand 
very clearly 
 0  
not at all 
affected  
emotionally 





Please list in rank-order the three most important factors that you believe caused your illness. 
The most important causes for me:- 


















Appendix 4.17 The Hospital Anxiety and Depression Scale (FORM E) 
 
Emotions play an important part in most illnesses. Being aware of these feelings may help you more when 
dealing with your B12 deficiency/PA. Read each item and underline the reply which comes closest to how 
you have been feeling in the past week. Don’t take too long over your replies; your immediate reaction to 







1.  I feel tense or’ wound up’ 
 
Most of the 
time 
A lot of the time  From time to time, 
occasionally 
Not at all   
2. I still enjoy the things I used to enjoy Definitely as 
much 
Not quite so 
much  
Only a little Hardly at all   
3. I get a sort of frightened feeling as if 




Yes, but not too 
badly  
A little, but it 
doesn’t worry me 
Not  at all   
4.  I can laugh and see the funny side of 
things 
As much as I 
always could 
Not quite so 
much now  
Definitely not so 
much now 
Not  at all   
5. Worrying thoughts go through my 
mind 
A great deal 
of the time 
A lot of the time  From time to time 
but not too often 
Only 
occasionally    
6. I feel cheerful 
 
Not at all Not often  Sometimes Most of the time    
7. I can seat at ease and feel relaxed Definitely Usually Not often Not at all  
8. I feel as if I am slowed down Nearly all the 
time 
Very often Sometimes Not at all  
9. I get a sort of frightened feeling like 
‘butterflies’ in the stomach 
Not at all Occasionally Quite often Very often 
10. I have lost interest in my appearance Definitely I don’t take so 
much care as I 
should 
I may not take as 
much care 
I take just as 
much care as 
ever 




Quite a lot not very much Not at all 
12. I look forward with enjoyment to 
things 
 
As much as I 
ever did 
Rather less 
than I used to 
Definitely less 
than I used to 
Hardly  at all 




Quite often Not very often Not at all 
14. I can enjoy a good book or radio or 
TV programme 




                         
Appendix 4.18 WHOQOL-BREF (FORM F) 
 
The following questions ask how you feel about your quality of life, health, or other areas of your 
life. Please answer all the questions. If you are unsure about which response to give to a 
question, Please choose the answer that appears most appropriate, this can often be your 
first response. Please keep in mind your standards, hopes, pleasures and concerns. We ask that 
you think about your life in the last four weeks. Please read each question, assess your 




 Very poor  Poor  
Neither poor 
nor good  
Good  Very good  
1.  How would you rate your 
quality of life?  










Satisfied  Very satisfied  
2.  How satisfied are you 
with your health?  
1  2  3  4  5  
 
 
The following questions ask about how much you have experienced certain things in the last 
four weeks. 
 
 Not at all  A little  
A moderate 
amount  
Very much  
An extreme 
amount  
3.  To what extent do you 
feel that physical pain 
prevents you from doing 
what you need to do?  
5  4  3  2 1  
4. How much do you need 
any medical treatment to 
function in your daily 
life?  
 
5  4  3  2 1  
5. How much do you enjoy 
life?  
1 2 3  4 5  
6. To what extent do you 
feel your life to be 
meaningful?  







 Not at all  A little  
A moderate 
amount  
Very much  Extremely   
7. How well are you able to 
concentrate?  
 
1 2 3  4 5 
8. How safe do you feel in 
your daily life?  
1 2 3  4 5 
9. How healthy is your 
physical environment?  
1 2 3  4 5 
 
The following questions ask about how completely you experience or were able to do certain 
things in the last four weeks. 
 
 Not at all  A little  Moderately  Mostly  Completely  
10.  Do you have enough 
energy for everyday life?  
 
1 2 3  4 5 
11. Are you able to accept 
your bodily appearance?  
1 2 3  4 5 
12. Have you got enough 
money to meet your 
needs?  
1 2 3  4 5 
13. How available to you is 
the information that you 
need in your day-to-day 
life?  
1 2 3  4 5 
14. To what extent do you 
have the opportunity for 
leisure activities?  





 Very poor  Poor  
Neither poor 
nor good  
Good  Very good  
15.  How well are you able to 
get around?  
 

















Satisfied  Very satisfied  
16.  How satisfied  
are you with your sleep?  
1 2 3  4 5 
17. How satisfied are you 
with your ability to 
perform your daily living 
activities?  
1 2 3  4 5 
18. How satisfied are you 
with your capacity for 
work?  
1 2 3  4 5 
19. How satisfied  
are you 
 with yourself?  
1 2 3  4 
5 
 
20. How satisfied are you 
with your personal 
relationships?  
1 2 3  4 5 
21. How satisfied are you 
with your sex life?  
1 2 3  4 5 
22. How satisfied are you 
with the support you get 
from your friends?  
1 2 3  4 5 
23. How satisfied are you 
with the conditions of 
your living place?  
1 2 3  4 5 
24. How satisfied are you 
with your access to 
health services?  
1 2 3  4 5 
25. How satisfied are you 
with your transport?  




The following question refers to how often you have felt or experienced certain things in the last four weeks. 
 
 
 Never  Seldom  Quite often  Very often  Always  
26.  How often do you have 
negative feelings such as 
blue mood, despair, 
anxiety, depression?  
 
5 4 3  2 1 
 
 
Thank you very much for your time. We would appreciate you to check that this survey is fully 
completed. 
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